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Development and application of high-performance liquid chromatography- and 
mass spectrometry- based two-dimensional methods for proteome analysis 
 
The availability of robust, sensitive and reliable analytic methods is a highly relevant 
requirement for proteome analysis. In this work two gel-free two-dimensional high-
performance liquid chromatography-matrix assisted laser desorption/ionization mass 
spectrometry (2D HPLC-MALDI-MS) platforms suitable for proteome analysis were 
developed and compared.  
To provide an alternative approach to the classical bottom-up method combining 
strong cation-exchange- and ion-pair reversed phase HPLC (SCX x IP-RP-HPLC), in 
which peptides are separated in both dimensions, a semi top-down method was 
elaborated. This new approach employed separation of proteins in the first and of 
peptides in the second dimension, respectively. Both separation dimensions of the 
new method were operated in the ion-pair reversed phase (IP-RP) chromatographic 
mode using poly-(styrene-divinylbenzene) (PS-DVB)-based monolithic columns and 
hydro-organic eluents at a pH value of 2.1. Both methods were validated using the 
same 10-protein mixture. 
The elaborated semi top-down- and the classical bottom-up approach were applied to 
the proteome analysis of a Glioblastoma multiforme tissue protein extract including 
the comparison of the two approaches. Fewer proteins were identified with the semi 
top-down approach. However, the sequence coverage of the proteins identified was 
slightly higher. The major advantage of this new method is the elution of proteins in 
less fractions of the first separation dimension than for the bottom-up approach. 
Thus, only the fractions containing the target proteins have to be digested in further 
experiments. Five of 13 potential biomarkers previously identified applying the 
SEREX (serological identification of antigens by recombinant expression screening) 
approach, could be confirmed on molecular level by combining the results of both 
chromatographic approaches.  
 
Key-words: proteome analysis, Glioblastoma multiforme, nano-flow HPLC, MALDI 
mass spectrometry, multidimensional high-performance liquid chromatography, 
biomarker, monolithic separation columns, orthogonality, peak capacity, retention 
behavior 
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Entwicklung und Anwendung von zweidimensionalen Methoden für die 
Proteomanalyse basierend auf Hochleistungsflüssigchromatographie und 
Massenspektrometrie  
 
Robuste, sensitive und zuverlässige Analysenmethoden sind eine enorm wichtige 
Voraussetzung für die Proteomanalyse. In dieser Arbeit wurden zwei zwei-
dimensionale gelfreie Plattformen basierend auf Hochleistungsflüssig-
chromatographie und matrixunterstützter Laser Desorptions-/Ionisations Massen-
spektrometrie (2D HPLC-MALDI-MS), die off-line gekoppelt wurden, entwickelt und 
miteinander verglichen. 
Eine Alternativmethode zur klassischen bottom-up Methode, welche starken 
Kationenaustausch- mit Ionenpaar-Umkehrphasenchromatographie verbindet (SCX x 
IP-RP-HPLC) und bei der in beiden Dimensionen Peptide getrennt werden, wurde 
erarbeitet. Diese alternative semi top-down Methode beinhaltete die Trennung von 
Proteinen in der ersten und von Peptiden in der zweiten Dimension. In beiden 
Dimensionen der neuen Methode wurde der chromatographische Ionen-
Umkehrphasen Modus (IP-RP-HPLC) in Verbindung mit Polystyrol-Divenylbenzol 
(PS-DVB) basierten Monolithen und hydro-organischen Eluenten bei einem pH Wert 
von 2.1 verwendet. Beide Methoden wurden mit einem 10-Proteinstandard validiert.  
Die erarbeitete semi top-down und die klassische bottom-up Methode wurden auf die 
Proteomanalyse eines Glioblastoma multiforme Gewebe Proteinextraktes angewandt 
und verglichen. Mit der semi top-down Methode wurden zwar weniger Proteine 
identifiziert, aber deren Sequenzabdeckung war höher. Der Vorteil dieser Methode ist 
die Elution der Proteine in weniger Fraktionen der ersten Dimension der Trennung. 
Nur die Fraktionen, die die Targetproteine enthalten, müssen in weiteren 
Experimenten verdaut werden. Fünf von 13 Biomarkern, die vorher mit der SEREX 
(serological identification of antigens by recombinant expression screening) - 
Methode identifiziert wurden, konnten auf der molekularen Ebene unter Verbindung 
der Ergebnisse beider chromatographischer Methoden, nachgewiesen werden. 
Schlagwörter: Proteomanalyse, Glioblastoma multiforme, nano-Fluss HPLC, 
MALDI-Massenspektrometrie, Biomarker, monolithische Trennsäulen, Orthogonalität, 
Peakkapazität, Retentionsverhalten 
  
Chapter I 
 
 
 
Principles of chromatography- and 
mass spectrometry-based  
human brain proteomics  
 
 
 
        Chapter I: Principles of chromatography- and mass spectrometry-based human brain proteomics 
   
3
1 Introduction 
 
The term “proteome” was introduced by Wilkins in 1995 who described it as “the total 
protein complement of a genome” [1]. Lottspeich expanded this definition explaining 
the proteome as the total protein content of an organism, a cell or organelle at a 
special time under exactly defined surrounding conditions [2]. These information are 
used to compare different states of tissues (e.g. healthy and diseased) as well as cell 
lines treated with drugs (treated and untreated), for instance. It is hoped to find any 
hints for target proteins which can be employed for diagnosis or even therapy of a 
disease. 
Three milestones made large-scale proteome analysis possible: the development of 
two-dimensional gel electrophoresis (2D-GE), mass spectrometry and multi-
dimensional chromatography. 
In 1975, Klose and O’Farrel independently published a new method for the 
separation of protein samples with high complexity [3;4]. They utilized isoelectric 
focusing in combination with gel electrophoresis. Today, 2D-GE (in combination with 
mass spectrometry) is still the most employed methodology in terms of proteome  
research [5].  
By operating 2D-GE, only a protein pattern of one condition can be compared to 
another one but no efficient identification is possible. Therefore, mass spectrometry 
has to be employed to fragment peptides generated by digestion of the in-gel 
separated proteins. The fragmented peptides then are identified using the knowledge 
of the fragment masses. Hence, it is important to know the underlying fragmentation 
rules depending on the applied mass spectrometer [6;7]. Although the first mass 
spectrometer was developed in 1899 by Thompson [8], it took almost one century to 
operate mass spectrometry as a routine method for protein analysis. A huge problem 
was the lack of “soft” ionization techniques able to transfer zwitterionic and polar 
macromolecules in the gaseous phase [9]. The immense technical achievements in 
the eighties and the nineties of the last century offered new opportunities to cope with 
this problem. In 1968, the concept of electrospray ionization (ESI) was already known 
[10;11] but it took until the late eighties for Fenn et al. to demonstrate the ionization of 
biopolymers by intact protein analysis with ESI-mass spectrometry (ESI-MS) [12]. 
Matrix assisted laser desorption/ionization (MALDI) as ionization technique for large 
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and labile biological components followed only few years later [13]. Now the road was 
clear for large-scale analysis of protein samples. 
Due to the immensely complex data sets generated computer-based data 
interpretation is compulsive for proteome analysis. The storage of protein sequences 
in databases permits rapid protein identification [14;15]. Database search engines use 
the fragment ion pattern of tandem mass spectra to identify the amino acid sequence 
of the fragmented peptides. The first developed database search engine  
(SEQUEST) [16-18] is still successful in proteome analysis. Other search engines like 
Mascot, OMSSA or Protein Prophet followed [19-21]. 
Mass spectrometry is an important factor in large-scale protein analysis according to 
its sensitivity and selectivity. However, efficient multi-dimensional separation methods 
prior to mass spectrometry are necessary to reduce the enormous complexity of the 
sample. The most prominent method in this context is the multi-dimensional protein 
identification technology (MudPIT) [22] employing ESI-MS. Here the capillary 
electrospray needle is directly filled with two stationary phase materials for cation-
exchange chromatography and reversed-phase chromatography. This setup permits 
on-line two-dimensional separation and on-line hyphenation to an ESI-MS analysis. 
Another successful method for proteome analysis is protein mapping based on pI 
value and molecular mass of the proteins [23-24]. The first dimension employs 
chromatofocusing (CF) which is based on ion-exchange chromatography of intact 
proteins. To perform separation of the proteins a pH-gradient is employed [25;26]. 
Subsequently the obtained fractions from the first dimension are separated utilizing 
reversed phase chromatography with on-line ESI-MS detection to obtain the exact 
intact protein masses. Recently, a micro-CF approach was introduced employing CF 
of intact proteins in the first dimension and separation of peptides in the second 
dimension with the advantage of low sample consumption [27]. 
The introduction of monolithic capillary columns contributed relevantly to highly 
efficient chromatographic separation prior to mass spectrometry. These separation 
columns are suitable for miniaturization which is necessary when small sample 
volumes and low concentrations of compounds are analyzed [28]. Moreover, these 
monolithic columns offer faster mass transfer with lower backpressure than observed 
with porous particle packed capillary columns since there is no diffusion of the 
analytes in and out of the pores. Especially for high resolution separation of peptides 
and proteins, which possess a low diffusion coefficient, stationary phases offering 
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fast mass transfer are required [29;30]. Today, chromatographic approaches in 
combination with mass spectrometry are well established and applied for proteome 
analysis [31]. Especially the so-called bottom-up or shotgun approach is used 
successfully for proteome analysis beside 2D-GE [32]. This procedure includes 
peptide separation in both chromatographic dimensions. Monolithic capillary columns 
are very convenient for the second dimension according to the mentioned 
advantages. 
This chapter provides information about strategies in proteome research including the 
underlying principles of chromatography and mass spectrometry. The focus is set on 
the human proteome, especially brain tumor proteomics with the search of efficient 
biomarkers improving diagnosis and therapy of diseases. 
        Chapter I: Principles of chromatography- and mass spectrometry-based human brain proteomics 
   
6
2 Proteome research 
 
2.1 Structure of proteins and peptides 
 
Proteins are macromolecules possessing a complex structure that may be subdivided 
into four layers: primary, secondary, tertiary and quaternary structure. The primary 
structure is determined by the order of α-amino acids in the protein sequence. These 
α-amino acids possess a central carbon atom (α) binding four different substituents: 
an amino group, a carboxyl group, a hydrogen atom and a so-called side chain. This 
side chain distinguishes the different amino acids and determines their chemical 
properties. As four different substituents are linked to the α-carbon atom, amino acids 
are chiral (except glycine) resulting in D- and L-isomers. In proteins only L-amino 
acids are incorporated.  A very important property of amino acids is their zwitterionic 
character. At a neutral pH value, the amino acids are mostly existent as dipolar ions 
with a protonated amino group (-NH3+) and a dissociated carboxyl group (-COO-). 
Peptides and proteins consist of amino acids that contain both basic and acidic 
functional groups, therefore they are ampholytes. Their charge depends not only on 
the amino acid composition, but also on the pH value of the surrounding medium. 
The pH value where a protein holds no net electrical charge is called isoelectric  
point (pI). 
As an abbreviation system for amino acids a three letter code was introduced. 
Because of troubles for presenting long protein sequences, a one letter code  
followed [33]. In Table 1 abbreviations, full names as well as structures of the  
20 proteinogenic amino acids are listed. 
The spatial arrangement of amino acids which are situated near each other in the 
linear amino acid chain is called secondary structure. The most important periodic 
structures are α-helices and ß-sheets suggested by Pauling and Corey in 1951 [34-36]. 
They are formed by a regularly appearing pattern of hydrogen bonds between −N−H− 
and −C=O− connections of the peptide bonds of amino acids laying near each other 
in the linear amino acid sequence. Hydrogen bonds between carboxyl and amino 
groups in the inner of the α-helices with a distance of four amino acids stabilize this 
structure, whereas the side chains are directed to the outside. One turn of an α-helix 
corresponds to 3.6 amino acids which causes direct vicinity of every fourth amino 
acid. Those with a distance of two amino acids between them are located on 
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opposite sides of the α-helix turn and can not interact with each other. All α-helices in 
natural proteins occur dextrorotatory because this direction of rotation is energetically 
more favorable due to less steric collisions between side chains and peptide 
backbone. The ß-sheet construction was also discovered by Pauling and Corey as 
second structure; hence, it was called ß-sheet. In contrast to α-helices this structure 
is craned and not coiled. The distances between adjacent amino acids are higher 
than for α-helices (0.35 nm and 0.15 nm, respectively) and their side chains are 
oppositely directed. While all the atoms of the peptide bond are situated in the same 
plane, the α-carbon atoms linger simultaneously in two planes. 
 
Table 1. Structure, three- and one-letter code for the 20 proteinogenic amino acids. 
 
amino acid 3-letter code (1-letter code) sequence amino acid 
3-letter code 
(1-letter code) sequence 
glycine Gly (G) 
C H
H
NH 3
+
O
O
 
asparagine Asn (N) 
CH
NH3
+
O
O
NH2
O  
alanine Ala (A) 
CH
CH3
NH3
+
O
O
 
glutamic acid Glu (E) 
CH
NH3
+
O
O
O
O
 
valine Val (V) 
CH
NH3
+
O
OCH3
CH3
 
glutamine Gln (Q) 
CH
NH3
+
O
O
NH2
O
 
leucine Leu (L) 
CH
NH3
+
O
O
CH3
CH3  
arginine Arg (R) CH
NH3
+
O
O
N
NH2
+
NH2  
isoleucine Ile (I) 
CH
NH3
+
O
OCH3
CH3
 
lysine Lys (K) 
OCH
NH3
+
O
NH3
+  
serine Ser (S) 
CH
NH3
+
O
O
OH
 
histidine His (H) 
CH
NH3
+
O
O
NH NH
+
 
threonine Thr (T) 
CH
NH3
+
O
OOH
CH3
 
phenylalanine Phe (F) 
CH
NH3
+
O
O
 
cysteine Cys (C) 
CH
NH3
+
O
O
SH
 
tyrosine Tyr (Y) 
CH
NH3
+
O
O
OH
methionine Met (M) 
CH
NH3
+
O
O
S
CH3 tryptophan Trp (W) CH
NH3
+
O
O
N
H  
aspartic acid Asp (D) 
CH
NH3
+
O
O
O
O  
proline Pro (P) NH2 + O
O
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The tertiary structure is specified by the spatial arrangement of the polypeptide 
chains. X-ray and nuclear magnetic resonance analyses for the first time permitted 
the investigation of the spatial arrangement with atomic resolution. The first protein 
structure which was determined by X-ray crystallography was that of myoglobin [37]. 
Every protein possesses a specific three-dimensional structure which is influenced by 
the surrounding medium. It depends, for instance, on polarity, viscosity, concentration 
and ionic strength of the surrounding solvent. Moreover, the presence of prosthetic 
groups has an impact on protein confirmation. These are molecules mostly covalently 
linked with the protein, but not consisting of amino acids. Biotin in carboxylases, 
heme in hemoglobin (not covalently linked) and cytochrome C as well as flavins in 
flavoproteins are ranked among prosthetic groups. Also post translational 
modifications, such as phosphorylation, acetylation or glycosylation are important 
parameters for protein confirmations. Besides hydrogen bonds, ionic, hydrophobic 
and van-der-Waals forces as well as covalent disulfide bonds between sulfhydryl 
groups of two cysteine moieties contribute to the stabilization of the three-
dimensional protein structure.  
Finally, the quaternary structure is formed by building of protein complexes. Proteins 
possessing more than one polypeptide chain are organized in so-called subunits. 
The quaternary structure of a protein describes the spatial arrangement of its 
subunits and the interactions among them which are mostly non-covalent.  
For protein quantification the Bradford assay is often employed. Here, the Coomassie 
Brilliant Blue G-250 dye binds mainly to basic and aromatic amino acid residues of 
the protein, especially to arginine [38]. By binding to these amino acids the color of the 
dye is shifting from red (465 nm) to blue (595 nm) [39;40]. The extent of color change 
correlates with the protein concentration [41]. With this method a high sensitivity is 
achieved because of the high extinction coefficient of the protein-dye complex. 
 
 
2.2 Functions of proteins in the human organism 
 
Proteins are involved in almost all processes in the human body. They are classified 
in several ways regarding structure, source and function (Table 2). The differentiation 
according to function allows a concrete view to the special task of every protein. 
Thus, examples are given in Table 2 and are mentioned in particular. 
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Table 2. Classification systems of proteins. 
 
structure function examples source 
fibrous 
globular 
structure 
enzymes 
transport 
agitation 
reservoir 
defense 
 
regulation 
elastin, fibroin, collagen, keratin 
extra classification 
hemoglobin, lipoproteins, albumin 
actin, myosin, tubulin 
casein, ovalbumin, ferritin 
immunoglobulins, cytokines, interferons, 
fibrinogen, thrombin 
human growth hormone, 
repressors/activators 
plant 
animal 
human 
 
Structure proteins determine the assembly of cells and inter-cellular compartments.  
As enzymes themselves are a very complex group, several classification systems 
exist for them. One with respect to their type of reaction is listed in Table 3. 
Hydrolases are of special interest in protein identification analysis, especially 
peptidases which catalyze cleavage of the peptide bonds. The most prominent 
endopeptidase for proteomic applications is trypsin which cleaves C-terminally after 
lysine and arginine when no proline follows in the amino acid sequence. Other 
peptidases often employed are pepsin, chymotrypsin, Glu-C-protease and Asp-N-
protease. 
 
Table 3. Classification of enzymes [42]. 
 
class subclasses 
oxidoreductases 
dehydrogenases, oxidases, peroxidases, 
reductases, monooxygenases, 
dioxygenases 
transferases C1-transferases, glycosyl-transferases, aminotransferases, phosphotransferases 
hydrolases esterases, glycosidases, peptidases (proteases), amidases 
lyases (synthases) C-C-lyases, C-O-lyases, C-N-lyases, C-S-lyases 
isomerases epimerases, cis-trans-isomerases, intra molecular transferases 
ligases (synthetases) C-C-ligases, C-O-ligases, C-N-ligases, C-S-ligases 
 
Transport proteins carry substances through cell membranes, and are then able to 
release these substances. Hemoglobin, for instance, carries oxygen and lipoproteins 
lipids. Albumins transfer hydrophobic substances which can not be transported by the 
        Chapter I: Principles of chromatography- and mass spectrometry-based human brain proteomics 
   
10
aqueous blood itself, such as fatty acids, bilirubin, vitamins, hormones, and 
micronutrients. Proteins of motion permit movement of tissues. Actin and myosin 
appear in filaments of the skeletal muscle cells where they realize contraction under 
energy consumption. Tubulin is a structure unit of microtubules as well as 
responsible for motility of the cell.  
Proteins storing components are called reservoir proteins. Casein, for instance, 
contains high amounts of calcium, and ferritin stores iron.  
In the human organism two different kinds of defense proteins are distinguished: 
Proteins of the immune system and proteins of blood clotting. To the latter group 
fibrinogen and thrombin are allotted and to the first immune globulins, cytokines and 
interferons. Their task is to maintain the healthy condition of the human body.  
The last group is the sub class of regulating proteins. To this class protein hormones 
like human growth hormone and parathormone as well as repressors and activators 
controlling the biosyntheses of proteins are classified.  
 
 
2.3 The Human Proteome Organization (HUPO) 
 
The human genome consists of 20,000-25,000 genes [43] which are stored in 23 
chromosome pairs. These genes encode approximately 500,000 different proteins, 
but the exact number still is unknown. The concentration of expressed proteins in the 
cell may vary in a dynamic range of 1-1010 due to their different functions [44].  
A large-scale project dedicated to human proteome analyses was started in 2001 by 
the Human Proteome Organization (HUPO). This organization aims to identify all 
human proteins and clarify their interactions, fostering the development of new 
proteomic approaches. Seven sub-projects are already initiated; inter alia brain, liver, 
and plasma proteome projects.  
Worldwide, 18 laboratories are working on the Brain Proteome Project (BBP) which is 
focused on brain development and associated diseases. In 2006, the pilot phase of 
the BBP was finished. Two-dimensional gel electrophoresis as well as approaches 
based on chromatography and mass spectrometry were applied both using 
bioinformatic data interpretation [45]. Initial information about the normal human brain 
as well as the mouse brain should be gained to yield a comprehensive comparison 
with the diseased brain to be investigated in the future. As a result 1,804 proteins 
could be identified and implicated in biological context [46]. Three main points 
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associated with sample and data handling were elaborated during this starting 
phase [47]: 
 
1. Sample handling, preparation, separation and identification have to be 
standardized to trace back differences and discrepancy in analytical results. 
2. Two or more different approaches and search engines have to be acclaimed 
as complementary. On the one hand identified proteins appearing in both 
methods can be confirmed and on the other hand additional proteins can be 
added to the data set. 
3. Only highly confident protein lists generated by rigorous database search 
parameters should be included in the search for biomarkers. 
 
 
2.4 Strategies for proteome research 
 
The aim of proteome research is to analyze preferably the entire protein content of 
cells, tissues or body fluids. Therefore, two main strategies have been developed 
successfully: The top-down and the bottom-up (= shotgun) approach. Whereas in the 
top-down approach the separation is performed at protein level, it is realized at 
peptide level in the bottom-up approach as outlined in Figure 1. 
Top-down proteome analysis is mostly realized by applying 2D electrophoresis (2D-
GE). This means in a first dimension, proteins are separated according to their 
isoelectric point, employing isoelectric focusing (IEF). In a second dimension, they 
are separated by size-dependent sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Bottom-up proteomics in contrast utilizes mostly 2D 
HPLC-MS approaches. 
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top-down bottom-up
peptide/protein identification
database 
search
MALDI-MS/MS ESI-MS/MS
protein
digest
protein
digest
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protein/s
2D protein 
separation
2D peptide 
separation
protein
digest
proteome
cell
 
 
Figure 1. Strategies in proteome analysis. 
 
After digestion and 2D separation, peptides are identified using mass spectrometric 
analysis with subsequent computer-based data interpretation. Therefore, the entire 
known proteins of a given organism are digested in silico and the calculated peptide 
masses are compared to the masses obtained by mass spectrometry. This procedure 
is called peptide mass fingerprint (PMF). The peptie mass information however is not 
sufficient to identify a peptide reliably. Peptides containing the same amino acids but 
in another order will result in the same peptide mass. For more specific identification 
peptide ions are fragmented in a tandem MS experiment in the mass spectrometer. 
The differences between the fragment masses are assigned to amino acid residues. 
With this so-called peptide fragment fingerprint (PFF) the amino acid sequence of the 
identified peptide as additional information is obtained. In recent proteome studies it 
is compulsive to perform tandem MS experiments to minimize false positive identified 
proteins. 
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2.5 Biomarker research 
 
Various definitions exist for the term biomarker. The National Institutes of Health 
(NIH) working group elaborated a comprehensive definition in 2001. According to 
them a biomarker is an objectively measured feature to indicate a normal 
physiological or pathogenic process or pharmacological feedback to a therapeutic 
intervention [48]. The easiest available biomarkers in practice are physiological 
measures like blood pressure for monitoring of cardiovascular diseases or blood 
glucose level for diabetes diagnosis and monitoring. However, for drug development 
more complex features have to be accessible for analysis like patterns of genotypes, 
disturbance of gene expression profiles or changes of protein and metabolite levels. 
In summary four entities today are described as biomarkers in drug development [49]: 
 
1. DNA - reflecting the genetic variability 
2. mRNA - displaying changes of gene expression 
3. proteins - representing cellular and enzymatic changes 
4. metabolites - highlighting physiological endpoints 
 
The aims after identification of biomarkers are usually validation, characterization, 
qualification and routinely measuring of these markers before they can be applied to 
diagnosis or drug development for therapy.  
 
 
2.5.1 SEREX as strategy for biomarker identification 
 
Serological identification of antigens by recombinant expression screening was 
developed by Pfreundschuh et al. 1995 [50]. The advantage of this method is 
overcoming the obstacle of tumor cell cultivation. Except of some special tumor types 
it is very difficult to establish cultured cell lines. By combination of autologous typing of 
cancer cells and a molecular cloning procedure cell cultures are no longer necessary. 
In Figure 2 the workflow of SEREX is depicted. First a cDNA library has to be 
constructed by purification of the tissue sample mRNA, amplification and reversed 
transcription to cDNA. The entire cDNA library is transferred into λ-phages, and the 
encoded proteins are expressed in E. coli. After a lytic infection of the bacteria the 
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proteins are blotted onto nitro cellulose membranes. Those membranes were 
incubated with autologous patient serum. Clones which are reactive with patient’s IgG 
antibodies are identified by a staining reaction using an enzyme- conjugated 
secondary antibody specific for human IgG as illustrated in Figure 2.  
Positive clones are then subcloned to isolate single plaques containing a single insert. 
The nucleotide sequence of the inserted DNA is accordingly determined [51]. For 
validation of the identified antigens spot assays are applied. Here, only the phage 
clones with the proteins of interest are expressed in E. coli instead of the whole cDNA 
library. 
 
nitro cellulose
membraneplaque
color response
anti-human IgG-
enzyme complex
serum
antibody
a) cDNA library assembly
tumor tissue
isolation of RNA
amplification of RNA
synthesis of cDNA 
ligation into expression vector (λ-phage)
transfection into Escherichia coli
expression
b) Immunoscreening
lytic infection 
of E. coli
blot onto nitro 
cellulose membranes
enzyme
 
 
Figure 2. SEREX technique [52]. 
 
More than 2,000 tumor-associated antigens (TAA) of 15 different tumor types were 
identified by SEREX [53]. Subsequently to the first SEREX phase (identification) a 
validation step follows by screening sera from healthy individuals and cancer patients 
by spot assays to show cancer-restricted immune response. The identification of 13, 
32 and 40 antigens reacting exclusively with cancer patient’s sera of renal [54],  
colon [55] and breast cancer [56], respectively, was achieved employing SEREX, for 
instance. Recently, the detection of 13 tumor-associated antigens for Glioblastoma 
multiforme was published [57].  
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2.5.2 Biomarker qualification process 
 
The US Department of Health and Human Services, Food and Drug Administration 
(FDA) developed a “Guidance for Industry Pharmacogenomic Data Submissions” 
where they described the regulatory aspects of biomarkers [58]. These are 
summarized in Figure 3.  
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Figure 3 [59].  Biomarker qualification process for drug-development defined by the 
US Food and Drug Administration (FDA). 
 
Three types of biomarkers are distinguished: “Exploratory Biomarkers”, “Probable 
Valid Biomarkers” and “Known Valid Biomarkers”. A certain proof of concept exists 
for “Exploratory Biomarkers” from in-house experiments or literature. Two 
requirements have to be fulfilled for such a biomarker to get the status of a “Probable 
Valid Biomarker”: 
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1. It has to be analyzed with a system of well-established performance 
characteristics. 
2. There has to be an established scientific framework that explains the 
physiological, pharmacological, toxicological or clinical significance of the test 
results. 
 
When the success of the requirements above is repeatable and confirmed in cross-
validation experiments, the biomarker finally attains the status of “Known Valid 
Biomarker”. 
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3 Chromatographic separations of proteins and peptides 
 
3.1 Chromatographic principles 
 
Several parameters are defined for the characterization of HPLC separations. First, it 
has to be distinguished between isocratic and gradient elution. In isocratic 
separations the plate number per meter is the most important factor for 
characterization of separation efficiency while for gradient separations the peak 
capacity is the crucial parameter. The higher these values are, the higher is the 
efficiency of the separation column. The complete set of HPLC separation 
characterization parameters is summarized in the IUPAC nomenclature compiled by 
Engelhardt and Rohrschneider [60]. 
 
 
3.1.1 Optimization of resolution 
 
The parameter for characterizing chromatographic separations aimed to be optimized 
in terms of efficiency is the peak resolution, describing the relative position of two 
analyte peaks to each other. To emphasize the influence of selectivity and plate 
number on the peak resolution, the equations for isocratic HPLC separation are given 
in equation (1) and (2).  
 
RS =
1
4
. k2
1+k2
. α-1
α
√N
          
efficiency       retention    selectivity   
       Equation (1) 
 
RS……...peak resolution 
N……….plate number 
k ……….retention factor 
α……….selectivity 
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The retention term is not affected by changing the column length as the flow time for 
an inert substance and the net retention time are changing in the same order of 
magnitude, too. Hence, the ratio of both (= k) stays the same. The selectivity term of 
the equation is not affected as well because the stationary phase, the mobile phase 
and the temperature are not changed. The only factor which alters by varying the 
column length is the efficiency term caused by the raising plate number with column 
length according to equation (2): 
 
N = 16
tR
wb
.
2
  
Equation (2) 
N……….plate number 
tR……….total retention time [min] 
wb……....peak width at basis [min] 
 
For instance, the plate number is increasing almost to square value as tR is doubling 
by doubling the column length (when wb remains nearly the same).  
Beside the variation of the efficiency term by changing the column length, the 
selectivity α (= k2/k1) can be changed by variation of the mobile phase, the stationary 
phase or the separation temperature [59]. 
However, these considerations are valid strictly only for isocratic HPLC separations. 
Nevertheless, the resolution for gradient separation is affected, too. A mathematical 
expression of N, k and α for gradient elution with the equations listed above is not 
strictly valid because no thermodynamic equilibration can adjust due to the 
permanently changing composition of the mobile phase. A formula for calculating the 
peak resolution of isocratic and gradient separations for two compounds (analyte 1 
and analyte 2) is revealed in equation (3): 
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RS = 
2 (tR2-tR1)
wb1+wb2  
          Equation (3) 
RS……….peak resolution 
tR1……….total retention time of analyte 1 [min] 
tR2……….total retention time of analyte 2 [min] 
wb1………peak basis width of analyte 1 [min] 
wb2……….peak basis width of analyte 2 [min] 
 
 
3.1.2 Peak capacity 
 
The theoretical peak capacity (P) is an important parameter to characterize a two-
dimensional separation system. It describes how many components can be 
separated by an HPLC method (RS = 1) in a particular gradient time. It is computed 
according to the equation [61]: 
 
tG
wb
P = 1+
 
       Equation (4) 
P……….peak capacity 
tG……….gradient time 
wb………peak width at the basis 
 
P is calculated by the ratio of the gradient time (tG) and the average peptide peak 
width (wb) at 4σ (= 13.4 % of peak height) [62]. The total peak capacity of a multi-
dimensional HPLC system is estimated by multiplying the peak capacities from the 
single dimensions [63]: 
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Ptotal = Pm x Pn…x Pz 
Equation (5) 
Ptotal…….peak capacity for the whole multi-dimensional system 
Pm………peak capacity of the first dimension 
Pn……….peak capacity of the second dimension 
Pz……….peak capacity of the last dimension 
 
 
3.1.3 Gradient volume concept 
 
For the transfer of an optimized gradient to another column length it is necessary to 
adapt the gradient volume which is calculated according to equation (6): 
 
VG = tG . F 
          Equation (6) 
VG……...gradient volume        
tG……….programmed gradient time [min] 
F……….solvent flow-rate [mL min-1] 
           
When a liner gradient is applied, the inner diameter and the stationary phase of the 
separation column remain the same, and the gradient volume is constant, then each 
analyte is eluted at a certain solvent concentration, and the separation is only 
changing in terms of analysis time [64]. Furthermore the start and end conditions of 
the gradient separation have to remain the same.  
Increasing the peak capacity can be achieved by increasing the column length. To 
employ the gradient volume concept first the hold up time of both columns has to be 
determined. The gradient time of the optimized gradient is known. The particular 
volumes are calculated by multiplication with the solvent flow-rate. To adapt the 
gradient volume for a column twice as long as the column where the gradient was 
optimized, the following computation is necessary: 
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VG1
VM1
=
VG2
VM2  
Equation (7) 
VG1……….gradient volume for optimized gradient [mL]  
VM1……….hold up volume for column where the gradient was optimized [mL] 
VG2……….adapted gradient volume for the longer column [mL] 
VM2……….hold up volume for the longer column [mL] 
 
 
VG2 =
VG1
VM1
. VM2
 
         Equation (8) 
 
tG2
VG2
F
=
 
         Equation (9) 
 
Employing a two-fold longer column would result in a doubling hold up time: 
 
 
VM2 = 2 . VM1 
          Equation (10) 
In Equation (8):  
VG2 = VG1 . 2 
         Equation (11) 
 
This means that when the column length is doubled, the gradient volume has to be 
doubled, too. This results in a doubled gradient time when the solvent flow rate 
remains the same. 
Furthermore, the gradient volume can be adapted to the application. In Table 4 the 
recommendations for chosen gradient volumes in terms of the employed application 
are summarized [64]. 
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Table 4. Adjustment of gradient volume to application. 
 
VG application characterization 
5 VM 
trace analysis of low 
complex samples 
small gradient volume 
leads to small peak 
volume, low dilution, high 
sensitivity 
10-15 VM 
optimized resolution of 
medium complex samples 
optimal resolution for 
moderate analysis time 
> 15 VM multi component analysis 
optimization of peak 
capacity 
 
      
3.2 Chromatographic modes 
 
Since the term and the technique of chromatography have been introduced in 1903 
by M. Tswett [65;66], over one century of development in this field has passed. A great 
variety of chromatographic modes are established today as a result of the enormous 
progress in technology. Beside gas chromatography (GC), high-performance liquid 
chromatography (HPLC) has become the most important technique in bioanalytics. 
As GC-MS dominates the field of metabolite analysis, HPLC-MS is the prevalent 
choice for proteomic approaches. Peptides and proteins are accessible to a variety of 
HPLC methods because of their various properties like charge, polarity, biological 
and metal affinity [67], as listed in Table 5 [68;69]. 
Size exclusion chromatography was introduced in 1956 [70]. Here, the analytes are 
not interacting with the material of the stationary phase, but are separated according 
to the accessable pore volume of the stationary phase.   
In 1990, the term hydrophilic interaction chromatography (HILIC) was introduced 
describing the combination of hydrophilic stationary and hydrophobic mobile phase 
more accurately than the historical term normal-phase chromatography [71]. This 
mode is especially used for separating sugars and oligosaccharides [72-77]. In recent 
studies HILIC has been also applied to proteome analysis in multidimensional 
peptide separation due to the orthogonality towards RPC [78;79]. 
Hydrophobic interaction chromatography (HIC) represents a special case of RPC and 
uses salt gradients of decreasing concentration to elute the adsorbed proteins. This 
method has been known since 1948 [80]. In contrast to ion exchange chromatography, 
a hydrophobic stationary phase material is applied, and the salt gradient starts at 
high ionic strength. The moderate eluting conditions are not affecting the tertiary and 
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secondary structure of proteins. As a consequence this chromatographic mode is 
highly suitable for protein purification without loss of protein activity. 
 
Table 5. High-performance liquid chromatography techniques for protein and peptide 
separation. 
 
method mobile phase 
principle of 
separation 
stationary 
phase 
abbrev-
iation 
alternative 
names /special 
cases 
non interactive methods  
size exclusion 
chromatography 
gradient of 
organic 
solvents or 
water 
varying 
molecule size 
silica or 
polymer gels 
with specific 
pore width 
SEC 
gel filtration  
(GF) 
gel permeation 
chromatography 
(GPC) 
interactive methods  
normal phase 
chromatography 
gradient of 
organic 
solvents 
(mixed) 
polar 
interactions 
silica gel 
aluminum oxide
dextran gel 
NPC 
hydrophilic 
interaction 
chromatography 
(HILIC) 
reversed phase 
chromatography 
 
gradient of 
organic 
solvents with 
water or 
buffer 
solvophobic 
interactions 
 
silanized silica 
gel, silica or 
PS-DVB 
RPC 
hydrophobic 
interaction 
chromatography 
(HIC) 
ion-pair reversed 
phase 
chromatography 
 
gradient of 
organic 
solvents with 
water or 
buffer and ion 
pair modifier 
solvophobic 
and 
electrostatic 
interactions 
silanized silica 
gel, silica or 
PS-DVB 
IP-RPC  
ion-exchange 
chromatography 
 
gradient of 
buffer 
solution 
electrostatic 
interactions 
silica or 
polymers with 
anionic or 
cationic 
functional 
groups 
IEC 
strong- or weak 
anion-exchange 
chromatography 
(SAX/WAX) 
strong- or weak 
cation-exchange 
chromatography 
(SCX/WCX) 
affinity 
chromatography 
gradient of 
buffer 
solution 
biospecific 
interactions, 
complex 
formation 
affinity carrier 
with specific 
ligands 
AC 
immobilized 
metal ion affinity 
chromatography 
(IMAC) 
 
Compared to small molecules, proteins and peptides differ mainly in their more 
complex structure and larger molecule size. This means that the analyte molecules 
can interact with the stationary phase of the separation column with more than one 
moiety. That effect is called multisite adsorption [81]. Therefore, a protein elutes only 
when the solvent strength has reached a special value and hence is high enough to 
desorb all groups of the protein interacting with the stationary phase. This 
phenomenon has been introduced as “on-off model” [82]. As a consequence, a steep 
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negative slope can be observed in a semilogarithmic plot of the retention factor 
versus the solvent strength, as depicted for lysozyme in Figure 4 in comparison to 
nitrobenzene. Furthermore, multisite adsorption leads to focusing of the analytes at 
the column head which allows the injecting of large volumes of biopolymer samples. 
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Figure 4. Desorption behavior of a small molecule (nitrobenzene, dashed lines) and 
a protein (lysozyme, solid lines) in RP-HPLC [83]. 
 
 
3.2.1 Reversed-phase and ion-pair reversed-phase HPLC 
 
In reversed-phase high-performance liquid chromatography (RP-HPLC), proteins and 
peptides are separated with respect to their hydrophobic properties. The hydrophobic 
moieties undergo solvophobic interactions to a hydrophobic stationary phase in a 
polar surrounding medium (mostly water). Elution of the analytes is realized by 
raising the concentration of organic solvents (e.g. methanol or acetonitrile). Small 
polar acids like formic, hydrochloric or phosphoric acid are often added to denaturate 
the proteins and circumvent secondary unspecific interactions with remaining silanol 
groups of silica-based stationary phases [84]. As a consequence, peaks with higher 
symmetry can be observed. Under the described conditions, elution processes take 
place mainly caused by solvophobic interactions [85]. Protein charge only affects 
separation by adjusting the hydrophobicity. 
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In ion-pair reversed-phase chromatography additional electrostatic interactions are 
induced by adding amphiphilic compounds like trifluoracetic- or heptafluorbutyric acid 
or bases like trietylammonium acetate to the mobile phase (=ion-pair modifiers). As a 
result, the hydrophobic moieties of the ion pair modifier adsorb on the hydrophobic 
stationary phase and generate an electrical surface potential, which attracts charged 
functional groups of the analytes [86]. Since the concentration of the amphiphile is 
usually not high enough to cover the complete surface of the stationary phase 
solvophobic interactions are still contributing to retention of the analytes  [87;88] as 
revealed in Figure 5a. 
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Figure 5. IP-RP- HPLC [89;90]. 
(a) Principle of IP-RP-HPLC, solvophobic as well as electrostatic interactions shown 
on the example of a peptide adsorbing to a hydrophobic octyl silica stationary phase 
applying TFA as ion-pair modifier. (b) IP-RP-HPLC separation of nine peptides. 
Column, PS-DVB monolith, 60 x 0.2 mm i.d.; mobile phase, (A) 0.05 % TFA in water, 
(B) 0.05 % TFA in acetonitrile; gradient, 0-50 % B in 15 min; flow rate,  
2.5 µL/min, temperature, 50 °C, detection, ESI-MS; peptide concentration, 1ng µL-1; 
injection volume, 1 µL. 
 
RP-HPLC and IP-RP-HPLC are the most efficient chromatographic separation 
methods because of protein denaturation. They provide the highest peak capacities 
caused by suppression of conformational isomers and maximization of the molecule 
surface available for interaction. Under the denaturing conditions proteins are 
unfolded and losing their three-dimensional structure but also their biological activity. 
To optimize the separations, selectivity can be influenced by temperature and choice 
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of stationary phase as well as mobile phase adjustment using other organic solvents 
or other ion-pair modifiers. An exemplary separation of nine peptides in a monolithic 
capillary column is demonstrated in Figure 5b.  
 
 
3.2.2 Ion-exchange high-performance liquid chromatography 
 
The principle of ion-exchange high-performance liquid chromatography (IEX-HPLC) 
is based on charge-charge interactions [91;92]. The positively or negatively charged 
analytes can electrostatically interact with charged functional groups of the stationary 
phase. For proteins and peptides such interactions are promoted by the amino- and 
carboxy-terminus, the charged side chains of acidic (aspartic and glutamic acid) and 
basic (lysine and arginine, histidine - depending on the pH value) amino acid 
residues as well as by post translational modifications like phosphate or sulfate 
groups. Depending on the pH value of the surrounding medium proteins and peptides 
can either be separated with anion exchange (AEX-HPLC) or with cation exchange 
high-performance liquid chromatography (CEX-HPLC) due to their ampholyte 
character [93].  
In Figure 6a and c exemplary protein separations applying AEX- and CEX-HPLC are 
shown and Figure 6b reveals schematically the principle of AEX-HPLC. 
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Figure 6.  Ion-exchange HPLC of proteins and peptides [89]. 
(a) Column, 250 x 0.4 mm i.d. ProPac SAX-10, 10 µm; gradient, 0-0.5 M NaCl in  
20 mM Tris-HCl within 10 min, pH 8.0;  flow rate, 1.0 mL min-1; temperature, ambient; 
UV-detection, 220 nm; injection volume, 10 µL. (b) Scheme of anion exchange for an 
octapeptide. (c) Column, 250 x 0.4 mm i.d. ProPac SCX-10, 10 µm; gradient, 0-0.5 M 
NaCl in 50 mM Na2HPO4 within 10 min, pH 6.0; flow rate, 1.0 mL min-1; temperature, 
ambient; UV-detection, 220 nm; injection volume, 10 µL. 
 
Although the net electrical charge is zero at the isoelectric point (pI) of a protein, 
retention can still be observed in IEX-HPLC. This phenomenon occurs because not 
exclusively the net electrical charge contributes to separation, but also the charge 
distribution. For separation of peptides and proteins with AEX-HPLC the pH value of 
the surrounding medium has to be higher and for CEX separations lower than the pI 
of the analyte. In general, the pH value should differ one pH unit to the pI of the 
analyte to get repeatable retention of peptides and proteins. 
The elution of analytes in IEX-HPLC is controlled by increasing the ionic strength of 
the solvent. As long as no extreme pH conditions are created the three-dimensional 
structure and the biological function of proteins are not impaired. However, the 
maintained complex structure leads to broader or even multiple peaks especially for 
proteins keeping their isomeric forms. As a result, in IEX-HPLC lower peak capacities 
are obtained than in RP- and IP-RP-HPLC. Furthermore, the high amounts of salt 
hamper online hyphenation to mass spectrometry. For protein purification [94] ion- 
exchange chromatography is a wide spread methodology. 
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3.3 Stationary phase materials for separation of proteins and peptides  
 
One main difficulty of HPLC separations of proteins and peptides is the slow mass 
transfer caused by the low diffusion constant of large molecules. The slow movement 
inside and out of the pores of a porous stationary phase material delays the mass 
transfer resulting in band broadening. To improve separation efficiency different 
phase morphologies were suggested as displayed in Figure 7. 
 
(a) (b) (c) (d)
 
 
Figure 7. Morphology of four different stationary phase configurations [90]. 
(a) Spherical, porous and large particles, (b) spherical, porous and small particles,  
(c) spherical, non-porous and small particles and (d) monolithic stationary phase. 
 
In Figure 7a a porous stationary phase is shown. It consists of large spherical and 
porous particles with high permeability and large interparticle voids. However, this 
design results in low separation efficiency caused by the long diffusion paths in the 
pores. To shorten them, smaller spherical, porous particles were introduced  
(Figure 7b). They actually achieved higher efficiency, caused by small interparticle 
voids and shorter pores, admittedly at the cost of lower permeability. As a result, the 
required pressure for pumping mobile phase through the column increases. Another 
stationary phase design, so-called pellicular stationary phases [95], is totally non-
porous as schematically demonstrated in Figure 7c. For this phase design the 
efficiency is also very high because of the small interparticle voids, but low 
permeability is caused by small particle sizes necessary to obtain sufficient surface 
area. Furthermore, only the surface material of the particles contributes to retention 
of analytes at the cost of separation area and so on sample loadability. The last of 
these four stationary phases is the monolithic design which offers a high permeability 
and efficiency discussed in detail in the next paragraph. 
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3.3.1 Monolithic columns for peptide and protein separation 
 
Monolithic separation columns characteristically consist of a single porous  
medium [96;97]. One advantage of this structure is the absence of interparticle voids. 
Thus, the mobile phase is pumped through the macro-pores of the separation 
medium [98]. The mass transfer hereby is supported by the convective flow through 
the macro pores (> 50 nm) [99]. Diffusion dependent mass transfer is restrained only 
to the meso- (2-50 nm) and micro- (< 2 nm) pores. A further advantage is the high 
permeability of monolithic columns allowing fast separation of biomolecules at high 
flow rates [100-103]. Caused by their flat van-Deemter curves at high linear velocities, 
monolithic columns combine excellent separation performance and short analysis 
times [104].  
There are two main strategies for monolith preparation: Polymerization of organic 
monomers and polycondensation of alkylsilane monomers. The first monolithic 
columns were organic, synthesized in 1974 based on polyurethane [96]. Since then a 
variety of organic monolithic materials based on the polymerization of acrylates, 
methacrylates, norbonene, styrene and other monomers have been shown [105]. PS-
DVB monoliths were recognized as monolithic columns with especially high efficiency 
for biopolymers (Figure 8). Compared to columns packed with 2 µm PS-DVB 
particles, they offer a three times higher efficiency demonstrated on nucleotides as 
biopolymers [104]. In these micropellicular monoliths no accessible micro- or meso-
pores are present for large biomolecules as nucleotides, proteins or  
peptides [101]. 
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Figure 8. PS-DVB-based monolithic columns and performance [106;107]. 
(a) 200 µm i.d. monolithic column, outwards: (1) monolithic stationary phase,  
(2) fused silica, (3) polyimide layer (scanning electron microscope image).  
(b) Globules of the monolithic phase (scanning electron microscope image).  
(c) Separation of 1.0 pmol human transferrin peptides. Column, monolithic PS-DVB 
60 x 0.2 mm i.d.; mobile phase, (A) 2.0 % acetonitrile and 0.05 % TFA in water,  
(B) 80 % acetonitrile and 0.05 % TFA in water, gradient, 0-40 % B in 30 min,  
40-100 % B in 10 min; flow rate, 1.70 µL min-1; temperature, 50 °C; UV-detection, 
214 nm  [107]. 
 
In the middle of the 90s, silica-based monoliths were introduced for HPLC sepa-
rations [108] which are synthesized by a combination of sol-gel reaction and 
agglomeration [109]. The most commonly adopted silica monomer is 
tetramethoxysilane (TMOS) which was first employed by Tanaka et al. [110-112]. Later, 
further monomers were tested separately or in combination: tetraethoxysilane 
(TEOS) [113], methyltrimethoxysilane (MTMS) [114], 2-cyanoethyltriethoxysilane 
(CEOS) [115], (3-aminopropyl) triethoxysilane (APTES) [116] and diglycerylsilane  
(DGS) [113;116]. First, silica monoliths were particularly valuable in the field of small 
molecules [117] and became then more and more applied in the field of peptidomics 
and proteomics [118;119] . 
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3.3.2 Strong cation exchange columns for peptide separation 
 
For 2D proteome analyses based on chromatography and mass spectrometry SCX is 
often applied in the first dimension for peptide separation and prefractionation. The 
SCX chromatography mode is chosen because the stationary phase materials are 
protonated over a broad pH range and hence keep their ability of cation exchange. A 
suitable pH for peptide separation would be around three where all carboxyl groups 
are protonated and not disturbing the interactions of positively charged peptide 
residues and the stationary phase. Both, silica as well as polymeric base materials 
are suitable for SCX as indicated in Table 6. 
 
Table 6. Common base materials and functional groups for SCX-HPLC [92;120]. 
 
materials 
property polymer-based silica-based 
ion exchange capacity high high 
loadability high medium 
pH range 2-14 2-8 
efficiency low high 
functional groups for ion exchange 
name formula 
sulfoethyl groups -O CH2CH2SO3        H
+
 
sulfopropyl groups O CH2CH2CH2SO3        H
- +
 
  
Poly(2-sulfoethyl aspartamide) was shown to be advantageous as silica-based 
column packing material for cation exchange [121]. Its structure is shown in Figure 9. 
Compared to sulfopropyl groups, undesirable secondary hydrophobic interactions are 
decreased. This is a critical point especially for hydrophobic peptides as they form 
interactions with the sulfopropyl moieties of the stationary phase. 
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Figure 9. Structure of poly(2-sulfoethyl aspartamide) (= PolySulfoethyl A) as 
stationary phase material in SCX-HPLC. 
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4 Mass spectrometry 
 
Mass spectrometry has become an important analytical technique for proteome 
research and bioanalysis at all. Due to its high selectivity, sensitivity and resolution 
power it is applied to 2D HPLC proteome analysis. Since a mass spectrometer 
consists of three modules (ion source, mass analyzer and detector) this chapter is 
arranged in the same way. First matrix assisted laser desorption/ionization (MALDI) 
as a “soft” ionization method for biopolymers is discussed. This is, beside 
electrospray ionization (ESI), the most common technique to transfer biopolymers 
like peptides, proteins and nucleic acids into the gaseous phase without 
fragmentation. 
The analytes enter the mass spectrometer charged by the pH value of the dissolution 
buffer. In the case of chromatography coupled to mass spectrometry the charge of 
proteins and peptides depends on their pI and the pH value of the mobile phase. 
After passing the ion source they travel the high vacuum region of the mass analyzer. 
Depending on the ionization technique and the employed setup the ion source either 
operates under vacuum or at atmospheric pressure. In a complex sample more than 
one analyte enter the mass analyzer simultaneously. Here they are separated 
according to their mass to charge ratio finally reaching the detector. 
 
 
4.1 MALDI as ionization technique for biopolymers 
 
Since the first publications of MALDI employed for protein ionization in 1988 by 
Karas, Hillenkamp [122] and Tanaka [123], it has become a widely spread technique for 
transferring large and non volatile molecules into the gaseous phase without 
fragmentation.  
The matrix employed in the MALDI process is usually a small organic molecule with 
the ability to absorb UV light. The matrix fulfills three tasks: it separates the sample 
molecules from each other, absorbs the laser energy partly (because otherwise the 
molecules would fragment immediately), and the third task of the matrix is to serve as 
a proton-acceptor or -donor to the analyte molecules for ionization.  
Analyte and matrix are separately dissolved in a suitable solvent like water, 
methanol, acetone, acetonitrile or a mixture of these for sample preparation. Then 
        Chapter I: Principles of chromatography- and mass spectrometry-based human brain proteomics 
   
34
both solutions are mixed to contain excess of matrix in the final solution (usually 
1,000:1 or higher [124]). Subsequently, both solutions are transferred to the surface of 
the sample carrier consisting mostly of stainless steel, but also gold or other metal 
surfaces are possible [125].  In Figure 10 the principle of MALDI is depicted 
schematically. 
 
TOF
+
+
++
+
laser-
beam
sample
molecules
sample
ions
matrix
molecules
matrix
ions
 
 
Figure 10.  Scheme of ion generation during MALDI process. 
 
After co-crystallization of matrix and analyte, a pulsed short wave laser shoots on the 
co-crystal whereas one shot lasts only few nano seconds. Its energy is sufficient to 
create analyte ions and transfer them into the gaseous phase. The whole ion-
generation process is very complex and yet not totally understood. It is suggested [92] 
that in the matrix molecules stored laser energy relaxes the solid state grid resulting 
in expansion of it. Before reaching a thermal equilibrium a phase transition takes 
place which resolves explosively a part of the solid state surface. In a specific range 
of laser fluence (106-107 W cm-2) [126] even large labile molecules, such as peptides 
and proteins, survive this process unfragmented. Most common applied UV lasers 
are nitrogen (337 nm) and Nd-YAG (266 nm or 355 nm) lasers. The fluence as well 
as the laser wavelength influence the analysis. The matrix absorbance should not 
overlap with the wave length of the laser. The mostly relevant matrices for proteomics 
and other fields in bioanalysis are listed in Table 7. 
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Table 7. Most common matrices suitable for MALDI. 
 
matrix abbreviation common applications structure 
α-cyano-4-
hydroxycinnamic 
acid 
HCCA peptides proteins 
 
sinapinic acid SA peptides proteins 
2,5-
dihydroxybenzoic 
acid 
2,5-DHB 
peptides 
phosphopeptides 
proteins 
carbohydrates 
glycolipids  
2-(4-hxdroxy-
phenyl azo)-
benzoic acid 
HABA proteins lipopolysaccharides
 
     
 
 
 
 
4.2 Mass analyzers 
 
4.2.1 Overview 
 
After generating an ion beam, the sample ions have to be separated which is realized 
in mass analyzers. A variety of them are available for bioanalytical research. A lot of 
different physical principles have been applied to construct mass analyzing systems. 
Some of them became very successful from the beginning of their existence, for 
others it took decades until their potential was recovered again. Although the perfect 
mass analyzer is exactly outlined [127], in spite of all recent improvements still none is 
ideal. However, very useful tools for structure determination, identification and 
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quantification of biological important substances, such as proteins, peptides, 
nucleotides and metabolites, are disposable today. The most common mass 
analyzers are listed in Table 8. 
 
Table 8. Common mass analyzers [128]. 
 
type acronym ion properties separation principle 
time of flight TOF time dispersion of a pulsed ion beam  time of flight 
magnetic 
sector B 
deflection of 
continuous ion beam 
momentum in magnetic field 
due to Lorentz force 
linear 
quadruplole Q 
continuous ion beam 
in linear radio 
frequency quadruple 
field 
stability of trajectories 
linear 
quadrupole 
ion trap 
LIT continuous ion beam and trapped ions 
storage and eventually 
separation in linear radio 
frequency quadrupole field due 
to stability of trajectories 
quadrupole 
ion trap QIT trapped ions 
in three-dimensional radio 
frequency quadrupole field due 
to stability of trajectories 
ion cyclotron 
resonance ICR trapped ions 
cyclotron frequency (Lorentz 
force) in magnetic field 
 
In the next paragraph, the time of flight mass analyzer will be described in detail 
because it is the applied system in the research of this thesis and very widespread in 
combination with ESI and MALDI ionization in bioanalysis. 
 
 
4.2.2 Time of flight mass analyzer 
 
Times of flight (TOF) instruments were first commercially available in the middle of 
the 1950s [129]. Due to poor performance they were soon pushed out of the market by 
linear quadruple analyzers. Their revival took until the late 1980s, when MALDI 
appeared as ionization technique for large biomolecules [130;131]. 
The basic principle of TOF-MS is the acceleration of analyte ions and subsequent 
drifting in a field free flight tube where they are separated according to their 
velocities. In the ion source all analyte ions are accelerated with the same kinetic 
energy. Based on their different masses however, the velocity of different ion species 
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will be diverse because the applied kinetic energy is equal for all ions and directly 
proportional to the mass and the velocity of an ion as revealed in Equation (12): 
 
Ekin = ½ mv 2 
          Equation (12) 
Ekin …… kinetic energy [m2 kg s-2] 
m ………mass of the analyte [kg] 
v ……….velocity of the analyte ion [m s-1] 
 
To yield the same kinetic energy, an accelerating voltage is applied to the analyte 
ions. Due to their different velocities this principle is used for determination of the 
mass-to-charge-ratio and in the end the mass of the analyte in a specific time domain 
and fixed flight path distance as shown in Equation (13): 
 
m/z =
2Ut2
D2   
          Equation (13) 
m/z……. mass-to-charge-ratio 
U ……… acceleration voltage [kV] 
t ……….. time of flight [s] 
D ………. flight path distance [m] 
 
ESI-TOF analyzers are very suitable for on-line hyphenation of nano-flow HPLC to 
mass spectrometry. Hyphenation of nano-flow HPLC to MALDI-TOF mass 
spectrometry however is normally realized in off-line mode caused by the need of co-
crystallization of the sample with the solid matrix.  
To reduce peak broadening and loss of resolution caused by initial time-, kinetic- 
energy- and space distribution effects, two strategies were developed. First, a so-
called reflector is installed at the end of the drifting path of the ions established by 
Mamyrin in 1994 [132]. The reflector consists of a series of metal rings or grids at rising 
potential, is located opposite the ion source and a voltage around 1.1 times higher 
than the ion source voltage is applied. Analyte ions penetrate the electric field of the 
reflector until their kinetic energy is reduced to zero and are then expelled in opposite 
direction. Ions of the same species subjected to time distribution effects in the ion 
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source can thus be focused. Summarized, three main factors support adoption of a 
reflector: 
 
1. substantially improved resolving power due to a longer flight path of the ions  
2. corrected time dispersion due to initial kinetic energy distribution of ions of the 
same mass 
3. neutral molecules are filtered out 
 
The reflector can be assembled in single-, two- and multiple-stage design. An 
additional detector is often installed behind the reflector, and by switching it on or off 
both a linear and a reflectron TOF can be realized in one instrument. The reflector 
process is schematically shown in Figure 11. 
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Figure 11. Principle of the reflector in TOF-MS.  
(a) Ion 1 and 2 possess the same mass and charge, but different velocities; (b) faster 
ions (ion 2) penetrate deeper in reflector field than slower ones (ion 1);  
(c) simultaneous arrival at the detector. 
 
The second strategy for sharpening ion distributions in the ion source was already 
introduced in 1955 - the time-lag focusing [133]. Caused by established patents every 
manufacturer has its own synonym for it: Time lag focusing (TLF, Micromass), 
Delayed extraction (DE, Applied Biosystems) and Pulsed ion extraction (PIE, Bruker 
Daltonik). However, the principle remains the same: A variable voltage plate is 
installed between the ion source and the entrance to the flight tube, as demonstrated 
in Figure 12 for a linear TOF (without reflector). When the sample is irradiated by the 
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short laser shot the created ions are not accelerated immediately but with a delay 
time of 100 to 500 ns [134]. During this time no voltage is applied to both sample plate 
and variable voltage plate. The ions spread out in the space between both plates 
according to their initial energy distribution as drafted in Figure 12a. Then voltage is 
switched on with a fast pulse at both plates but on the variable voltage plate only a 
percentage of the sample plate; in the example of Figure 12b 90 %. As a 
consequence, a voltage gradient is formed which accelerates slow ions more 
because they remain in the stronger voltage field. As a result, the initial energy 
distribution is adjusted and all ions of one species offering the same mass-to-charge 
ratio reach the detector to the same time (Figure 12c). With the next laser pulse the 
high voltage is switched off again and the cycle starts anew. This pulsed ion 
generation permits very fast data acquisition. 
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Figure 12. Time-lag focusing technique.  
(a) No electric field is applied, ions of same mass and charge with different velocities; 
(b) an electric field gradient is applied to focus ions of the same mass; (c) ions of the 
same species arrive the detector simultaneously after traveling the field free drifting 
zone. 
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4.2.3 Precursor selection and peptide fragmentation in a MALDI-TOF/TOF mass 
analyzer 
 
The pulsed laser shoots on the sample/matrix spots of the target which is situated in 
the ion source. Thereby, generated ions are focused with delayed extraction 
(paragraph 4.2.2) and accelerated for mass analysis. After traveling the field free 
drifting passage in the flight tube the ions reach the reflector (paragraph 4.2.2) where 
a further focusing follows decreasing the time- and energy haziness. Then the 
analyte ions are accelerated again and impinge onto the detector. There, the signal is 
amplified and converted into an electric current which can be observed with a PC-
based operating system. Now, the masses for fragmentation are chosen 
automatically by the software. A set number of precursors (e.g. five) are selected for 
one spot whereas the strongest signal is fragmented first (or last when selected). 
This does not mean that the five strongest signals of one spot are fragmented, but 
refers to the whole first analysis of intact peptide masses. When the highest peptide 
signal in one spot is not fragmented it is even stronger in another spot and there 
selected for fragmentation. In a second mass spectrometric run the precursors can 
be fragmented without using the CID chamber as post source dissociation (PSD) with 
subsequent acceleration [135] or by additional collision with gas molecules (CID). The 
metastable decomposition of the peptides takes place in the field free drifting 
passage they pass after the first acceleration. By then the precursor and fragment 
ions possess the same velocity because they were accelerated as one ion, and 
during the metastable decay process no decelerating effect occurred according to the 
vacuum applied in the flight tube. Therefore, they pass the timed ion selector (TIS) at 
the same time as illustrated in Figure 13. 
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Figure 13.  Schematic sketch of precursor passing controlled by the timed ion 
selector (TIS). (a) A selected precursor passes the TIS and (b) a non selected ion is 
deflected. 
 
The TIS lets only the selected precursor mass-to-charge-ratio (m/z) pass by including 
all fragment masses; here demonstrated with the black ion of a mass m2 with its 
symbolic fragments fx-z (Figure 13a). As the white ion with a mass m1 has a higher 
mass, it is slower than the black ones after acceleration with the same energy and 
deflected as shown in Figure 13b. Hence, the TIS has to be triggered with a start 
signal when the ions enter the field free drifting passage to let the selected precursor 
pass at exactly its arrival time at the TIS. This time is calculated by the software for 
each precursor ion.  
 
 
4.3 Detectors in mass spectrometry 
 
The last module of a mass spectrometer is devoted to ion detection and digitalization 
of the signals for computer processing. All currently employed detectors are 
secondary electron multipliers (SEM). 
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4.3.1 Overview of secondary electron multipliers 
 
An overview to the state of the art detectors for mass spectrometry is given in  
Table 9. All SEMs are working with the same principle: An ion impinges onto the 
metal or semiconductor surface of a dynode leading to the emission of secondary 
electrons.  An electrode is installed opposite of this dynode, holding a more positive 
potential. The emitted electrons are accelerated then and hit the opposite electrode, 
emitting in turn several electrons each. After passing 12-18 discrete dynodes an 
electric current is created large enough to be detected by a sensitive preamplifier. 
The SEMs have to be operated in vacuum due to air sensitivity of the emission layer 
and prevention of arcing caused by the high voltage applied. 
 
Table 9. Overview of SEMs as detectors in mass spectrometry. 
 
detector synonym acronym principle of operation 
discrete dynode 
electron multipliers - 
classic 
SEM 
arriving ions emit electrons from 
dynode surface which are amplified in 
a cascade 
channel electron 
multipliers channeltron CEM SEM in continuous tube 
microchannel 
plates 
multichannel plate, 
channel electron 
multiplier array 
MCP 
CEM in reduced size to µm-
diameters; bundled to millions of 
those tubes 
post-acceleration 
and conversion 
dynode 
- - 
acceleration prior to detector (10-30 
kV) to circumvent discrimination of 
slower ions 
focal plane 
detectors array detectors FPD 
ions arriving at focal plane on surface 
of MCP  are converted to electrons; 
on the backside of MCP electrons 
converted into photons by phosphor 
screen; light image guided onto photo 
array detector 
 
The microchannel plate detector is the most commonly employed detector in mass 
spectrometry and also integrated in the mass spectrometer used for this thesis. 
Therefore, it is described in the next paragraph. 
 
 
4.3.2 Microchannel plate detector 
 
In channeltron electron multiplier (CEM) detectors materials withstanding the high 
voltages around 2 kV are required. This is realized by an emissive layer of silicon 
dioxide. This coats a conductive layer of lead oxide on the supporting heavily lead-
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doped glass tube [136;137]. By reducing the size of a linear CEM to µm-diameters the 
cross section would be much too small to generate sufficient electric currents. 
Therefore, millions of these are bundled. Employing this array design an effective 
detector is created occupying as little space as possible _ the microchannel plate 
detector (MCP) which is displayed in Figure 14. The channel diameters ranging from 
8 to 25 µm with a length 40-80 times the diameter and the center-to center distance 
in the range from 6 to 32 µm [138]. A voltage of 1-2 kV is applied. The amplification of 
the electrons can reach up to 105 [139]. 
 
1-2 kV
electrons
 
 
Figure 14. Microchannel plate detector [140]. 
 
In MCP detectors slow ions are discriminated. They are not arriving at the detector 
because a threshold energy density is required for electron emission. To gain higher 
sensitivity a conversion dynode is installed prior to the detector. These are rugged 
electrodes set on high voltages (5-20 kV) of opposite polarity of the ions leaving the 
mass analyzer. Furthermore, this dynode removes photons and neutral particles from 
the ion current when not installed in-line.  
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5 Two-dimensional HPLC-MS for proteome analyses 
 
5.1 Overview of chromatographic mode combinations 
 
Due to the enormous complexity of biological samples especially in proteome 
research, 1D chromatographic approaches are not sufficient to achieve the 
demanded resolving power and removing of matrix effects. To optimize selectivity 
and separation efficiency comprehensive 2D-chromatography was advocated. Here, 
two columns supporting different chromatographic modes are hyphenated on-line. 
Another opportunity is the so-called heart-cutting mode where only selected fractions 
obtained from the first dimension are transferred on-line into the second  
dimension [141]. Off-line coupling is also possible, providing the advantage of storing 
the fractions obtained from the first dimension. Furthermore, multiplex analyses of 
them by only one sample injection into the first dimension are possible. There are 
several criteria which ideally should be fulfilled in a truly comprehensive 2D HPLC 
system [142;143]. The first criterion, also called the orthogonal criterion, implies the 
separation of the substances with two different separation mechanisms. This is 
realized either by two different stationary phases or by changing the mobile phase. 
As second point, all analytes have to pass both dimensions at equal percentages 
(100 % or less) and finally reach the detector. This is only relevant for on-line and 
heart-cutting mode where a split ratio has to be defined. The last criterion is the 
maintenance of separation resolution, or at least the resolution reduction should not 
exceed 10 %. However, in most current applications, the sampling rate is not as high 
as recommended because the more fractions collected in the first dimension the 
higher becomes the time-consumption of the total 2D analysis. 
The possibilities of 2D HPLC setups are multifarious. A selection of common 
combinations is listed in Table 10.  
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Table 10. Common combinations of chromatographic modes in 2D HPLC and 
selected applications. 
 
first dimension 
chromatography 
mode 
second dimension 
chromatography 
mode 
analytes Example(s) of application 
change of stationary phase 
IEX-HPLC (IP)-RP-HPLC peptides proteome of S. cerevisiae
 [144]; 
proteome of M. xanthus [145] 
AC (IP)-RP-HPLC peptides human plasma/serum [146] 
IMAC (IP)-RP-HPLC peptides phosphopeptides [147;148] 
SEC (IP)-RP-HPLC proteins, peptides 
proteome of E. Coli [149]; 
human serum [150] 
HILIC (IP)-RP-HPLC peptides murine erythroleukemia (MEL) cells [151] 
change of mobile phase 
RP-HPLC (IP)-RP-HPLC peptides proteome of C. glutamicum [152] 
 
As detector for identification of peptides a mass spectrometer is usually employed 
providing excellent selectivity, resolution and sensitivity, but no efficient separation. 
This is why a 2D HPLC system has to be installed prior to mass spectrometric 
sample analysis. 
 
 
5.2 Nano-flow HPLC-MALDI-MS as platform for proteome research 
 
The development of efficient TOF mass spectrometers with the capability of 
precursor fragmentation at the beginning of this century [153-155] made MALDI-MS 
appealing for proteome analysis. As alternative to nano-flow HPLC-ESI-MS, methods 
were introduced employing nano-flow HPLC-MALDI-MS. Although the mixing of a 
matrix and subsequent sample/matrix co-crystallization hampers an on-line 
hyphenation to mass spectrometry both, on-line and off-line approaches were 
developed.  
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5.2.1 Interfaces for nano-flow HPLC-MALDI mass spectrometry 
 
The simplest and most straightforward method for off-line HPLC-MALDI mass 
spectrometry is the collection of a series of individual spots directly onto the MALDI 
target [156]. A heated droplet interface was introduced [157] where the MALDI target as 
well as the HPLC effluent transfer tubes are heated. The droplets are hanging at the 
outlet of the transfer tube and as much of the carrier solvent as possible is 
evaporated without spraying. The temperature of the MALDI plate is adjusted above 
the boiling point of the least volatile solvent. When the droplet lands on the plate, the 
remaining carrier solvent is evaporated immediately, depositing the analyte/matrix 
spot in a small area of the MALDI target. Miliotis et al. introduced a method for 
spotting the HPLC effluent employing a piezoelectric flow-through micro- 
dispenser [158]. By applying a short voltage pulse at a frequency of 15 Hz, pressure 
pulses are generated that eject 60-nL droplets onto the target. This is entirely 
precoated by air-brushing with a matrix (α-cyano-4-hydroxycinnamic acid)/ 
nitrocellulose layer. On the contrary to discrete spot generation continuous sample 
deposition is  
described [159;160]. Here, the target is precoated with matrix and the analytes eluting 
off the HPLC system are deposited onto a track on the MALDI target. The continuous 
deposited tracks preserve chromatographic integrity. Resolution and sensitivity are 
determined by the drive speed. 
Another approach applies electrospray for deposition of the sample/matrix mixture 
onto the target [161;162]. The advantage of this method is the fast solvent evaporation 
and more homogeneous sample/matrix co-crystal due to small droplets generated by 
electrospray. However, the electrospray is distributed over a relatively broad circular 
area (approximately 2.5 cm). An approach also based on electrical fields was 
developed by Ericson et al. [163]. The end tip of the capillary separation column is fixed 
in a capillary clamp which is installed 2-5 mm above the MALDI target. Here, an 
electrically grounded droplet is generated by the sample/matrix solution. Then a short 
(20 ms) negative voltage impulse (-2 kV) is applied to the target stage. This polarizes 
the droplet which is then forced towards the target surface by the electrical field. 
Electrospray deposition in this approach is prevented by applying relatively low 
electrical field strength at the droplet surface and the pulsed nature of the applied 
voltage. Therefore, the sample/matrix mixture is concentrated in discrete spots. 
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In the previously presented interfaces the analyte/matrix deposition is operated off-
line to the mass spectrometric analysis. Also on-line approaches were reported. 
The rotating ball inlet (ROBIN) was used for on-line MALDI MS [164]. Here, a stainless 
steel ball (10 mm diameter) is installed in the MS vacuum chamber and is rotated by 
a drive shaft connected to a gear motor which is positioned outside the vacuum 
chamber. The sample/matrix solution is delivered from the end of a capillary to the 
ball surface. The ball rotates past a polymer gasket and the volatile solvents are 
evaporated into the vacuum region. The laser ablates the sample directly from the 
ball surface. However, this approach is limited in terms of resolution due to the 
relatively high pressure (5 x 10-5 torr) and nonparallel fields in the MALDI ion source. 
Furthermore, signal intensities are influenced by irregularities in the ball surface. 
A MALDI-MS interface especially used for on-line coupling with capillary 
electrophoresis (CE) was developed by Karger et al. [165]. In principle, the 
sample/matrix mixture is deposited onto a rotating quartz wheel and then transferred 
to the repeller, where the MALDI process takes place. 
Today, the collection of discrete spots and subsequent off-line transfer to the mass 
spectrometer is the most employed interface in terms of nano-flow HPLC-MALDI- 
MS [166]. Automatic spotting units are commercially available while no on-line spotting 
approach is commercialized today. 
 
 
5.2.2 Proteomes analyzed by 2D-HPLC-MALDI tandem mass spectrometry 
 
The most approaches applying MALDI mass spectrometry are gel-based [167] 
according to low volumes necessary for sample preparation (usually 0.5 µL of sample 
solution) and higher salt tolerance than required for ESI mass spectrometry. 
However, in the last decade gel-free nano-flow HPLC-MALDI-MS methods also 
became relevant with emerging of mass spectrometers capable of tandem MS 
experiments. In the following table, proteome analysis based on chromatography and 
MALDI mass spectrometry are summarized in the order they were published divided 
into human, non-human and quantitative analysis. 
All of these studies were realized employing bottom-up proteomics. This means, prior 
to separation all extracted proteins were enzymatically digested and separation was 
performed exclusively at peptide level. 
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Table 11. Proteome analysis employing chromatography and MALDI mass 
spectrometry (PSD = post source decay, CID = collision induced fragmentation,  
ICAT = cleavable isotope-coded affinity tag, iTRAQ = isobaric tag for relative and 
absolute quantitation). 
 
species material aim of the work HPLC-MALDI setup 
number of 
ident. 
proteins 
reference 
non-human 
neat 
mito-
chondrial 
ribo-somes 
protein 
identification 
from the large, 
39s subunit of 
bovine mito-
chondrial 
ribosomes  
discrete spot 
collection, 
C18 precolumn: 
1.0 x 0.3 mm i.d. 
 3 µm particle size 
C18 separation 
column:  
150 x 0.18 mm i.d. 
 3 µm particle size 
Quadrupole/ 
TOF (CID) 
43 
Bodnar et al. 
J. Am. Soc. 
Mass 
Spectrom. 
2003 
14, 971-9 
Saccharo-
myces 
cerevisiae 
(yeast) 
strain YP 
H499 
extract 
maximum 
amount of 
information 
from HPLC-
MALDI_MS 
experiments 
 
discrete spot 
collection, 
C18 precolumn: 
1.0 x 0.3 mm i.d. 
 3 µm particle size 
C18 separation 
column:  
150 x 0.075 mm i.d. 
 3 µm particle size 
TOF/TOF (CID) 
271 
(at least 
two 
peptides 
per protein) 
Karger et al. 
Anal. Chem. 
2004 
76, 6017-28 
Escherichi
a coli 
strain 
HM22 
optimization of 
precursor 
exclusion list 
strategy 
discrete spot 
collection, 
C18 separation 
column: 
150 x 0.1 mm 
5 µm particle size 
TOF/TOF (CID) 
 
362 
Karger et al. 
Anal. Chem. 
2005 
77, 7816-25 
 
Coryne-
bacterium 
glutamicum 
whole cell 
lysate 
large-scale 
proteome 
analysis 
discrete spot 
collection, 
monolithic precolumn 
(PS-DVB-based): 
10 x 0.2 mm i.d. 
Monolithic separation 
column: 
60 x 0.1 mm i.d. 
TOF/TOF (CID) 
1,208  
(at least 
two 
peptides 
per protein) 
Lasaosa et 
al. 
Anal. 
Bioanal. 
Chem. 
2008 
submitted 
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Table 11 - continued 
species material aim of the work HPLC-MALDI setup  
number of 
ident. 
proteins 
reference 
human 
human  tears 
combination 
of several 
proteome 
analysis 
techniqes 
heated droplet 
interface, 
C18 separation column: 
150 x 1.0 mm i.d. 
Quadrupole/ (CID) 
TOF 
44 
(HPLC-
MALDI-
MS) 
Li et al. 
J. Proteome 
Res. 
2005 
4, 6, 2052-61 
human  
multi-
potent 
adult pro-
genitor 
cells from 
bone 
marrow 
four stage 
HPLC 
selection of 
methionyl 
peptides for 
peptide 
centric 
proteome-
analysis 
discrete spot collection, 
C18 precolumn:  
5.0 x 0.3 mm i.d.  
C18 separation column:  
 3 µm particle size 
10 0x 0.15 mm i.d. 
TOF/TOF (PSD) 
2,151 
Gevaert et al. 
J.Proteome 
Res. 
2006 
5, 1415-28 
human  liver tissue 
capillary 
array (18 
channels) 
RP-HPLC 
MALDI-MS 
for high 
throughput 
proteome 
analysis 
discrete spot collection, 
precolumn:  
silica-based monolith  
5.0 x 0.32 mm i.d. 
C18 separation column: 
5 µm particles,   
250 and 320 µm i.d. 
TOF/TOF (CID) 
462 
Zhang et al. 
J. Proteome 
Res. 
2006 
5, 3186-96 
quantitative 
Saccharo-
myces 
cerevisiae 
(yeast) 
two strains: 
HFY1200 
and 
HFY871 
quanti-
fication 
strategy 
employing 
ICAT 
discrete spot collection, 
C18 precolumn: 
 3 µm particle size, 
5.0 x 0.3 mm i.d. 
C18 seperation column: 
 3 µm particle size 
150 x 0.1 mm i.d. 
TOF/TOF (CID) 
quantifi-
cation of 
700 
proteins 
Parker et al. 
Mol. Cell. 
Proteomics 
2004 
3, 625-59 
human 
serum and 
plasma 
samples 
relative 
quantitation 
in large-scale 
proteomics 
without 
isotope 
tagging 
reagents 
discrete spot collection, 
C18 precolumn: 
 3 µm particle size, 
5.0 x 0.3 mm i.d. 
C18 seperation column: 
3 µm particle size 
150 x 0.1 mm i.d. 
TOF/TOF (CID) 
126 
Hattan and 
Parker 
Anal. Chem. 
2006 
78, 7986-96 
mouse 
hippo-
campal 
synapses 
of brain 
optimization 
of an iTRAQ- 
based 
labeling 
technique for 
quantify-
cation of 
membrane 
proteins 
discrete spot collection, 
C18 precolumn: 
1.0 x 0.3 mm i.d. 
 3 µm particle size 
C18 separation column:  
150 x 0.1 mm i.d. 
 3 µm particle size 
TOF/TOF (CID) 
1,122  
(at least 
three 
peptides 
per protein) 
Li et al. 
J. Proteome 
Res. 
2007 
6, 3127-33 
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Table 11 – continued 
species material aim of the work HPLC-MALDI setup  
number of 
ident. 
proteins 
reference 
human  
cerebro-
spinal 
liquid 
quantitative 
proteomics 
with the use 
of isotopic-
labeled 
synthetic 
peptides as 
reference 
discrete spot collection, 
precolumn, 
C18 separation column:  
 3 µm particle size 
150 x 0.1 mm i.d. 
TOF/TOF (CID) 
absolute 
quantitation 
of 5 
peptides 
from 5 
proteins 
Zhang et al. 
J. Proteome 
Res. 
2008 
7, 720-30 
 
No comprehensive proteome study for Glioblastoma multiforme based on 
chromatography and mass spectrometry was accomplished so far. The highest 
number of identified proteins (2,151) was reported by Gevaert and colleagues. 
However, it is mostly difficult to find out the validation procedure for the identified 
proteins, especially in older publications. 
 
 
5.3 Software tools for result generation, validation and interpretation  
 
To cope with the enormous complexity of datasets, computer-based methods for 
handling them are essentially.  
For in silica digest and comparison with experimentally gained mass spectrometric 
data, several search engines are available on-line. The most prominent are listed in 
Table 12. 
 
Table 12. On-line available search engines for protein identification. 
 
search engine location 
Mascot http://www.matrixscience.com 
Protein Prospector http://prospector.ucsf.edu/ 
Profound http://prowl.rockefeller.edu/prowl-cgi/profound.exe 
OMSSA http://pubchem.ncbi.nlm.nih.gov/omssa/omssacgi.cgi?searchsettings=etd.xml 
 
For obtaining a correct search result the treatment of the protein sample has to be 
known to set parameters in the identification software such as the employed enzyme 
for digestion as well as fixed- and variable modifications. 
        Chapter I: Principles of chromatography- and mass spectrometry-based human brain proteomics 
   
51
The obtained list of protein hits then has to be validated with suitable software. 
Subsequently, the confirmed proteins have to be put in biological context employing 
appropriate software tools again. 
 
 
5.3.1 Peptide fragmentation 
 
As basis for search engines the peptide fragmentation rules have to be known. Most 
mass analyzers today are equipped with the opportunity of tandem mass 
spectrometric (MS/MS) experiments where a selected analyte ion is fragmented after 
detection of the intact (precursor) ion mass-to-charge ratio. To identify peptides not 
only with the help of their intact masses, but also determining the primary structure of 
them, fragmentation is necessary. The intact peptide mass is not a unique property 
for a peptide. In order to identify peptides confidently on the basis of their amino acid 
sequence, peptides are subjected to sequence-specific fragmentation reactions. The 
most commonly applied technique is the so-called collision induced dissociation 
(CID) or collisionally activated dissociation (CAD), respectively. Hereby, the peptide 
ions are transferred into a collision chamber where gas molecules such as air, 
helium, or argon are present. These molecules collide with the peptide ions and 
induce translational energy conversion to oscillation energy of the peptide ions  [168]. 
This process leads to structure specific fragmentation. Especially the peptide bonds 
(= peptide backbone) along the sequence are susceptible to such fragmentations. 
Three typical cleavage sites are observed for peptides: 
 
1. cleavage prior to peptide bond: a- and x-ions are created 
2. cleavage past peptide bond: c- and z-ions are created 
3. cleavage of peptide bond: b- and y-ions are created 
 
By the cleavage of one peptide ion two fragments emerge. If the peptide charge 
remains at the N-terminus a-, b- and c-ion series are created and for remaining at the 
C-terminus x-, y- and z-ion series, respectively. This scheme is depicted in Figure 15. 
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Figure 15. Nomenclature for peptide fragmentation sites introduced by Roepstorff 
and Fohlman [169]. 
 
The knowledge of defined fragment patterns in peptide dissociation permits the 
assignment of the amino acid sequence to the peptide and further the protein. This is 
exploited in bioinformatic algorithms for peptide- and protein identification in mass 
spectrometry-based proteomics. 
 
 
5.3.2 Mascot search engine 
 
The most prominent search engine beside SEQUEST is the Mascot software. 
Proteins are identified by comparing experimental obtained peptide fragment mass 
spectra with in silico generated ones from protein sequences stored in a database. 
The so-called MOWSE Score (molecular weight search) is generated by a 
probability-based implementation of the MOWSE algorithm [170] in the Mascot 
software. Here, the probability for an assigned hit to be a random event is computed. 
The lower this probability, the better is the identification quality. Because this is quite 
confusing the scores are reported as -10 x log10 (P). The higher these scores the 
lower is the probability of a false assigned hit and as a consequence the higher is the 
probability of correct peptide and protein identification. 
For a small number of peptide queries the protein MOWSE Score consists of the sum 
of the ion scores of unique peptides achieved for an individual protein. To reduce the 
weight of low-scoring random hits, a slight correction is applied. This is a function of 
        Chapter I: Principles of chromatography- and mass spectrometry-based human brain proteomics 
   
53
the total number of hits for a protein and the width of the set peptide tolerance 
window [171]. Usually this correction is very small.  
 
 
5.3.3 Scaffold Proteome software 
 
For result validation, Scaffold proteome software was developed using statistical 
algorithms evolved in the Institute for Systems Biology (Seattle, WA, USA). These 
algorithms are implemented in software known as Peptide- and Protein Prophet. In 
Scaffold these algorithms are implemented independently.  
Mascot offers probability estimation with respect to the database size and not on 
sample characteristics. As Scaffold involves the sample specific distribution by 
creating discriminant scores for peptides, it provides a more real estimation of correct 
hit probabilities [172].  
This software uses Mascot “.dat” files for further processing. The X!tandem search 
engine can be browsed additionally to Mascot, and Peptide- and Protein Prophet are 
used for validation. Peptide identifications are accepted if they could be established at 
higher than 95 % probability as specified by the Peptide Prophet algorithm [173]. This 
algorithm first creates a discriminant score for all peptides which is independent of the 
used search engine. Then Bayesian statistics is applied to calculate that the 
identification is correct or incorrect. Protein identifications are accepted if they could 
be established at higher than 99 % probability and contained at least two identified 
peptides. Protein probabilities are assigned by the Protein Prophet algorithm [174]. The 
final protein identifications are less than the Mascot identification hits, because only 
the minimum list of proteins adequate to explain the peptide imputations using the 
expectation-maximization algorithm is gained with Scaffold.  
The number of peptide mass spectra observed is referred to as spectrum count [40]. 
The spectrum count can be used for relative protein quantification of two samples in 
comparison or for an estimation of protein abundance in one sample.  
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5.3.4 Gene ontology-based interpretation software 
 
The gene ontology project (GO) [175] makes controlled vocabulary for the description of 
gene and gene product attributes of any organism available. Three ontologies are 
distinguished, each providing a key concept of molecular biology: molecular function, 
biological process the genes or gen products are involved in, and their localization to 
cellular components. To categorize the identified proteins to gene ontologies 
GeneTrail software (http://genetrail.bioinf.uni-sb.de) can be employed. The gene 
products can be active in more than one cellular component as well as in more 
biological processes and molecular functions. Cellular components describe the 
locations where the gene products are situated. These can be subcellular structures 
and macromolecular complexes. Biological processes represent sequences of events 
or molecular functions of the gene products like metabolic processes, but no 
pathways. By matching a molecular function the activity of a gene product is meant at 
molecular level, such as enzyme activities. 
PANTHER (protein analysis through evolutionary relationships) [176] is a classification 
system based on gene functions as well as GeneTrail (www.pantherdb.org). This 
software uses the terms biological process and molecular function similar to the GO, 
but much simplified to allow high throughput analysis.  
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6 Brain tumors 
 
6.1 Overview of brain tumors 
 
Tumors arise when oncogenes become activated and tumor suppressor genes 
inactivated within neoplastic cells. The factors and mechanisms leading to such 
regulation are rarely understood and purpose of intense research today. Brain tumors 
are intracranial tumors evolving either in the brain itself (primary) or spread from 
other tissues (secondary). Affected areas of the brain can be the cranial nerves, the 
brain envelope, skull, pituitary and pineal gland and brain cells itself, such as 
neurons, glial cells (astrocytes, oligodendrocytes and epidymal cells), lymphatic 
tissue and blood vessels. In Germany, every year 436,000 new patients suffer from 
cancer, and 211,500 are going to die each year [177]. In 2006 a percentage of 3.2 % of 
the male and 3.4 % of the female cancer patients died of brain tumors [178]. In the 
United States, specific cancer statistics are published regularly. In 2008 [179], the 
number of new cancer cases in the United States is estimated to 1.44 million 
whereas 21,810 (1.5 %) of them are going to be brain tumors; 13,070 patients of 
them are evaluated to die. The five-year survival rate increased from 24 % to 35 % 
since 1977 for brain tumors, in general.  
Subsequently, the most frequently appearing brain tumors are briefly summarized. To 
get a glimpse of their location the human brain assembly is depicted in Figure 16. 
 
 
 
Figure 16. Side view of the human brain [180]. 
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6.1.1 Primary brain tumors 
 
The primary brain tumors in principle can appear in the entire brain. Most commonly, 
they are distinguished due to their origin cells, from which they developed as listed in 
Table 13. The widespread classification system of grade I-IV was defined by the 
World Health Organization (WHO) [181].  
 
Table 13. Overview of primary brain tumors. 
 
tumor WHO-grades appearing 
astrocytic I-IV 
ologiodendroglial II+III 
oligoastrocytic II+III 
epidymal I-III 
choroid plexus I-III 
other neuroepithelial I+II 
neuronal and mixed neuronal-glial I-III 
pineal  I-IV 
embryonal IV 
cranial and paraspinal nerves I-IV 
meningeal I-III 
sellar region I 
tumor grade description 
I 
least malignant, 
slowly growing, microscopically almost normal 
appearance 
II 
slightly faster growing and abnormal 
microscopic appearance, may recur as grade 
III or IV tumor 
III 
malignant, 
actively reproducing abnormal cells, invade 
surrounding normal tissue, recur frequently, 
often as  grade IV 
IV 
most malignant, 
invade wide areas of surrounding tissue, 
reproduce rapidly, necrotic in center  
 
Other distinction criterions often applied are the location in the brain where the tumor 
appears or the differentiation of benign and malign tumors.  
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6.1.2 Secondary brain tumors 
 
Malignant tumor cells are able to spread across the entire body with the bloodstream 
or lymphatic system and form secondary tumors (metastasis). Their incident in brain 
tumors is higher than for primary ones. The most frequently tumor afflicted origin 
organs are kidney, lung, skin (melanoma, other skin tumors scarcely metastasize), 
breast and colon. The cells in the secondary tumor are very similar to those in the 
origin tumor. Therefore, the cell type can be examined microscopically for 
identification of the origin tissue. However, in some cases the primary tumor remains 
unidentified.  
 
 
6.2 Diagnosis, therapy and prognosis 
 
A lot of unspecific symptoms like headache, seizures, gastrointestinal symptoms and 
even strokes appear with the occurrence of brain tumors.  Depending on the location 
in the brain, different symptomatic manifestations can be observed as indicated in 
Table 14. 
 
Table 14. Symptomatic of brain tumors referring to their local occurrence [182]. 
 
tumor location symptoms 
cerebrum 
frontal lobe dementia, personality changes, gait disturbances, generalized or focal seizures, expressive aphasia (loss of speech) 
parietal lobe receptive aphasia, sensory loss, hemianopsia (bisection of visual field), spatial disorientation 
temporal lobe complex partial or generalized seizures, quadrantanopsia (loss of one quarter of the visual field), behavioral alterations 
occipital lobe contralateral hemianopsia 
others 
thalamus contralateral sensory loss, behavioral changes, language disorder 
cerebellum 
ataxia (motion disorder), dysmetria (disorder of haphazard 
trajectories), nystagmus (irrepressible rhythmic motion of 
muscles, mostly ocular muscle) 
brain stem 
cranial nerve dysfunction, ataxia, papillary abnormalities, 
nystagmus, hemiparesis (partial paralysis of one side of the 
body), autonomic dysfunction 
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First parts of the diagnosis are common checks of vision, hearing, balance, 
coordination and reflexes. Remains the suspicion of brain cancer, one or a 
combination of the following methods has to be applied: 
 
• Computerized tomography (CT) scan: Here, detailed two-dimensional 
images of the brain are taken using X-rays. A special dye can be injected to 
visualize the brain tumor. This method usually lasts less than ten minutes. 
• Magnetic resonance imaging (MRI) scan: Magnetic fields and radio waves 
are applied for brain image acquisition. A special dye to distinguish tumor and 
healthy cells can be injected into the bloodstream. This procedure can last 
between fifteen minutes and an hour. 
• Angiogram: Here, a special dye is injected into the bloodstream which can be 
observed with X-ray radiography. Blood vessels in and around the tumor are 
visualized. 
• X-ray radiography of head and skull: With this test, bone alterations which 
can be associated with brain tumors are identified. However, this test is not as 
sensitive as a brain imaging. 
• Other brain scans: Tests like single-photon emission computerized 
tomography (SPECT), magnetic resonance spectroscopy (MRS) and positron 
emission tomography (PET) can be applied to observe brain activity, such as 
metabolism, chemistry and blood flow within the brain. Often they are used in 
combination with MRI for further analysis of the tumor but not for initial 
diagnosis. 
 
The therapy of brain cancers depends on the age and overall health situation of the 
patient as well as location, size and grade of the tumor. When the tumor is 
accessible, surgery is one common treatment. Hereby, the strategy includes the 
attempt to remove carefully as much as possible of the tumor tissue and as little as 
necessary of healthy tissue. Some tumors can be removed totally, others only partly. 
Secondary therapy strategy is high energy radiation to destroy the tumor cells. Last 
of the three main treatments is chemotherapy where drugs are introduced orally or 
intravenously into the body, helping to kill cancer cells. Mostly, all of these strategies 
are adopted in combination. Once vanquished, a brain tumor can recur any time 
when just a few cells have survived the initial treatment. 
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Prognosis of survival depends of numerous patient-specific details, such as type of 
the tumor, extent of surgical tumor removement and age of the patient, for  
instance [183]. An average survival time dependent on patient’s age is published by 
the central brain tumor registry of the United States (CBTRUS) [184]. This study is 
based on data from 1973 to 2004 shown in Table 15. As expected, the chances of 
five-year survival drop with rising age. 
 
Table 15. Average five-year survival rates of primary brain tumors. 
 
age at diagnosis percentage of five-year survival [%] 
0-19 66.0 
20-44 49.2 
45-54 24.0 
55-64 11.1 
65-74 6.7 
75 or older 4.7 
 
However, not only the age is important for prognosis. The kind and grade of brain 
tumor are also pivotal. For type II tumors a surviving over five years is common 
whereas for grade III tumors usually two to three years are predicted [185]. Prognosis 
of grade IV patients depends on the specific tumor properties. For instance, 
cerebellar medulloblastomas as grade IV tumors are expeditiously fatal if not 
immediately treated, but with an appropriate radiation and chemotherapy the five-
year survival chance can exceed 60 %.   
 
 
6.3 Glioblastoma multiforme 
 
The most aggressive and most common primary brain tumor is Glioblastoma 
multiforme (GBM). This tumor occurs in 52 % of all primary brain tumors and 20 % of 
total intracranial tumors [185]. After its appearance, it rapidly infiltrates other parts of 
the brain resulting in difficult treatment. In men it is more often diagnosed than in  
women [186] with an average age of 55. This grade IV astrocytoma often appears 
abruptly and sporadic without any genetic disposition. No associations could be 
verified for Glioblastoma multiforme and smoking, diet, cellular phones, 
electromagnetic fields or viral infection [187-192]. The average survival time of these 
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thuggish tumors is less then 16 months with an estimated five-year survival rate of  
5 % [193]. An image of a Glioblastoma multiforme in a patient’s brain is shown in 
Figure 17. 
 
 
 
Figure 17. Image of Glioblastoma multiforme in a patient's brain. 
 
 
6.4 Human brain proteomics-where are we standing? 
 
In the last two decades numerous reports of proteomic research with efforts on brain 
and brain diseases were published. Especially the comparison between the healthy 
and the diseased brain is challenging because healthy brain tissue samples are very 
rarely available. Non tumor tissue is often yielded at epilepsy brain surgeries.  
Furthermore, the investigation of the fetal brain is very promising to get information 
about the development of the very complex composition and function of the human 
brain. In 1991, the HUPO Brain Proteome Project (BPP) was launched to achieve a 
deeper understanding of the healthy and diseased brain. The following selection of 
brain proteomic studies listed in Table 16 should give a short overview of studies 
focused on the human brain proteome in healthy and tumor affected tissue. 
Identification of proteins in all studies was performed with mass spectrometry. All 
projects involved in the HUPO Brain Proteome Project are marked with BPP. The 
content of Table 16 is classified into the tissue origin of the tumor or normal tissue. All 
studies implied exclusively brain or brain tumor tissue, no cell line studies are 
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considered.  The rare application of 2D HPLC-MS is noticeable; almost all studies 
were accomplished adopting 2D-GE. A method for relative quantification of proteins 
in the 2D-GE is named DIGE (differential gel electrophoresis). Two polyacrylamide 
gels with two different sample states (for instance tumor and normal tissue) are 
generated, and both are treated with a different dye. The proteins expressed only in 
one stage will appear in one of both dyes clearly whereas proteins occurring in both 
states emerge as mixture of both dyes. This way the differential expression of 
proteins can be observed. 
  
Table 16. Overview of the recent brain proteome studies. 
 
analysis 
method material 
biopsy 
(b) or  
autopsy 
(a) 
aims results reference 
normal fetal brain 
2D-GE  
cerebellum of 
human fetal brain 
of aborted fetuses 
in the early second 
trimester (18.2 ± 
2.2 weeks) 
a 
comprehensive 
information of  
early neuronal 
processes 
437 proteins 
identified, 
assembly of 
fetal brain 
database  
Fountoulakis et 
al. 
Proteomics 
2002, 2, 1547-
76 
2D-GE  
whole brain of 
human fetal brain 
of aborted fetuses 
in the early second 
trimester (18.2 ± 
2.2 weeks 
a 
updating the map 
of fetal brain 
proteins 
identification 
of 543 
proteins, 314 
of them never 
found before 
in fetal brain 
Shin et al. 
Electrophoresis 
2005,26, 2759-
78 
children brain tumor tissue 
DIGE  
pediatric primitive 
neuroectodermal 
tumors (PNET) and 
ependymoma 
tissue 
b 
identification of 
biomarkers for 
PNET and 
ependymomas 
biomarker for 
PNET: 
stathmin, for 
ependymoma
s: annexin A1 
and 
calcyphosine  
De Bont et al. 
J. Neuropathol. 
Exp. Neurol. 
2007, 66, 505-
16 
normal adult brain 
MUDPIT 
enriched nuclear 
extracts of eight 
human key tissues: 
brain, heart, liver, 
lung, muscle, 
pancreas, spleen, 
testis 
a+b 
access level of 
proteome 
diversity in 
different tissues 
most proteins 
are detected 
in single 
tissue 
Cagney et al. J. 
proteome Res. 
2005, 4, 1757-
67 
2D HPLC  
a: prostate cancer, 
no signs of 
neurodegeneration, 
b: epilepsy surgery 
Both: superior 
temporal gyrus 
(temporal lobe of 
cerebrum) 
 
a+b 
protein 
identification 
using shotgun 
approach 
identification 
of 209 
proteins 
Dumont et al. 
Proteomics 
2006, 6, 4967-
77 
 
(BPP) 
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Table 16 - continued 
analysis 
method material 
biopsy 
(b) or  
autopsy 
(a) 
aims results reference 
2D-GE 
cerebrum temporal 
lobe tissue from 
non tumor patients, 
b: epilepsy patient 
a: no 
neurodegenerative 
disease 
a+b 
understand 
function of 
central nerve 
system in 
normal and 
pathologic state
267 proteins 
identified, 6 down 
and 23 up 
regulated in 
autopsy sample 
He et al. 
Proteomics, 
2006, 6, 4987-
96  
 
(BPP) 
2D-GE  
white matter of 
human brain 
(frontal parietal, 
temporal, occipital 
lobe of cerebrum), 
no neurodegener-
ation 
a 
protein 
expression 
profile analysis 
identification of 
64 proteins for 
initial reference 
map and 
database for 
proteins of white 
matter 
Mucelli et al. J. 
Chromatogr. B 
2006, 833, 80-
90 
2D-GE 
MS/ 2D 
HPLC  
brain tissue a+b 
putting results 
of initial BPP in 
biological 
context 
identification of 
1,804 human 
brain proteins 
and their 
biological impact 
Müller et al. or 
rather 
Reidegeld et al. 
Proteomics 
2006,6, 5059-
75 and 4997-
5014, 
respectively 
  
(BPP) 
1D GE 
with prior 
functional 
fractio-
nation 
temporal lobe of 
cerebrum 
fractionation in 
cyto- and 
nucleoplastic, 
membrane and 
other structural and 
DNA-binding 
proteins 
b 
identify as 
much as 
possible 
proteins from 
hum an brain 
1,553 proteins 
identified 
Park et al. 
Proteomics 
2006, 6 4978-
86 
 
(BPP) 
1D GE 
micro-
HPLC 
neuromelanin 
(NM)granules, no 
disease referring to 
brain 
a 
Isolate intact 
highly pure NM 
granules from 
human 
substantia 
nigra for 
subcellular 
proteomics 
72 proteins 
identified for 
insight in NM 
granule building 
processes 
Tribl et al. Mol. 
& Cell. 
Proteomics 
2005, 4, 945-57 
2D-GE 
hippocampus 
tissue (part of 
cerebrum), no 
disease referring to 
brain 
a 
protein map for 
hippocampus 
proteins 
165 proteins 
identified 
Yang et al. 
Electrophoresis 
2004, 25, 1169-
74 
tumor adult brain 
2D-GE  
fibrillary 
astrocytoma  
(grade II) and 
Glioblastoma 
multiforme (grade 
IV) 
b 
comparison of 
protein pattern 
between low- 
and high-grade 
astrocytomas 
few differences 
reproducibly 
observable, initial 
reference map for 
astrocytomas 
Odreman et 
al.J. Proteome 
Res. 2005, 4, 
698-708 
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Table 16 - continued 
analysis 
method material 
biopsy 
(b) or  
autopsy 
(a) 
aims results reference 
capillary 
isoelectr. 
focusing 
(CIEF) 
nano-
flow-
HPLC 
Glioblastoma 
multiforme b 
comparison 
CIEF/SCX as 
first dimension 
1,820 proteins 
identified, CIEF 
less fraction-to-
fraction peptide 
carry over than 
SCX (10-15 % 
and 40-80 %, 
respectively) 
Wang et al. 
Anal. Chem. 
2005, 77, 6549-
56 
comparison healthy and tumor adult brain 
DIGE 
non tumor 
(epilepsy) and 
grade II-IV 
astrocytoma tissue 
b 
provide 
information 
about 
differentially 
expressed 
proteins of 
healthy and 
tumor tissue 
91 diferentially 
expressed 
proteins, 20 of 
them identified 
for the first time 
Khalil  
Cancer Sci., 
98, 201-13 
MALDI 
MS 
protein 
profiling 
grade II-IV 
astrocytomas b 
use of protein 
patterns for 
classification of 
astrocytomas 
and survival 
diagnosis 
distinction of 
normal and 
astrocytoma as 
well as grade-to-
grade distinction, 
short time and 
long time survival 
prediction 
Schwartz et al. 
Cancer Res. 
2005, 65, 7674-
-81 
 
In the following work the focus is set on identification of proteins expressed in 
Glioblastoma multiforme tissue with methods based on chromatography and mass 
spectrometry. An additional aspect is the confirmation of previous indirectly identified 
potential biomarkers for this type of tumor.  
        
 
  
 
Chapter II 
 
 
 
Aim of the thesis 
 
  
 
   Chapter II: Aim of the thesis 
   
67
Since the late 80s, the mapping and sequencing of the human genome stood in the 
focus of the global research interest [194]. In 1920 the term genome was established 
by H. Winkler who generated a portmanteau of the words gene and chromosome. 
The first encoded DNA-genome was the one of phage phi x 174 by Sanger et al. in 
1977 [195;196]. In 2004, the human genome was decoded totally resulting in 20,000-
25,000 protein encoding genes [43]. From this point proteomic research became more 
and more important. Now the proteins expressed from these genes playing a major 
role in maintenance of physiological and pathological activity should be investigated. 
Their structure, function and location in the cell were of major importance as they tell 
the story of human life. Today, the total amount of human proteins still can only be 
estimated.  
In this thesis the focus is set on proteome analysis based on chromatogeraphy and 
mass spectrometry as revealed in the previous chapter. Beside 2G-GE gel-free 
methods have become enormous relevant in the last few years. Especially for 
shotgun proteomics applying MALDI mass spectrometry after the second separation 
dimension, a rapid development was observable during the last five years. The most 
straightforward of the numerous nano-flow HPLC-MALDI mass spectrometry 
interfaces is the position of discrete sample/matrix spots directly onto the MALDI 
target and off-line transfer of the target into the mass spectrometer [156]. Different 
proteomes were analyzed using this design in the second separation dimension: 
Saccharomyces cerevisiae, Escherichia coli, Corynebacterium glutamicum, 
hippocampal synapses of mouse brain, mitochondrial ribosomes (neat) and human 
liver tissue as well as human multi-potent adult progenitor cells from bone marrow, 
serum and plasma samples and cerebrospinal liquid [138;176;197-203]. No report of a 
proteome analysis of Glioblastoma multiforme employing this setup is known so far. 
The aim of this thesis was to develop a semi top-down approach as alternative to the 
classical bottom-up approach for proteome analysis. Therefore an efficient HPLC 
method for intact protein separation in the first dimension should be established. To 
accomplish peptide separation in the second dimension an efficient nano-flow HPLC-
MALDI-MS/MS method should be developed. Therefore, polymer-based monolithic 
capillary columns should be used as separation- and preconcentration columns for 
high speed, resolution and sensitivity. The new semi top-down- and the standard 
bottom-up approach should be established with moderate complex standard 
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samples. Then the optimized methods should be applied to a proteome study of a 
human brain tumor tissue (Glioblastoma multiforme) for comparison with each other.  
Previously, a set of biomarker proteins was identified indirectly by SEREX for the 
investigated kind of tumor. Biomarkers are proteins specific for one kind of disease 
as for Glioblastoma multiforme brain tumors, for instance. These should be employed 
for early disease diagnosis which is of urgent importance especially in the case of 
cancer. Not only an individual protein can function as such biomarker but rather a 
combination of proteins up to ≥ 50 proteins for one organism [204]. Such a set 
consisting of 13 potential biomarker proteins was identified for Glioblastoma 
multiforme recently [205]. To confirm at least some of these proteins on molecular level 
with the developed methods, was a further goal of this thesis. 
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1 Introduction 
 
Reversed-phase high-performance liquid chromatography (RP-HPLC) is the mostly 
used chromatographic mode in terms of hyphenation to mass spectrometry. The 
advantage in comparison to other chromatographic modes is the compatibility of the 
used eluents with electrospray ionization (ESI) and matrix assisted laser 
desorption/ionization (MALDI) techniques, permitting on-line coupling to mass 
spectrometry. For increase of resolution, speed and sensitivity of the separation prior 
to mass spectrometric analysis two strategies were introduced. In ultra-pressure 
liquid chromatography (UPLC) small C18 particles (sub 2 µm) are applied for column 
packing, and the columns are operated at very high pressures (about 10,000 psi). 
Hence, separation efficiency is maintained while analysis time is reduced [206;207]. 
Another approach employs capillary separation columns with monolithic stationary 
phases on silica or polymer (mostly PS-DVB) basis instead of microparticles [208-210]. 
Both methods have been shown to be very suitable for separation of highly complex 
peptide mixtures due to their high speed and resolution. 
After separation, peptides are fragmented by mass spectrometry and computer- 
based identified. On-line nano-flow HPLC-ESI-MS is a very efficient and fully 
automated combination for separating and identifying peptides sensitively from a 
highly complex mixture as required for proteome analysis [211;212]. However, in on-line 
nano-flow HPLC-ESI-MS only in the short peptide retention window of typically  
10-30 s the precursor ion is available for fragmentation [213]. The introduction of 
MALDI mass spectrometers with MS/MS capability [214-216] stimulated the interest in 
nano-flow HPLC-MALDI-MS interfaces for proteome analysis. In nano-flow HPLC-
MALDI-MS the sample is deposited and stored on a target prior to MS and MS/MS 
analysis. Thus, in contrast to real-time nano-flow HPLC-ESI-MS off-line nano-flow 
HPLC-MALDI-MS permits a more detailed precursor selection [217] with no time 
restriction by completing the MS data set before starting MS/MS data generation. 
Furthermore, the whole sample analysis can be repeated for several times until the 
sample is consumed. Especially when only small sample amounts are available this 
approach becomes very advantageous.  
In this context the development of an alternative approach to the classical bottom-up 
method in proteome analysis should be developed. No defined term exists for such a 
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method including intact protein separation in the first dimension, subsequent 
digestion of the proteins in the individual fractions and separation of peptides in the 
second dimension. We called this method “semi top-down” approach because it 
stands between top-down and bottom-up proteome analysis. Chromatographic semi 
top-down approaches were introduced in proteome analysis to circumvent the 
distribution of peptides over several fractions collected in the first chromatographic 
dimension. The development of the first dimension separation method of intact 
proteins should be presented in this chapter. 
Furthermore an efficient nano-flow IP-RP-HPLC-MALDI-MS method should be 
presented for second dimension separations of proteome analysis, employing the 
newest generation of MALDI-TOF/TOF instruments. Thus, a high sensitivity, efficient 
precursor selection and fragmentation should be achieved. The application of 
polymer-based monolithic separation columns should assure high resolution, speed, 
sensitivity and repeatability of the separation prior to mass spectrometry.  
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2 Experimental 
 
2.1 Chemicals and Materials 
 
The water used for all experiments was prepared with a Purelab Ultra system (Elga, 
Siershahn, Switzerland). The following materials were purchased from Sigma-Aldrich 
Steinheim, Germany): acetonitrile (E Chromasolv), dithiothreitol (min. 99 %),  
2-mercaptoethanol (> 98 %), benzoylated dialysis tubing (MWCO 2,000 Da), 
cytochrome C (type V-A, bovine heart), carbonic anhydrase (bovine), serum albumin 
(bovine, ≥ 97 %), ß-lactoglobulin A (bovine milk), catalase (bovine liver), lysozyme 
(chicken egg, 95 %), myoglobin (horse, 95-100 %), ribonuclease A (bovine pancreas, 
85 %), transferrin (bovine, 98 %), α-lactalbumin (type I, bovine milk, 85 %), α-cyano-
4-hydroxycinnamic acid (4-HCCA), ≥ 98 %) and human (Glu1)-fibrinopeptide B  
(glu1-fib). Urea (≥ 99.5 %), ammonium hydrogen carbonate (≥ 99.5 %), iodoacetic 
acid (≥ 99.5 %),  formic acid (FA, p.a.) trifluoroacetic acid (TFA, ≥ 99.5 %), 
heptafluorobutyric acid (HFBA, ≥ 99.5 %) and ammonium formate ((NH4)OAc,  
≥ 97 %) were obtained from Fluka (Buchs, Switzerland) and sodium dihydrogen 
phosphate (p.a.) from Merck (Darmstadt, Germany). Modified trypsin for protein 
digestion was ordered from Promega (Madison, WI, USA). The capillary tubing 
utilized for device connections was purchased from Polymicro Technologies 
(Phoenix, AZ; USA) and the PEEK capillary tubing, tubing sleeves, microtight unions 
and microtight fittings from Upchurch Scientific (Oak Harbor, WA, USA). The thermo 
mixer was purchased from Eppendorf AG (Comfort, Hamburg, Germany) as well as 
the vacuum concentrator (Concentrator 5301). The utilized centrifuge was procured 
from Heraeus (Biofuge13, Heidelberg, Germany). 
 
 
2.2 Tryptic digest of the proteins 
 
To establish an nano-flow IP-RP-HPLC-MALDI-TOF/TOF platform for proteome 
analysis a ten-protein mixture digest prepared by C. Schley and H.J. Toll (Saarland 
University, Saarbruecken, Germany) was employed. Protein concentrations in the 
mixture for digest, 1D and 2D analysis are listed in Table 17. 
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Table 17. Ten-protein standard mixture for digestion. 
 
no dilution dilution 1:9 
dilution 
1:4 
protein abbreviation concen-
tration for 
digest 
[pmol µL-1] 
concen-
tration for 
1D analysis 
[pmol µL-1] 
concen- 
tration for 
2D analysis 
[pmol 50 µL-1] 
cytochrome C  CYC_HORSE 16.18 1.62 161.80 
carbonic anhydrase 2 CAH2_BOVIN 6.89 0.69 68.90 
ß-lactoglobulin A* LACB_BOVIN 10.89 1.09 108.90 
catalase CATA_BOVIN 3.47 0.35 34.70 
lysozyme C LYSC_CHICK 13.98 1.40 139.80 
myoglobin MYG_HORSE 11.80 1.18 118.00 
ribonuclease A RNAS1_BOVIN 14.62 1.46 146.20 
transferrin  TRFE_BOVIN 2.51 0.25 25.10 
α-lactalbumin LALBA_BOVIN 14.10 1.41 141.00 
bovine serum albumin BSA_BOVIN 7.51 0.75 75.10 
* In the Swiss Prot database only ß-lactoglobulin B is listed. The variants A and B differ only by two 
amino acids at position 64: glycine is substituted by aspartic acid in variant A and in position 118: 
instead of alanine valine is incorporated in the protein sequence [218;219]. None of both peptides 
including these positions was identified in this study. 
 
Proteins were dissolved in a mixture of 8 M urea and 0.5 M ammonium hydrogen 
carbonate and denatured for 30 min with gentle shaking at a temperature of 37 °C. 
Disulfide bonds were broken by adding 50 µL of 0.3 M aqueous dithiothreitol solution 
and incubating at 37 °C for 4 h in the thermo mixer. Subsequently the cysteine 
sulfhydryl groups were carboxymethylated with 20 µL of 2 M iodoacetic acid for 5 min 
at room temperature. The excess of alkylation reagent was removed by adding 40 µL 
of 0.1 M 2-mercaptoethanol and incubated for 15 min. Dialysis of the treated protein 
mixture followed as final step prior to digestion (12 h, 1 L distilled water). In the 
thermo mixer 30 µg trypsin were activated for 30 min at 37 °C with 30 µL acetic acid 
(50 mM) and were then added to the modified protein mixture. Sequencing grade 
modified trypsin (modified by reductive methylation) was used to minimize auto 
proteolysis [220]. After incubation over night the reaction was quenched by addition of 
1 vol. % TFA. Prior to injection of 1 µL the peptide mixture was diluted 1:9 (10 µL 
digest plus 90 µL eluent A) in 0.05 % aqueous TFA solution for 1D analysis. For 
injection of 50 µL into the first dimension of 2D analysis the peptide mixture was 
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diluted 1:4 (20 µL digest plus 80 µL eluent A) in sodium dihydrogen phosphate  
(5 mM, pH 3) or  ammonium formate (10 mM at pH 3), respectively. 
 
 
2.3 SCX-HPLC for peptide separation 
 
Two different buffer systems were compared for SCX-HPLC of peptides. Sodium 
dihydrogen phosphate (5 mM, pH 3) as eluent A and sodium dihydrogen phosphate 
(5 mM, pH 3) plus sodium chloride (500 mM, pH 3) as eluent B were utilized as buffer 
system (1), both eluents contained 20 % acetonitrile. Buffer system (2) consisted of 
ammonium formate (10 mM, pH 3 for eluent A and 500 mM, pH 6.8 for eluent B,  
25 % acetonitrile for A and B). To both eluent solutions, acetonitrile was added to 
suppress unspecific secondary solvophobic interactions with the separation column. 
An analytical HPLC system (Model 1100, HP, Waldbronn, Germany) was used to 
perform peptide separation at room temperature. It was equipped with an external 
six-port injection valve (Model 7125, Rheodyne, Rohnert Park, CA, USA) endowed 
with a 100-µL sample loop (Rheodyne). The sample was diluted 1:4 with eluent A  
(20 µL digest and 80 µL eluent A) prior to injection of 50 µL of the protein digest  
(= 1.02 nmol corresponding to 22.99 µg). The gradient started with 0-100 % B in  
10 min and was then held for 10 min at 100 % B. The polymeric Polysulfoethyl A  
200 x 2.1 mm i.d. column (PolyLC, 5µm, 200 Å, Columbia, MD, USA) was operated 
at a flow rate of 200 µL min-1. UV chromatograms were acquired at 214 nm. Two-min 
fractions were collected except for fraction 1 (1.5 min), resulting in 10 fractions 
obtained in 19.5 min. The fractions were frozen at a temperature of -30 °C. Prior to 
injection into the second separation dimension the eluents remaining from the SCX 
separation were evaporated until approximately 10 µL remained in the vial. For 
analysis the fractions were completed with 90 µL of 0.1 % aqueous HFBA (= solvent 
of loading pump). To fraction 01 only 65 µL were added to a final volume of 75 µL 
corresponding to 25 % less original fraction volume than fractions 02-10 (only 1.5 min 
collected). 
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2.4 IP-RP-HPLC for separation of intact proteins 
 
An analytical HPLC system (Model 1050, HP), equipped with an external six-port 
switching valve (Model 7125, Rheodyne) with a 5-µl sample loop (Rheodyne) was 
employed for protein separation. Furthermore an in-house made column oven was 
used to maintain a temperature of 50 °C. UV chromatograms were recorded at  
280 nm with an UV/VIS detector (Model 433, Kontron, Eching, Germany). A linear 
gradient of 15-50 % acetonitrile containing FA, TFA or HFBA as mobile phase 
additives in the eluent A and B was used on one or two 50 x 4.6 mm i.d. ProSwift-RP-
1S PS-DVB based monolithic columns (Dionex, Sunnyvale, CA, USA). When using 
two columns, they were connected in series. The gradient time for separation of ten 
standard proteins was set to 10 min and 20 min for one column and 20 min for two 
columns, respectively. 
 
 
2.5 Nano-flow IP-RP-HPLC separation of peptides 
 
Ten microliters of the fractions collected and concentrated after SCX-separation were 
injected into the ion-pair reversed-phase nano-flow HPLC system (= second 
dimension) in partial-loop injection mode. In 1D peptide separation without 
prefractionation, 1 µL(= 10.20 pmol corresponding to 229.92 ng) was injected in full-
loop injection mode. The setup consisted of a capillary HPLC system (Ultimate, LC 
Packings, Amsterdam, The Netherlands), an automatic injection unit (Famos, LC-
Packings) and a loading pump (Model K-1001, Knauer, Berlin, Germany) with a  
10-port switching valve (Model C2-1000D (stator) and 06A-8029C (rotor), VICI, 
Schenkon, Switzerland). The detector was equipped with a 3 nL Z-shaped flow cell 
(Model Ultimate), and the UV chromatogram was recorded at 214 nm. A short 
precolumn (10 x 0.2 mm i.d.) was used to desalt and concentrate the samples 
obtained from the first dimension. The separation column (60 x 0.1 mm i.d.), as well as 
the precolumn, consisted of a monolithic PS-DVB based stationary phase material [221] 
(available from LC Packings, Dionex Corporation, Sunnyvale, USA). When a 
precolumn was installed, peptides were isocratically concentrated and desalted for  
3 min. The flow rate of the loading pump delivering 0.1 % aqueous HFBA was set to 
10 µL min-1. After valve switching, peptides were eluted in back-flush mode onto the 
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separation column. Then, a 40-min gradient of 0-40 % acetonitrile in 0.05 % aqueous 
TFA was applied at a flow rate of 0.7 µL min-1 and a temperature of 55 °C. The eluting 
analytes were spotted onto an Opti-TOF 123 x 81 mm stainless steel target (ABI, 
Framingham, MA, USA) with an automatic fractionation unit (Probot, Dionex 
Corporation, Sunnyvale, CA, USA). Alpha-cyano-4-hydroxycinnamic acid in  
70 % acetonitrile and 0.1 % aqueous TFA was utilized as matrix with human glu1-
fibrino-peptide B (= glu1-fib, sequence given in Table 18) in a concentration of 15 fmol 
µL-1. The matrix flow was adjusted to 2.9 µL min-1 for a spotting time of 5 s per spot  
(242 nL matrix per spot) or to 1.2 µL min-1 for a spotting time of 10 s per spot  
(200 nL matrix per spot), respectively. Altogether, 45 min of the HPLC run were 
spotted (min 5 to 50). Spectra for peptide and protein identification were acquired 
using a MALDI-TOF/TOF mass spectrometer (4800 TOF/TOF Analyzer, ABI, 
Framingham, MA, USA).  
 
 
2.6 MALDI-TOF/TOF data acquisition 
 
The spectra were generated in positive reflector mode within a mass range of 800-
4,000 m/z. In MS mode 25 laser shots were summarized to one sub-spectrum, and  
20 sub-spectra were accumulated to the final spectrum (500 shots) with a frequency of 
200 Hz and a laser wavelength of 355 nm (Nd/YAG laser). Prior to analysis, the mass 
spectra were calibrated using a six-peptide calibration mix (ABI) as revealed in  
Table 18, on eight external calibration spots for each MALDI plate. The manufacturer 
recommended procedure (Plate Model Calibration) was applied resulting in a mass 
accuracy of 50 ppm (= default calibration). For optimized mass accuracy (5 ppm) an 
internal calibration on the mass-to-charge ratio of glu1-fib (m/z 1570.677) was 
performed during data acquisition. When this additional calibration failed due to signal 
suppression especially in spectra with high sample peptide signal intensity, default 
calibration was automatically used (50 ppm).  The mass-to-charge ratio of glu1-fib was 
set on the precursor selection exclusion list to circumvent fragmentation of it. 
Calibration of the instrument for MS/MS experiments was performed using four 
fragments of glu1-fib. In one sub-spectrum 40 laser shots were accumulated, and  
25 sub-spectra were summarized to the final spectrum (1,000 shots in total). 
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Table 18. Six-peptide standard for calibration of the MALDI-mass spectrometer. 
 
peptide name 
concen-
tration on 
target  
[pmol] 
sequence 
monoisotopic 
mass  
(m/z, z = 1) 
des-Arg1-bradykinin 1.02 PPGFSPFR 904.4681 
angiotensin I 2.01 DRVYIHPFHL 1296.6853 
glu1-fibrinopeptide B 1.30 EGVNDNEEGFFSAR 1570.6774 
ACTH* (1-17 clip) 2.01 SYSMEHFRWGKPVGKKR 2093.0867 
ACTH* (18-39 clip) 1.51 RPVKVYPNGAEDESAEAFPLEF 2465.1989 
ACTH* (7-38 clip) 3.01 FRWGKPVGKKRRPVKVYPNGAEDESAEAFPLE 3657.9294 
* = adrenocorticotropic hormone, sequence given in Estivariz et al. [222]. Remaining peptide sequences   
      supplied by ABI. 
 
For peptide fragmentation, precursors were selected in the mass range of  
m/z 900-3,000. Fragmentation of five precursors per spot at maximum was realized 
without using the collision induced dissociation (CID) chamber as a metastable decay 
process [223]. Here peptide fragmentation is realized by post source decay (PSD) and 
subsequent acceleration without additional collision of the analytes with gas 
molecules. The CID fragmentation of peptides was tested as well. Air as collision gas 
for peptide fragmentation was used, applying a pressure of 1.7 x 10-9 bar in the source 
chamber 2 (= collision chamber). In MS/MS mode 25 sub-spectra containing 40 laser 
shots each, were summarized to finally 1,000 shots for peptide fragment detection 
(same conditions for CID and PSD). The precursor selection window was set to 280, 
which corresponds to a 3.6-Da-window for a precursor with the m/z of 1,000, for 
instance. 
 
 
2.7 Data processing 
 
The recorded MS/MS spectra were smoothed with Savitsky-Golay algorithm using 
three points across the peak and a polynomial order of four. For exporting data to 
create Mascot generic files (“.mgf”) the following settings were used in MS/MS peak 
filter: mass range: 60 m/z to precursor mass -35 Da; peak density: maximum 20 peaks 
per 200 Da; minimum S/N: 10; minimum area: 200 and maximum 65 peaks/precursor. 
To identify proteins, the “.mgf”s were sent to Mascot software (version 2.2.03, Matrix 
Science, London, UK) which uses the MOWSE (molecular weight search) algorithm to 
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create scores based on identification quality. The following settings were applied: 
database: Swiss Prot (Version 54.7, January 15th, 2008); taxonomy: chordata 
(vertebrates and relatives; 70,931 sequences); enzyme: trypsin; variable modification: 
methionine oxidation + cysteine carboxymethylation; peptide tolerance: 100 ppm; 
MS/MS tolerance: 0.5 Da; maximal missed cleavages: 1 and ion-score cut off for 
peptides: 0.05 (95 %). This means that only peptide hits identified with a probability to 
be a correct hit ≥ 95 % remain in the identification list. The probability of an 
identification as a random event for proteins was set to 0.05, too. Thus, only proteins 
with ≥ 95 % probability for correct identification were considered. When the parameter 
settings differ from the listed above it is mentioned in the text. 
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3 Results and Discussion 
 
3.1 IP-RP-HPLC for intact proteins as first dimension in 2D analysis  
 
3.1.1 Influence of column length on separation performance 
 
To establish an HPLC method for intact protein separation as first dimension of semi 
top-down proteome analysis a ten-protein standard was used. The proteins were 
obtained from different organisms: chicken (lysozyme C), neat (bovine serum 
albumin, transferrin, catalase, ß-lactoglobulin, cytochrome C, carbonic anhydrase 2, 
α-lactalbumin and ribonuclease A) and horse (myoglobin). For protein separation a 
PS-DVB-based monolithic column was utilized (ProSwift-RP-1S monolith,  
50 x 4.6 mm i.d., Dionex, Sunnyvale, CA, USA). The gradient was chosen to start at 
15 % acetonitrile in 0.05 % aqueous TFA and not as generally handled for proteins at 
20 %. This was decided because later for the proteome analysis it was expected that 
not only intact, but also fragments of proteins are present in the tissue protein 
sample.  
To achieve higher resolution, the column length was doubled by coupling two 
columns in series. Thus, the gradient time was doubled too, according to the gradient 
volume concept (explained in chapter I, paragraph 3.1.3). The resulting UV 
chromatograms are depicted in Figure 18. A clear increase in resolution is 
observable for coupling two columns and applying a gradient time of 20 min. For one 
column using a gradient time of 10 min (Figure 18a), three unresolved peaks are 
observed, whereas the third contains even three proteins. By increasing the gradient 
time by a factor of two (Figure 18b), only two unresolved peaks with each containing 
two proteins remain. By increasing the column length by a factor of two (Figure 18c), 
only one peak containing two compounds of the ten-protein standard (catalase and 
carbonic anhydrase 2) is left due to better resolution. 
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Figure 18. Separation of ten intact proteins on monolithic column(s). Gradient,  
15-50 % acetonitrile + 0.05 % aqueous TFA; flow rate, 0.8 mL min-1; temperature, 
 55 °C; injection volume, 5 µL; cprotein, 0.2 µg µL-1; cBSA, 0.5 µg µL-1; wavelength, 
 280 nm. (a) One column; tG = 10 min. (b) One column; tG = 20 min. (c) Two columns, 
tG = 20 min. 
 
The corresponding peak width at half height (wh) for every protein peak in Figure 18 
is given in Table 19. Except for catalase and carbonic anhydrase 2, all protein peaks 
were at least partly separated using two columns and a gradient time of 20 min. 
Furthermore, wh for the proteins remains almost constant, being 0.13 min for one 
column with a gradient time of 10 min, 0.11 min for one column applying a gradient 
time of 20 min and 0.12 min for two columns with a gradient time of 20 min. To 
compute average wh only ribonuclease, cytochrome C and lysozyme C were included 
as they were base-line separated in all three cases.  
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Table 19. Peak width at half height (wh) of the ten proteins. 
 
one column two columns 
protein peak number (a) wh  [min]  (tG = 10 min) 
(b) wh  [min] 
 (tG = 20 min) 
(c) wh [min] 
 (tG = 20min) 
RNAS1 1 0.11 0.09 0.08 
CYC 2 0.15 0.12 0.18 
LYSC 3 0.14 0.13 0.09 
TRFE 4 0.23 
LALBA 5 0.17 0.14 0.10 
BSA + MYG 6 + 7 0.17 0.17 0.28 
LACB 8 0.11 0.09 
CATA + CAH2 9 + 10 0.25 0.12 0.13 
 
Although the gradient time was doubled the average wh remained almost the same. 
For a 60-min gradient of 15-60 % acetonitrile in 0.05 % aqueous TFA (as applied for 
proteome analysis in the next chapter) an average wh for the three proteins of  
0.25 min was obtained. The changing peak capacities (P) (Chapter I, paragraph 
3.1.2) for different gradient times and the two column lengths are given in Table 20. 
Gradient times for one and two columns were chosen considering the gradient 
volume concept. 
 
Table 20. Peak capacities (P) for two column lengths and different gradient times. 
 
one column (50 mm) two columns (100 mm) 
gradient 
time [min] 
average 
wb 
[min] 
peak 
capacity 
gradient 
time 
[min] 
average wb 
[min] 
peak 
capacity 
7.5 0.19 40 15 0.23 66 
15 0.24 62 30 0.31 80 
30 0.37 82 60 0.49 124 
 
It can be observed from Table 20 that by increasing the gradient time of a factor F the 
peak capacity rises about the square root of F. By increasing the gradient time from 
15 to 60 min, for instance, the peak capacity increases about two-fold. 
With doubling the column length the peak capacity was increased about one third. 
Peak capacity of 249 was obtained applying a 50-min gradient for peptide separation 
on a 150 mm C18 RP column and 113 for peptides separated with a 50 mm SCX 
column and a gradient time of 80 min, reported by Gilar et al. [224]. However, proteins 
generate broader peaks due to their more complex structure. As a result wb at 4 σ 
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(13.4 % of peak height) is increased and thus, the peak capacity is decreased for 
proteins in comparison to peptides. 
In two-dimensional proteome analysis based on chromatography peak capacity of the 
whole chromatographic system is determined by the number of fractions collected in 
the first dimension. It is not possible to collect as much fractions in the first dimension 
as peak capacity is obtained due to time and sample concentration restrictions. 
Nevertheless an efficient separation in the first dimension is required to circumvent 
distribution of the collected proteins or peptides over plenty of fractions. 
 
 
3.1.2 Mobile phase additives 
 
The selectivity of a separation system can be influenced by temperature and choice of 
stationary and mobile phases. After optimizing the efficiency of separation, the 
selectivity should be considered. This was realized by testing different mobile phase 
additives. FA was used only to adjust a low pH for protein denaturation and HFBA as 
well as TFA additionally as ion-pair modifiers. These are amphiphilic compounds 
which are added to the mobile phase and adsorb on the surface of the stationary 
phase with their hydrophobic moiety. The hydrophilic residue (in this case negatively 
charged) initiates electrostatic interactions to the positively charged analytes [225]. 
Figure 19 reveals the UV chromatograms of separations applying two different ion-pair 
modifiers (TFA and HFBA) in comparison to addition of a small polar acid (FA) in 
similar concentration to the mobile phase: HFBA (410 mg), TFA (375 mg) and FA (305 
mg) which were added as 0.05 vol. % in 1L mobile phase. 
The best selectivity was achieved using TFA as ion-pair modifier. Obviously only with 
TFA even the critical peak pair bovine serum albumin and myoglobin (peaks 6+7) was 
at least partly separated.  
Originally, it was assumed that the proteins separated with FA as mobile phase 
additive would elute with the lowest retention time because FA has no hydrophobic 
moiety and is added in the lowest concentration. By proving the elution window it 
could be observed that separations performed with FA actually generated the shortest 
retention window; 6.3 min in comparison to 10.0 min for TFA. The proteins which were 
separated with HFBA as ion-pair modifier offered the longest retention times as 
expected. 
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Figure 19.  Separation of the ten-protein standard with different mobile phase 
additives. Gradient, 15-50 % acetonitrile + 0.05 % ion-pair modifier or FA; flow rate, 
0.8 mL min-1; temperature, 55 °C; injection volume, 5 µL; cprotein, 0.2 µg µL-1;  
cBSA, 0.5 µg µL-1; wavelength, 280 nm; (a) 0.05 % FA, (b) 0.05 % HFBA and  
(c) 0.05 % TFA. 
 
Peak widths at half height for the protein peaks are listed in Table 21. The obtained 
average peak width at half height for proteins separated is the lowest with FA added to 
the mobile phase (0.12 min). For separation of intact proteins with HFBA and TFA as 
ion-pair modifiers average peak widths at half maximum were almost the same  
(0.14 min and 0.15 min, respectively). As the attained selectivity for TFA is the 
highest, this ion-pair modifier was used for the following separations. 
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Table 21. Peak width at half height for the ten-protein mix separated with different 
mobile phase additives. 
 
protein peak number 
(a) wh  [min] 
0.05 % FA 
(b) wh  [min] 
0.05 % HFBA 
(c) wh  [min] 
0.05 % TFA 
RNAS1 1 0.08 0.10 0.08 
CYC 2 0.10 0.11 0.18 
LYSC 3 0.10 0.10 0.09 
TRFE 4 0.13 0.10 0.23 
LALBA 5 0.08 0.14 0.10 
BSA + MYG 6 + 7 0.28 
LACB 8 0.32 0.09 
CATA + CAH2 9 + 10 
0.23 
0.11 0.13 
 
These three mobile phase additives were chosen because they are compatible with 
MALDI as ionization technique for mass spectrometry due to their high volatility. As 
TFA provided the best selectivity it was applied as ion-pair modifier to the proteome 
analysis of Glioblastoma multiforme in the next chapter.  
 
 
3.1.3 Repeatability of IP-RP-HPLC intact protein separations 
 
Another very important parameter to discuss is the repeatability of the established IP-
RP-HPLC method for protein separation. In Figure 20 the UV chromatograms of three 
consecutive separations are displayed. The previously optimized column length  
(100 mm) and ion-pair modifier (0.05 % TFA) were applied as well as 20 min gradient 
time. The high repeatability of retention times demonstrated in Figure 20 is proven by 
computing standard deviations for retention times of the protein peaks in these three 
runs shown in Table 22. 
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Figure 20. Separation repeatability of the ten-protein mixture.  
Gradient, 15-50 % acetonitrile + 0.05 % aqueous TFA ; flow rate, 0.8 mL min-1 ; 
temperature, 55 °C; injection volume, 5 µL; cprotein, 0.2 µg µL-1; cBSA, 0.5 µg µL-1; 
wavelength 280 nm. 
 
Table 22. Repeatability of retention time for the ten proteins of the standard mixture. 
 
protein peak number 
average 
retention time 
[min]  
standard 
deviation  
[%] 
RNAS1 1 5.6 3.7 
CYC 2 8.5 0.4 
LYSC 3 10.5 0.1 
TRFE 4 12.2 0.7 
LALBA 5 12.5 0.2 
BSA  6 13.6 0.3 
MYG 7 13.8 0.3 
LACB 8 14.8 0.3 
CATA + CAH2 9 + 10 15.3 0.4 
 
The standard deviation was below 0.8 % for all peaks except ribonuclease A. For this 
protein a higher variation is observable. It is quite difficult to explain why only 
ribonuclease A elutes so inconstantly. It might be this way because it elutes as first of 
the proteins (at 24.8 % acetonitrile + 0.05 % aqueous TFA) and there is a similar 
variation of the hold-up time of the column, too (3.5 %), caused by the manual 
injection. 
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3.2 Validation of a nano-flow HPLC MALDI-TOF/TOF system as second 
dimension in 2D analysis 
 
3.2.1 Configuration of the separation and identification system 
 
The setup for the off-line HPLC MALDI-TOF/TOF system is depicted in Figure 21. 
After injection (1) the peptides were flushed onto the trap column (5) when installed. 
Subsequently to 3-min accumulation time the eluents mixed by the gradient pump 
transferred the peptides onto the analytical column (6). Here, the peptides were 
separated using a 40-min gradient (0-40 %) of acetonitrile in 0.05 % aqueous TFA. 
After UV detection the eluting peptides were mixed with matrix (α-cyano-4-
hydroxycinnamic acid) in a T-piece and spotted onto a stainless steel target. 
Subsequently to co-crystallization of matrix and peptides, the target was manually 
transferred into the MALDI-TOF/TOF mass spectrometer (Figure 21b). Here the 
peptides were ionized in the ion source (8) by MALDI, passed the reflectron (12) and 
reached the microchannel plate detector (13) in a first analysis. Then the precursors 
were selected and in a second analysis fragmented either with or without using the 
CID chamber (11). Protein identification was performed by database search against 
the Swiss Prot database using the Mascot search engine. 
1
2
3
45
6
7
8
10
11
12
13
(a) (b)
9
 
 
Figure 21.  Nano-flow IP-RP-HPLC-MALDI-TOF/TOF setup. (a): 1 = automatic 
injection unit, 2 = loading pump, 3 = gradient pump, 4 = spotter, 5 = trap column,  
6 = analytical column, 7 = UV detector, (b): MALDI-TOF/TOF: 8 = sample loading 
chamber/ion source 1, 9 = flight tube, 10 = Nd/YAG laser, 10 = CID chamber/ion 
source 2, 11 = reflectron, 12 = microchannel plate detector 
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3.2.2 Variation of spotting time 
 
For all validation steps, the same ten-protein standard mixture as for establishing of 
the HPLC method for intact proteins was used, this time digested. The protein 
concentration before digest was adjusted to 0.3-1.6 pmol µL-1 (inj. volume: 1 µL). 
Tryptic digestion of this mixture resulted in 395 different peptides in the set mass 
range of m/z 900-3,000, considering one missed cleavage. Peptide masses including 
the selected modifications carboxymethylation of sulfhydrylgroups in cysteine moieties 
and methionine oxidation were not counted as individual peptide masses.  
In the literature the spotting time varies from 5 s [226] to 30 s [227] per spot. It was 
decided to test 5 and 10 s because the ten-protein standard digest is a moderately 
complex sample in comparison to sample complexity in proteome analysis. For this 
test, a loading pump and a trap column were not installed. This was possible because 
no desalting step was necessary prior to analysis, since salts and excessive reagents 
were removed by dialysis prior to digestion. The peptides of the ten-protein standard 
mixture digest were separated applying a 40-min gradient of 0-40 % acetonitrile in 
0.05 % aqueous TFA. As shown in Figure 22 for both spotting times, 5 s and 10 s 
respectively, 45 min (min 5 to 50) were spotted of which 35 min (min 5 to 40) were 
analyzed with the MALDI-TOF/TOF mass spectrometer.  
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Figure 22. Separation of the ten-protein digest peptides; grey area (dark): spotted 
with Probot (min 5-50); grey area (light): analyzed with MALDI-TOF/TOF (min 5-40). 
 
For each spotting time three replicates were performed whereas for every analysis 
the minimum MOWSE Score for a positive identification was 33 for proteins.  
The following four parameters characterizing best the quality of analysis will be 
discussed for each validation step: The obtained MOWSE Score for the proteins and 
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peptides, the number of identified unique peptides and the sequence coverage for 
the proteins. The protein MOWSE Score indicates the quality of protein identification, 
but since it is a sum of the peptide scores of one protein, identifying five peptides with 
a low score (for example 20) would result in a similar score for the same protein 
identified with less peptides assigned with a high score (for example two peptides 
with the score of 50). Therefore the average peptide MOWSE Score is considered, 
too. Furthermore, the number of identified peptides shows the quality of the digest 
and also of the separation and identification system. However, all proteins differ in 
size and number of tryptic cleavage sites. To account for this fact the sequence 
coverage is always given in combination with the number of identified peptides. 
The more peptides identified for one protein and the better the identification of these 
peptides the higher the MOWSE Score will be. Identification quality for the peptides is 
determined by the quality of the underlying MS/MS spectra. Clear signals without 
intense noise peaks and completeness of complementary b- and y-ion series are 
important factors for the quality of peptide identification [228]. With a score of 44 for  
5-s spotting and a score of 46 for 10-s spotting ribonuclease A was the protein with 
the lowest computed MOWSE Score (Figure 23a). This protein was identified for both 
spotting times in only two of the three replicates. For all proteins and peptides the 
MOWSE Score was higher for the 10-s spotting, observing an average increase of  
15.0 %. The average peptide score was computed by averaging all scores for one 
protein in one replicate. Then the three values for one protein obtained from the three 
replicates were averaged again. As for protein scores before, peptide scores are also 
increased with the 10-s spotting (Figure 23b). The highest average peptide score was 
obtained for myoglobin (73 for 5-s spotting and 90 for 10-s spotting, respectively). 
The clearest difference in the average peptide score can be observed for carbonic 
anhydrase 2. Here, for 10-s spotting a 35 % higher peptide MOWSE Score was 
obtained. Altogether, a 17.0 % higher average peptide MOWSE Score was obtained 
for 10-s spotting. 
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Figure 23. Mascot MOWSE Scores of the identified ten proteins, spotted with 5 s and 
10 s per spot, respectively (average of three replicates). Numbers show percentage 
of additional scores for 10-s spotting. (a) Protein scores, (b) peptide scores. 
 
Looking at Figure 24a, the low MOWSE Score of ribonuclease A becomes 
reasonable. This small protein was identified with only one peptide. As the MOWSE 
Score is a cumulative one, proteins with a high number of identified peptides are 
more likely to yield a high MOWSE Score. In the case of ribonuclease A, a small 
protein consisting of only 150 amino acids resulting in a molecular mass of 16.5 kDa 
is digested. This protein produces only four peptides with zero missed cleavages in 
the considered mass range and ten peptides with one missed cleavage site. In the 
relatively low complex ten-protein digest mixture consisting of 395 peptides (referring 
to the sum of peptides without and with one missed cleavage) ribonuclease A could 
be identified, but for a more complex sample it might be difficult. Moreover in a real 
proteome analysis this protein identification would be discarded because it would be 
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considered as “one-hit wonder”. These are proteins identified by only one peptide. In 
Figure 24b it can be observed that this one identified peptide for ribonuclease A is 
still sufficient to achieve sequence coverage of 15.3 %. α-Lactoglobulin identified with 
two peptides attains for the 5-s spotting only a sequence coverage of 10.8 %. 
A remarkable fact can be observed in Figure 24. Although the protein scores seen in 
Figure 23 are all higher for the 10-s spotting, this is not the case for the identified 
peptides per protein and the sequence coverage. For almost all proteins an equal 
amount of peptides is identified with the 5-s spotting. For myoglobin and carbonic 
anhydrase 2 even more peptides can be assigned with the 5-s spotting, and only for 
BSA more peptides were observed with a spotting time of 10 s. Altogether, only four 
peptides more were identified with 10-s spotting. The sum given for the peptides 
identified is not equal to the sum of the bar values (because they are average 
values), but shows the sum of unique peptides identified for the ten-proteins in the 
standard mixture digest. 
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Figure 24. Characterization of the identified ten proteins for 5-s and 10-s spotting, 
respectively (average of three replicates). (a) Identified peptides for the single 
proteins, numbers show additional peptide identification for 10-s spotting.  
(b) Sequence coverage of the single proteins, numbers show percentage of rise in 
sequence coverage for 10-s spotting. 
 
Although the number of identified peptides for both spotting times of the most 
proteins is equal, as displayed in Figure 24a, the sequence coverage for these 
proteins in Figure 24b is not. This effect occurs because the sequence coverage is 
averaged for the three replicates, too. For instance α-lactalbumin is identified twice 
with two peptides and once with one peptide with 5-s spotting whereas for 10-s 
spotting this protein is observed once with one, once with two and once with three 
peptides. The average peptides of both are two, but the sequence coverage for three 
identified peptides is 24.6 % and for one peptide 7.0 % in the case of α-lactalbumin. 
As a result the average sequence coverage varies for both spotting times. The 
protein with the highest sequence coverage is lysozyme C with 53.5 % obtained for 
10-s spotting. 
All ten-proteins could be identified with this setup by spotting 5 s per spot as well as 
10 s per spot. Although only small differences were observed between 5 s and 10-s 
spotting in terms of sequence coverage (averaged 6.7 % higher with 10-s spotting) 
and peptides per protein (four peptides more with 10-s spotting) the MOWSE Scores 
for the proteins as well as for the peptides were higher applying 10-s spotting (15.0 % 
and 17.0 % higher, respectively). This effect is caused by the higher peptide 
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concentration per spot due to the double spotting time and hence better spectra 
quality. Therefore, the 10-s spotting was chosen for further system validation 
consistent with the moderate complexity of the sample compared to a real proteome 
analysis. To enrich enough material for MS analysis 10 s per spot were more 
suitable. On the other hand, 5 s per spot were used for second dimension of 
proteome analysis to reduce the tremendous sample complexity. 
 
 
3.2.3 Preconcentration of peptides 
 
Strong cation-exchange high-performance liquid chromatography (SCX-HPLC) is a 
proper retention mode for proteome analysis, applying reversed-phase high-
performance liquid chromatography (RP-HPLC) in the second dimension. A high 
orthogonality is achieved with this combination. However, utilizing SCX in the first 
dimension leads to a high salt load in the collected fractions which is not compatible 
with mass spectrometry used for identification after the second separation dimension. 
Therefore a short desalting column is coupled on-line prior to the separation column 
which in our case consists of the same stationary phase as the separation column 
(PS-DVB monolith). In recent approaches two-dimensional systems utilizing RP-HPLC 
in both dimensions were introduced [229]. The retention modes vary mainly by applying 
first a basic pH (10.0) and second an acidic one (2.1) in the mobile phase of peptide 
separation. Even for this method, the desalting column is advantageous because the 
sample is concentrated (“trapped”) prior to separation. This is why the pre-column is 
also called trap column. Moreover, the trap column setup is very robust and therefore 
suitable for high-throughput analysis as necessary in proteome research [230]. In the 
developed nano-flow IP-RP-HPLC setup installing of the trap column was realized by 
positioning a further pump (Knauer, Berlin, Germany) connected to a 10-port switching 
valve (VICI, Schenkon, Switzerland) between the automatic injection unit and the 
gradient pumping system (Figure 21). This pump was run isocratically with 10 µL min-1 
0.1 % aqueous HFBA for loading the trap column. Figure 25 illustrates the difference 
of acquired signals in the UV chromatogram without trap column prior to separation 
and with an installed trap column. 
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Figure 25. UV chromatograms of three-fold separation of the ten-protein digest  
(a) without trap column and (b) employing a trap column. 
 
Obviously, using a trap column sharpens the peptide peaks and rises the signal 
intensity due to preconcentration on this small monolith. Whereas without the trap 
column peptide peak intensity never rises above 6.0 mAU it increases to 9.5 mAU for 
the chromatograms recorded for the separations using the trap column for each of the 
three replicates. 
In Figure 26 the average protein and peptide MOWSE Scores are shown. A 
remarkable increase of protein scores for the three replicates using the trap column is 
observed in Figure 26a except for cytochrome C, up to 85 % for ribonuclease A. This 
protein is now identified in all three analyses. The average increase of the Mascot 
MOWSE Scores of the ten-proteins is 35.0 %. 
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Figure 26. Mascot MOWSE Scores of the identified ten proteins, without and with 
utilizing a trap column, respectively (average of three replicates). Numbers show 
percentage of additional scores applying the trap column. (a) Protein scores, (b) 
average peptide scores. 
 
An increase is also observable for the average peptide scores, but more moderate 
than for the protein MOWSE Scores (percental rise of 17.0 %). Only ribonuclease A 
shows a remarkable increase of 58.6 % for the average peptide MOWSE Score when 
a trap column was applied. 
Figure 27 depicts the identified peptides for the particular proteins and the sequence 
coverage of the ten proteins. A striking increase of peptide identification for the 
replicates involving the trap column is seen (Figure 27a). Altogether, 24 additional 
peptides could be identified. Especially for ribonuclease A which is the most critical 
protein two peptides instead of one were observed. As a result this protein would no 
longer be considered as one-hit wonder in a real proteome analysis.  
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Now BSA is the protein with the highest sequence coverage (62.5 %, Figure 27b) 
and not longer lysozyme C (59.6 %), resulted from 34 identified peptides for BSA and 
six peptides for lysozyme C.  
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Figure 27. Characterization for the ten proteins separated either with or without trap 
column (average of three replicates). (a) Identified peptides for the individual 
proteins, numbers show different peptide identification for the runs analyzed using a 
trap column. (b) Sequence coverage, numbers show percentage of difference in 
sequence coverage for runs analyzed using the trap column. 
 
For further validation of the separation and identification platform, the trap column 
was installed applying 10-s spotting. 
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3.2.4 Fragmentation of tryptic peptides 
 
An alternative to the collision induced dissociation (CID) is using post source decay 
(PSD) with re-acceleration for peptide fragmentation. The peptide ions are generated 
and accelerated in the ion source 1 and also activated. During the field free drifting 
passage the metastable ions decay into b and y ion fragment series. Then the timed 
ion selector isolates the chosen precursor together with the fragment ions because 
they have the same velocities at this moment (however different kinetic energies). The 
CID chamber remains evacuated during PSD experiments and is only used for a 
second acceleration of the passing ions. 
The utilized MALDI-TOF/TOF analyzer is equipped with a CID chamber, offering the 
opportunity of additional CID tandem mass spectrometric experiments. The CID 
chamber is vented with air molecules; the peptides collide with them and break mainly 
on their peptide backbone using medium collision energy.  
After deceleration for precursor selection the ion package is accelerated to the 
reflector. There the precursor and the fragment ions are separated with respect to 
their mass. This means that the ions possessing a higher mass infiltrate deeper in the 
reflectron field than the lighter ones. Finally, the precursor and the fragment ions reach 
the microchannel plate detector at different times; first the fragment ions, later the 
precursor ions. 
There is no clear evidence which fragmentation method is more suitable for proteome 
analysis for peptide and protein identification. Here, both methods were tested to find 
possible differences. Therefore, three replicates of the previous described ten-protein 
standard mixture digestion were performed for each approach. 
Figure 28 shows two representative spectra for CID and PSD generated fragmentation 
patterns for the peptide GAGAFGYFEVTHDITR obtained from catalase. In Figure 28a 
the PSD spectrum and in Figure 28b the CID spectrum is depicted with only the b- and 
y-ion series marked which were recognized by Mascot search engine to keep 
clearness of the spectra. For the PSD spectrum an ion score of 143 was obtained and 
for the CID spectrum a score of 135. In the CID spectrum in the low mass range more 
signals appear, caused by the higher fragmentation energy applied for CID. In this 
region immonium ions and amino-acid signals are located. Although more fragments 
could be assigned to the peptide using CID the score for the PSD spectrum is higher. 
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Figure 28. MS/MS spectra for the peptide GAGAFGYFEVTHDITR obtained from 
catalase, acquired (a) with PSD and (b) with CID. 
 
Using only the absolute spectra intensity for estimation of quality is critical in MALDI 
mass spectrometry because so-called hot spots appear during analysis. This means 
that the co-crystallization of matrix and sample is not homogeneous at all. In the hot-
spot areas the sample is higher concentrated than in others. The laser shoots 
arbitrarily on the spot and so even in one replicate spectrum the intensity can be 
higher than in another independently of any device parameters or sample 
concentrations. Therefore the intensity of the fragment base peak (y3, m/z 389.35) 
was taken to normalize both spectra. For the CID spectrum the absolute intensity of y3 
was 7.2 % higher than for the PSD spectra. Now comparing the normalized intensity 
of the most sequence relevant ion types (b and y) which appear in both spectra the 
normalized intensities for the CID spectrum signals are 3.8 % lower than for the PSD 
spectrum. This might explain the slightly higher score for the PSD spectrum. In  
Table 23, the ion types are listed corresponding to the example spectra for both 
fragmentation methods.  
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Table 23. Ion type distribution of an example spectrum for PSD and CID, 
respectively. 0 = fragment minus H2O, * = fragment minus NH3 
 
ion type PSD CID 
immonium 1 4 
a 2 4 
a0 1 1 
b 9 9 
y 14 13 
y* 6 4 
y0 1 0 
internal fragments < 700 Da 8 18 
 
Altogether 42 fragments were assigned to this exemplary peptide using PSD and 53 
using CID. However, the fragmentation methods differ mainly in the number of internal 
fragments < 700 Da which do not provide as much sequence information as b- and y-
ion series [231]. Surprisingly losses of ammonia and water mainly appeared in the PSD 
spectrum. It was expected because of the higher energy applied for fragmentation 
using CID that higher neutral losses would emerge employing this fragmentation 
method. Due to theory with CID fragmentation more immonium ions, which crop up in 
the low mass range, could be observed compared to PSD fragmentation. Finally, 30 b- 
and y-ions could be observed with PSD and 26 with CID. This might be an additional 
reason for the higher PSD spectrum score. However, it is difficult to say which 
fragmentation method is more suitable for proteome analysis, in general. Following, 
the known ten-protein standard mixture digest is used to characterize identification of 
peptides applying both approaches. 
Figure 29 depicts the obtained average protein and peptide Mascot MOWSE Scores 
applying CID and PSD for peptide fragmentation, respectively. It is observed that no 
protein score for peptide fragmentation generated with CID is higher than for PSD 
spectra. Only one average peptide MOWSE Score (carbonic anhydrase 2) is higher 
applying CID. However, the average variation differs only slightly with 15.6 % higher 
scores for the proteins and 5.7 % for the peptides.  
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Figure 29.  Mascot MOWSE Scores using PSD and CID for peptide fragmentation, 
respectively (average of three replicates). Numbers show percentage of varying 
scores applying CID. (a) Protein scores and (b) peptide scores. 
 
In Figure 30, the identified peptides per protein as well as the sequence coverage are 
revealed. Altogether, 113 peptides could be identified with PSD and 101 with CID. 
Only for ribonuclease A one peptide more was obtained with CID, resulting in a 
higher sequence coverage.  
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Figure 30. Characterization of the ten-proteins with peptide fragmentation performed 
either with PSD or CID (average of three replicates). (a) Unique peptides for the 
single proteins, numbers show different peptide identifications for CID. (b) Sequence 
coverage, numbers show percentage of difference in sequence coverage for 
peptides fragmented with PSD. 
 
For proteome analysis aiming the identification of proteins, it is difficult to say which 
method is more suitable for peptide fragmentation. For special purposes like structure 
analysis of carbohydrates CID is preferred, permitting the determination of  
linkages in polysaccharides [232;233]. In proteomic content, determination of 
glycosylation moieties of post-translationally modified proteins is a prominent 
application [234;235]. Moreover, quantitation using the iTRAQ reagent strictly requires 
CID because the reporter ions, used for quantitation are low mass ions [236]. PSD with 
subsequent acceleration was applied for remaining validation of the nano-flow IP-RP-
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HPLC-MALDI-MS platform because the focus was not set on identification of post-
translational modifications but on peptide identification. 
 
 
3.2.5 Repeatability of nano-flow IP-RP-HPLC peptide separations 
 
For further analysis it was decided to use 10-s spotting for low complex samples as 
the ten-protein standard mixture digestion and 5-s spotting for higher complex 
samples. Furthermore, a trap column was installed and PSD was utilized for peptide 
fragmentation. Now the repeatability of the validated nano-flow IP-RP-HPLC off-line 
MALDI-TOF/TOF system was verified using the ten-protein standard mixture digest 
again. As seen in Figure 31, an adequate repeatability was achieved using the 
established separation platform. However, retention shifts are observable. 
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Figure 31. Repeatability of five chromatographic runs of the ten-protein standard 
mixture digest. 
 
For four peptide peaks retention time was determined to evaluate the repeatability of 
retention time. Although it is difficult to integrate the peaks correctly when no baseline 
is available it was done by using the start and end point of the peak. So this is no 
absolute retention time assignment, but an approximation to show repeatability. To be 
sure the chosen peaks are peptide signals they were confirmed with mass 
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spectrometry analysis. The HFBA peak elutes with a relative standard deviation of  
0.2 % as revealed in Table 24. Because of this precision the absolute peptide 
retention times were taken for evaluation repeatability. Usually, the run-to-run 
repeatability as an indicator for the system quality of the used HPLC platform should 
be better than 1.0 % [237]. The relative standard deviation is below this threshold for 
three peaks but for peak number 2 it is higher. Shifting of retention time for this peak 
can already be observed in the UV chromatograms in Figure 31 without integration. In 
contrast to the other considered three signals, peak 2 has a high intensity, so there 
might exist column overloading effects, and therefore a shift in retention time occurs. 
The four peptides were assigned from three of the five shown chromatograms  
(Figure 31c-e) with help of MALDI-TOF/TOF mass spectrometry to prove the peaks at 
the given retention times actually are peptide signals. The retention time revealed in 
Table 24 is the average of the three replicates. As the spotting time is 10 s per spot 
the retention time of MS analysis can only be assigned to the decimal place precision 
of 0.16 min. Peak 4 varies more than that 10 s offset what might result from the 
difficulty of integration. Moreover peptide KPVTDAENCHLAR from transferrin was 
identified in only two of the three MS runs. 
 
Table 24. Characterization of repeatability of retention times for the established RP-
HPLC system using a trap column, 10-s spotting and PSD as peptide fragmentation 
method.  
 
peak  
retention 
time 
[min] 
relative 
standard 
deviation 
[%] 
sequence protein origin 
retention 
time MS 
[min] 
HFBA 5.77 0.20  
1 13.27 0.62 KPVTDAENCHLAR transferrin 13.25 
2 18.23 1.88 LVNELTEFAK albumin 18.36 
3 21.97 0.53 LVQFHFHWGSSDDQGSEHTVDR carbonic anhydrase 2 21.81 
4 26.33 0.70 NLCNIPCSALLSSDITASVNCAK lysozyme C 25.92 
 
 
It was further determined how many of the identified peptides elute in all three 
replicates taken for the chosen method using 10-s spotting, the trap column and PSD 
fragmentation for the peptides. Of the identified 113 peptides, 81 (= 71.7 %) were 
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identified in all three replicates as indicated in Figure 32. This high repeatability is 
another indicator for the quality of the established HPLC-MS platform. 
 
 
12.4 %
(14) 15.9 %
(18)71.7 %
(81)
once twice three-fold  
 
Figure 32. Repeatability of peptide identification for three replicates. 
 
 
For further validation the repeatability for the optimized nano-flow IP-RP-HPLC-
MALDI-TOF/TOF approach applying 10-s spotting, a trap column and PSD to 
fragment the peptides with respect to peptide identification repeatability for the 
individual proteins was tested. 
As given in Figure 33 for three proteins (bovine serum albumin, cytochrome C and 
carbonic anhydrase 2), all three replicates delivered the same number of peptides.  
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Figure 33. Repeatability of peptide identification for the single proteins. 
 
The remaining seven proteins were assigned with only a slight variation in the 
number of peptides. These differences can be mainly explained by the 
       Chapter III: Development and validation of HPLC-MS approaches for 2D proteome analysis 
   
105
heterogeneous composition of the matrix/sample co-crystal and resulting hot-spot 
formation. This leads to poor shot-to-shot and sample-to-sample repeatability [238]. By 
shooting arbitrarily on the sample/matrix spot and summarizing shots to sub spectra 
which are again summarized to the final spectrum the repeatability is improved. 
Diverse sample preparation methods were elaborated to circumvent sample 
concentration heterogeneity: applying liquid matrices [239;240], forming a binary matrix 
by adding co-matrices like fucose [241], using highly volatile solvents for fast 
evaporation approaches [242], using 4-HCCA-thin layer preparation with aerospray 
sample deposition [243], systems on sol-gel basis [244] or sample preparations without 
solvents [245]. However, all these methods are developed for special purpose. Today 
the prevalent approach for peptide identification still is using crystalline α-cyano-4-
hydroxycinnamic acid as matrix. 
 
 
3.3 Comparison of two buffer systems for SCX-HPLC of peptides in the first 
dimension 
 
In the previous sections of this chapter the suitability of a nano-flow HPLC system 
using a trap column, 10-s spotting and PSD for peptide fragmentation for the 
separation and identification of a ten-protein standard mixture digest was 
demonstrated. In proteome analysis however, two-dimensional methods are 
necessary to cope with the tremendous complexity of the sample. Now the established 
nano-flow HPLC-MALDI-TOF/TOF approach should be evaluated in combination with 
SCX-HPLC of peptides in the first separation dimension employing two different buffer 
systems. Buffer system (1) consisted of sodium dihydrogen phosphate whereas the 
ionic strength through the gradient was increased with additional sodium chloride. In 
system (2) ammonium formate was utilized, increasing the ionic strength by elevating 
the ammonium ion concentration and simultaneously changing the pH. As ammonium 
possesses a pKA of 9.24, there are still ammonium ions left at the adjusted pH of 6.8 
whereas acidic analytes which have a pKA lower than 6.8 are less charged and 
therefore elute off the column. Hence, in buffer system (1) the separation is performed 
by changing the ionic strength only while for system (2) an extra effect by changing 
the pH is prevalent. Figure 34 depicts the UV chromatogram of the ten-protein 
standard mixture digest separation utilizing buffer system (1). The chromatogram for 
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separation with ammonium formate buffer is not shown because at 214 nm it is UV 
absorbent itself and so no discrete peaks are observable from the UV chromatogram.  
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Figure 34. SCX separation of the ten-protein digest. Separation was performed using 
a sodium dihydrogen phosphate buffer system. The blue line shows the gradient 
profile. 
 
Fractions were collected every two minutes for the fractionation of the ten-protein 
digest in the first dimension except for fraction 01 (1.5 min, 300 µL). As observed in 
Figure 34 UV signals were obtained only in fractions 06-10 and only in these fractions 
peptides were analyzed by nano-flow IP-RP MALDI-MS/MS. The same parameters as 
for the validation steps before will be considered. The recorded MS raw data for 
fractions 06-10 were merged into one single file for each buffer system and submitted 
to Mascot for peptide and protein identification. Here 50 ppm instead of 100 ppm was 
applied for precursor mass tolerance, in order to be closer to requirements for 
proteome analysis. All other definitions remained the same as for 1D analysis. First, 
the MOWSE Scores for proteins and peptides are shown in Figure 35. In Figure 35a 
the protein scores are obviously higher than for 1D analysis where the highest 
achieved score was 2,805. This occurs because for multidimensional analysis another 
protein scoring is adopted by the Mascot software. The peptides count no longer only 
for their score, but additionally the average of their homology threshold is added (or 
identity when no homology threshold is available). 
On average, the MOWSE Scores for all proteins are 24.1 % higher applying the 
ammonium formate buffer system. Only myoglobin is identified with a lower score. 
However, for peptide MOWSE Scores no significant advantage was observed with the 
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ammonium formate method. Employing the ammonium formate buffer system 1.6 % 
higher scores for the peptides were obtained on average.  
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Figure 35.  Mascot MOWSE Scores for the identified ten proteins with SCX 
separation in the first dimension and two different buffer systems. Numbers show 
additional scores for buffer system (2). (a) Protein scores and (b) average peptide 
scores. Buffer system (1) = sodium dihydrogen phosphate, buffer system (2) = 
ammonium formate. 
 
Furthermore, the number of peptides per protein and the sequence coverage were 
evaluated as shown in Figure 36.  
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Figure 36. Characterization of the ten-protein digest separated with two different 
buffer systems for SCX in the first dimension. (a) Unique peptides for the individual 
proteins, numbers show difference in peptide identifications for buffer system (2) and 
(b) sequence coverage, numbers show percentage of difference in sequence 
coverage for buffer system (2). 
 
For all proteins except cytochrome C and carbonic anhydrase 2, more peptides were 
identified using the ammonium formate buffer. Altogether, 11 peptides more were 
assigned utilizing buffer system (2) which corresponds to 8.7 % increase. A higher 
sequence coverage was obtained for α-lactalbumin with buffer system (1) in spite of a 
slightly higher number of peptide identifications. This effect occurs because using 
buffer system (1) two peptides were identified: one with 10 amino acids and one with 
17. When employing buffer system (2) three peptides were assigned to α-lactalbumin: 
one was a hit with 10, the second with 8 and the last with 9 amino acids, but the last 
was the same as the second peptide, containing one missed cleavage. So only the 
additional sequence information of one amino acid was obtained. Altogether, there 
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were 27 amino acid residues identified with buffer system (1) and only 19 with buffer 
system (2). This explains the higher sequence coverage for α-lactalbumin using 
sodium dihydrogen phosphate buffer in spite of more identified peptides using 
ammonium formate. The most notable difference was found for ß-lactoglobulin, where 
three more identified peptides resulted in an increase of sequence coverage of 66.7 % 
with respect to buffer system (2). 
Altogether 115 peptides could be identified with the sodium dihydrogen phosphate 
buffer system, which is equal to 1.8 % more identified peptides in comparison to 1D 
analysis. With the ammonium formate buffer system 126 peptides were assigned to 
proteins corresponding to 11.5 % additional peptide hits compared to 1D separation, 
although here the MS mass window in Mascot software was narrower than in 1D 
analysis (50 ppm and 100 ppm, respectively). The precursor mass tolerance was set 
as for 1D (100 ppm) for both methods, to achieve a more accurate comparison. No 
change of peptide identification was observable for buffer system (2) where still 126 
peptides were assigned to the proteins. However, with buffer system (1) 120 instead 
of 115 peptides could be assigned to the ten-protein standard which increases the 
percental additional identification in comparison to 1D analysis from 1.8 % to 6.2 %. 
The comparison of 1D analysis and the two different buffer systems is shown in 
Figure 37. 
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Figure 37. Identified unique peptides for the ten proteins with both buffer systems 
and 1D analysis in comparison. 
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Two proteins were identified with less peptides than in 1D analysis: myoglobin and α-
lactalbumin. This might be caused by the triplicate analysis of 1D whereas for 2D 
only two replicates were measured. The remaining proteins were identified with an 
equal or higher number of peptides for buffer system (2). However, by employing 
buffer system (1) additionally less peptide hits for lysozyme C were obtained. 
These results indicate that the extra separation effect caused by the simultaneously 
applied pH and salt gradient leads to higher peptide identification. This resulted in  
11 peptides assigned additionally in comparison to buffer system (1), applying a 
precursor mass tolerance of 50 ppm. Five peptides more were identified, setting it to 
100 ppm, respectively. Altogether, with the formate buffer system 32 % of the in silico 
calculated peptides for the considered mass range could be covered. Finally, the 
ammonium formate buffer system was utilized for the proteome analysis of a 
Glioblastoma multiforme tissue protein extract following in the next chapter. 
 
 
3.4 Mascot search parameters for proteome analysis 
 
There are a variety of possibilities to set Mascot parameters for proteome analysis. 
Five different parameter sets were chosen for the ammonium formate buffer system 
as shown in Figure 38. The MOWSE Score of proteins is not considered in this case.  
The precursor tolerance was modified (50 and 100 ppm) as well as the confidence 
interval of proteins and peptides. For peptides the ion score cut-off can be set as 
confidence interval or as fixed value.  
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Figure 38.  Settings of Mascot parameters for proteome analysis. (a) Unique 
peptides, sequence coverage and average peptide MOWSE Score for different 
Mascot settings and (b) false positives rate for different Mascot settings. ISCO = ion 
score cut-off. 
 
The highest unique peptide identification and therefore the highest average sequence 
coverage were achieved with 50 ppm precursor tolerance and an ion score cut-off of 
zero. In contrast, only slight differences between 50 ppm and 100 ppm precursor 
tolerance are seen with an ion score cut-off of 95 %. This indicates that the impact of 
the ion score cut-off is more pronounced than that of the precursor tolerance. 
Choosing a fixed value of 31 for the ion score cut-off (suggested by Mascot) leads to a 
decrease in the identified unique peptides. This is reasonable because Mascot 
computes an appropriate ion score for every individual peptide hit above which the set 
confidence interval is reached (in this case 95 %). By setting a fixed ion score cut-off 
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all peptides below this value are dismissed whether or not reaching their specific ion 
score for the set confidence level.  
The false positives rate should be below 5 % and 1 %, respectively. Actually the value 
is always above 6 % for protein confidence of 95 %, and 2 % for 99 %. These high 
false positives rates are probably caused by the small dataset. For 100 ppm the 
highest level with 7 % is obtained because of the lower mass accuracy. Hence, for the 
false positives rate the precursor tolerance seems to be more relevant than the ion 
score cut-off. 
For proteome analysis a precursor tolerance of 50 ppm was chosen, a confidence 
interval for proteins of 99 % and for peptides of 95 % resulting in a false positives rate 
of 1.2 % (shown in the next chapter). 
The mass tolerance for the peptide fragment ions was set to 0.5 Da for this 10 protein 
standard because the proteins to be identified were already known. In proteome 
analysis however, a stricter mass tolerance has to be applied because the results of 
protein identification have to be reliable and it is mostly unknown which proteins are 
present in the sample. Therefore, a mass tolerance for fragment ions of 0.2 Da was 
applied in proteome analysis. 
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4 Summary 
 
In this chapter two approaches for 2D proteome analysis based on chromatography 
and mass spectrometry were established. First, an IP-RP-HPLC approach for intact 
protein separation as first dimension of semi top-down proteomics was optimized. 
Here, the focus was especially on separation efficiency and selectivity as well as the 
repeatability of the intact protein separation.  
Furthermore, a nano-flow HPLC-MALDI-TOF/TOF platform for peptide separation in 
the second dimension of proteome analysis was elaborated. The impact of spotting 
time, preconcentration and fragmentation method for tryptic peptides to the protein 
and peptide identification were investigated. The most distinct effect on system 
performance was obtained by installing a trap column and consequent 
preconcentration of the peptides. 
The established nano-flow IP-RP-HPLC MALDI-TOF/TOF approach was applied as 
second dimension of a bottom-up approach including SCX-HPLC of peptides of a 
moderately complex (395 peptides) standard protein digest sample in the first 
dimension. Two buffer systems were compared: a sodium dihydrogen phosphate 
buffer system with increasing ionic strength and an ammonium formate buffer system 
offering additional changing of pH. The ammonium formate buffer system was chosen 
for application in proteome analysis due to 8.7 % more identified peptides in 
comparison to the sodium dihydrogen phosphate buffer system. Compared to 1D 
analysis 11.5 % additional peptide identification could be achieved applying the 2D 
bottom-up strategy with ammonium formate as buffer system. 
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5 Conclusions 
 
The established bottom-up and semi top-down approaches should be applied to a 
proteome analysis in the next chapter. According to the elaborated optimization in this 
chapter the following conditions were used for intact protein separation as first 
dimension for the semi top-down proteome analysis: 
 
1. Two 50 x 4.6 mm monolithic columns were coupled in series to achieve higher 
separation efficiency. 
2. As ion-pair modifier for IP-RP-HPLC 0.05 % TFA was added to the mobile 
phase. 
3. The gradient was expanded due to the immense complexity of the sample to 
15-60 % acetonitrile in 0.05 % aqueous TFA in 60 min. 
 
The following parameters were elaborated for the second dimension nano-flow IP-RP-
HPLC peptide separation of both methods:  
 
1. The spotting time was set to 5 s for one spot due to the tremendous complexity 
of the sample. 
2. The peptides were concentrated and desalted prior to separation realized by 
installing a monolithic trap column. 
3. The tryptic peptides were fragmented by PSD with subsequent acceleration. 
 
Finally, the evaluation of Mascot search paramters resulted in the following settings for 
proteome analysis: 
 
1. The precursor mass tolerance was set to 50 ppm. 
2. The fragment mass tolerance was set to 0.2 Da. 
3. The confidence interval for peptide identification was set to 95 %. 
4. The confidence interval for protein identification was set to 99 %. 
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1 Introduction 
 
The analysis of complex proteome samples is a challenging task. Until today, 
interactions in the human proteome including hundred thousands of proteins in an 
extremely broad dynamic range are rarely understood [246]. Therefore, it is essential 
to develop efficient methods for proteome analysis to get a deeper understanding of 
the functionality and tremendous complexity of the human proteome.  
Three fundamental developments have made large scale proteome analyses 
possible: Two-dimensional gel electrophoresis, high-performance liquid 
chromatography and mass spectrometry. 
Gel-based approaches are very powerful but suffer from some drawbacks: the 
observable mass and pI range are restricted; especially basic, very large and small 
as well as very hydrophobic proteins are underrepresented in the analysis  
results [3]. Chromatographic approaches are advantageous since they offer higher 
coverage of mass- and pI range. 
The classical chromatographic-based strategy in proteomics is the bottom-up 
approach. Here, in both dimensions peptides are separated using different 
chromatographic modes. The peptides of the proteins detected with the bottom-up 
approach are distributed over the set of fractions obtained from the first dimension. 
Thus, even when only few proteins are of interest, as in diagnostics, the whole 
proteome analysis has to be repeated. By applying semi top-down approaches the 
distribution of peptides over the first separation dimension is circumvented. Here 
peptides are concentrated in distinct fraction(s) where the corresponding protein 
elutes in the first dimension. In further analysis only the fractions of interest 
containing the demanded proteins have to be digested. In the case of diagnostic 
application the proteome analysis in total has to be operated once and then only 
distinct fractions from the first dimension have to be investigated. This approach is 
advantageous in terms of micropreparation for proteins and sequence determination 
e.g. for biomarkers. 
Recently, a micro semi top-down approach was introduced which employs 
chromatofocusing (CF) for intact protein separation in the first dimension applying 
weak anion exchange (WAX)-HPLC aqpplying a pH gradient [247]. Fractions collected 
in the first dimension are subsequently digested, and the peptides are analyzed in 
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the second dimension. This approach provides the important information of the pI 
value for the identified proteins.  
The aim of the presented study should be to apply the elaborated semi top-down 
approach to proteome analysis of a human Glioblastoma multiforme tissue sample. In 
this new semi top-down approach the retention time as characteristic information of a 
protein is obtained alternatively to the pI in CF. This alternative method should be 
compared to the classical shotgun proteomics approach. 
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2 Experimental section 
 
2.1 Chemicals and materials 
 
Sodiumdihydrogen phosphate (NaH2PO4, min. 99 %), was purchased from Merck 
(Darmstadt, Germany). Trifluoroethanol (TFE, ≥ 99.5 %), tributylphosphine  
(TBP, 97 %), acetonitrile (E Chromasolv), α-cyano-4-hydroxycinnamic acid  
(4-HCCA), ≥ 98 %) and human (Glu1)-fibrinopeptide B (glu1-fib) were obtained from 
Sigma-Aldrich (Steinheim, Germany). Trifluoroacetic acid (TFA, ≥ 99.5 %), 
heptafluorobutyric acid (HFBA, ≥ 99 %), ammonium formate ((NH4)OAc, ≥ 97 %) and 
ammonium hydrogen carbonate (NH4HCO3, ≥ 99.5 %) were purchased from Fluka 
(Buchs, Switzerland). Trypsin (sequencing grade modified) was purchased from 
Promega (Madison, WI, USA) and fused silica tubing from Polymicro Technologies 
(Phoenix, AZ, USA). Polyetheretherketone (PEEK) capillary tubing, tubing sleeves, 
microtight unions and microtight fittings were obtained from Upchurch Scientific (Oak 
Harbor, WA, USA). The utilized water was purified by a Purelab Ultra system (Elga, 
Siershahn, Switzerland). The thermo mixer was purchased from Eppendorf AG 
(Model Comfort, Hamburg, Germany) as well as the vacuum concentrator (Model 
Concentrator 5301). The centrifuge was procured from Heraeus (Model Biofuge13, 
Heidelberg, Germany). The Glioblastoma multiforme tissue was obtained from the 
group of Prof. Dr. Meese (Saarland University, Institute of Human Genetics, 
University Hospital, Homburg, Germany). The biopsy samples were immediately 
deep frozen after surgery at -70 °C. For protein quantification prior to digestion or 
injection of intact proteins into the first dimension the Bradford Assay was applied 
(Bio-Rad, Hercules, CA, USA).  
 
 
2.2 Preparation of human brain tumor tissue protein extracts 
 
To pieces of 10-15 mg of Glioblastoma multiforme tissue, 100 µL phosphate buffer  
(5 mM NaH2PO4) at pH 7.0 were added. After shaking (vortex genie 2, 
Bender&Hobein AG, Zurich, Switzerland) for 3 min the samples were incubated for  
1 h at room temperature with gentle shaking and then sonicated for 5 min in ice-
water. Addition of 100 µL trifluoroethanol (TFE), incubation for 2 h at 60 °C and 
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sonication for 2 min in ice-water followed [248]. Subsequently the protein concentration 
of the samples was determined using the Bradford Assay. The proteins were 
digested on the same day for bottom-up approach (paragraph 2.5). The samples for 
the semi top-down approach were stored two days at -30 °C prior to digestion 
(paragraph 2.4). To reduce the disulfide bonds 50 mM tributylphosphine (TBP) was 
added to a final concentration in the solution of 4.5 mM (20 µL TBP to 200 µL protein 
extract) and incubated for 30 min at 60 °C directly before injection into the first 
dimension of the semi top-down approach. 
 
 
2.3 IP-RP-HPLC prefractionation of intact proteins as first dimension of the semi 
top-down approach 
 
Approximately 860 µg of proteins (quantified with Bradford assay) in 500 µL were 
injected into an analytical HPLC system (Model 1050, HP, Waldbronn, Germany) to 
perform separation with IP-RP-HPLC. The proteins were separated employing two  
50 x 4.6 mm i.d. monolithic reversed-phase columns (ProSwift RP-1S, Dionex 
Corporation, Sunnyvale, CA, USA) connected in-series using a flow rate of  
0.8 mL min-1 and operating at 50 °C. The external six port injection valve (Model 7125, 
Rheodyne, Rohnert Park, CA, USA) was equipped with a 1 mL sample loop. Proteins 
were eluted with a 60-min gradient of 15-60 % acetonitrile in 0.05 % aqueous TFA.  
UV chromatograms were recorded at 280 nm, fractions were collected every second 
minute and stored at -30 °C. 
 
 
2.4 Tryptic digest of the extracted proteins for the semi top-down approach 
 
For the semi top-down approach every fraction obtained from the first dimension was 
evaporated to dryness in the vacuum concentrator and 100 µL of 50 mM ammonium 
hydrogencarbonate were added. The data from Bradford assay were used to adjust 
the enzyme/protein ratio to approximately 1/20 (40 µg trypsin to 860 µg proteins). 
Therefore two vials of trypsin each containing 20 µg were dissolved in 40 µL acetic 
acid (50 mM) and combined to 80 µL trypsin solution. The mixture was activated at  
37 °C for 30 min in the thermo mixer (550 rpm) and then added to the proteins in the 
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fractions of the first dimension. The added trypsin mass was estimated based on the 
UV signals observed from the chromatogram of the fractionation as revealed in  
Table 25 (chromatogram depicted in Figure 41a). 
 
Table 25. Distribution of trypsin solution over 28 fractions obtained from SCX-HPLC 
separation of peptides in the first dimension. 
 
fraction 
number 
added trypsin solution 
[µL] 
added trypsin  
 [µg] 
01 4 2.0 
02 4 2.0 
03 1 0.5 
04 1 0.5 
05 2 1.0 
06 2 1.0 
07 2 1.0 
08 2 1.0 
09 2 1.0 
10 4 2.0 
11 4 2.0 
12 4 2.0 
13 4 2.0 
14 4 2.0 
15 4 2.0 
16 4 2.0 
17 4 2.0 
18 4 2.0 
19 4 2.0 
20 4 2.0 
21 4 2.0 
22 4 2.0 
23 2 1.0 
24 2 1.0 
25 1 0.5 
26 1 0.5 
27 1 0.5 
28 1 0.5 
 
The solutions were incubated for 15 h at 37 °C and 550 rpm in the thermo mixer. 
Subsequently, the reaction was quenched by adding 10 µL aqueous trifluoroacetic 
acid (1 % v/v) to each fraction. The fractions then were frozen at -30 °C. Prior to 
injection into the nano-flow HPLC-MALDI-TOF/TOF system 100 µL of aqueous 0.1 % 
HFBA solution were added to every fraction. 
 
 
 
 
Chapter IV:Application of the established approaches to proteome analysis of Glioblastoma multiforme 
   
122
2.5 Tryptic digest of the extracted proteins for the bottom-up approach  
 
After protein quantification utilizing Bradford Assay 20 µL of 50 mM TBP (4.5 mM 
final concentration in the solution) were added to 200 µL (100 µL phosphate buffer 
plus 100 µL TFE) of the protein extract. This protein solution was diluted 1:4 (220 µL 
protein solution plus 880 µL NH4HCO3) with ammonium hydrogencarbonate (50 mM) 
at pH 7.9 to reduce the TFE concentration. The enzyme/protein ratio was adjusted to 
approximate 1/50 using the protein concentration determined with Bradford assay. 
Twenty micrograms trypsin were dissolved in 20 µL of 50 mM acetic acid and 
activated in the thermo mixer for 30 min at 37 °C and 550 rpm. Of this solution 8.5 µL 
(= 8.5 µg) were added to the protein extract and incubated for 15 h in the thermo 
mixer at 37 °C and 550 rpm. The digest was quenched by addition of 10 µL aqueous 
TFA (~1 % v/v). The peptide solution was evaporated to dryness in the vacuum 
concentrator and was then stored at -30 °C. Prior to injection into the first dimension 
the peptides were dissolved in 200 µL ammonium formate (10 mM, pH 3 = eluent A 
in SCX-HPLC). 
 
 
2.6 SCX-HPLC prefractionation of peptides for the bottom-up approach 
 
About 426 µg/200 µL of peptides (quantified with Bradford assay) were injected into 
an analytical HPLC system (Model 1050, HP) to perform peptide separation by SCX-
HPLC. The peptides were separated on a SCX-column (Polysulfoethyl A,  
200 x 2.1 mm i.d., 5µm, 200 Å, PolyLC, Columbia, MD, USA) using a 10 x 2.1 mm i.d. 
guard column and a flow rate of 0.2 mL min-1 operating at 25 °C. The external six-port 
injection valve (Model 7125, Rheodyne) was equipped with a 200-µL sample loop 
(Rheodyne). Eluent A consisted of 10 mM ammonium formate at pH 3 and eluent B of 
500 mM ammonium formate at pH 6.8. Both mobile phase solvents contained 25 % 
acetonitrile. After injection of the peptide sample the system was held for 10 min at  
10 mM ammonium formate (pH 3). Then the gradient for peptide separation started 
raising within 40 min to 250 mM ammonium formate (pH 4.9) followed by ramping to 
500 mM ammonium formate (pH 6.8) within 10 min. For the last 10 min the system 
was held at 500 mM ammonium formate (pH 6.8). The UV chromatogram was 
recorded at 214 nm. Fractions were collected every two minutes and then frozen at  
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-30 °C. Prior to injection into the second dimension 100 µL of 0.1 % aqueous HFBA 
solution were added to the fractions. 
 
 
2.7 Nano-flow IP-RP-HPLC MALDI-MS of peptides 
 
Ten micoliters of sample (prepared as described in paragraphs 2.2-2.6) were injected 
into the second-dimension ion-pair reversed-phase nano-flow HPLC system. The 
experiment was performed in triplicate for the semi top-down approach and in 
duplicate for the bottom-up approach, respectively. The setup consisted of a nano-flow 
HPLC unit (Model Ultimate, LC Packings, Amsterdam, The Netherlands), an automatic 
injection unit (Model Famos, LC-Packings) and a loading pump (Model  
K-1001, Knauer, Berlin, Germany) with a 10-port switching valve (Model C2-1000D 
(stator) and 06A-8029C (rotor), VICI, Schenkon, Switzerland). The detector was 
equipped with a 3 nL Z-shaped flow cell (Model Ultimate). The UV chromatogram was 
recorded at 214 nm. A short precolumn (10 x 0.2 mm i.d.) was used to desalt and 
concentrate the peptide samples obtained from the first dimension. The separation 
column (60 x 0.1 mm i.d.) as well as the precolumn contained a monolithic PS-DVB-
based stationary phase material synthesized according to the published protocol [221] 
(available from LC Packings, Dionex Corporation, Sunnyvale, USA). After injection 
into the second dimension the peptides were isocratically concentrated and desalted 
on the precolumn for 3 minutes. The flow rate of 0.1 % aqueous HFBA solvent, 
delivered by the loading pump was set to 10 µL min-1. After switching the valve the 
peptides were eluted in back-flush mode onto the separation column. A 50-min 
gradient of 0-30 % acetonitrile in 0.05 % aqueous TFA was applied followed by 
ramping to 100 % acetonitrile in 10 min at a flow rate of 0.7 µL min-1. Separation was 
performed at a temperature of 55 °C. The eluate from the HPLC system was spotted 
onto a stainless steel target (Opti-TOF 123 x 81 mm, ABI, Framingham, MA, USA) 
with a spotting unit (Model Probot, LC Packings, Dionex Corporation). As matrix 3 mg 
mL-1 α-cyano-4-hydroxycinnamic acid in 70 % acetonitrile and 0.1 % aqueous TFA 
was utilized. The matrix solution contained human (Glu1)-fibrinopeptide B  (glu1-fib) in 
a concentration of 15 fmol µL-1. The matrix flow was set to 3.1 µL min-1 with a spotting 
time of 5 s per spot (258 nL per spot). Sixty-seven minutes of the HPLC run (min 8 to 
75) were spotted. For protein identification a MALDI-TOF/TOF mass spectrometer 
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(ABI 4800 TOF/TOF Analyzer, ABI) was used. The spectra were generated in positive 
reflector mode in a mass range of m/z 800-4,000. In MS mode 25 laser shots were 
summarized to one sub-spectrum and 40 sub-spectra were accumulated to the final 
spectrum (1,000 shots) with a frequency of 200 Hz and a laser wavelength of 355 nm. 
For optimized mass accuracy an internal calibration on the m/z of glu1-fib (m/z 
1570.677) was performed during sample acquisition. The m/z of glu1-fib was excluded 
from precursor selection for the peptide ions. Fragmentation of maximum six 
precursors was realized in a metastable decay process with re-acceleration [223]. No 
additional collision gas was used for fragmentation. Stop conditions were set to 
achieve optimal quality of the MS/MS spectra: Between 750 and 3,000 laser shots 
were recorded for one spectrum. 50 laser shots were acquired for one sub-spectrum, 
minimum 15 sub-spectra and maximum 60 sub-spectra were recorded. When 3,000 
laser shots or a signal to noise ratio (S/N) of 35 for at least 10 peaks were achieved 
the fragment ion data acquisition stopped. 
Calibration of the mass spectrometer was performed as described in Chapter III 
(paragraph 2.6). MS calibration was initiated prior to each analysis, MS/MS calibration 
prior to every second analysis. 
 
 
2.8 Data processing 
 
The MS/MS spectra were smoothed with Savitsky-Golay algorithm using three points 
across the peak and a polynomial order of four. For exporting data to create Mascot 
generic files (mgf) the following settings were used in the MS/MS peak filter:  
Mass range: m/z 60 to precursor mass -35 Da; peak density: maximum 20 peaks per 
200 Da; minimum S/N: 10; minimum area: 200 and maximum 65 peaks/precursor. To 
identify proteins the “.mgf”s were sent to Mascot software (version 2.2.03, Matrix 
Science, London, UK) which uses the MOWSE (Molecular weight search) algorithm. 
These settings were applied: database: Swiss Prot (Version 54.7, January 15th, 2008); 
taxonomy: homo sapiens (18,117 sequences); enzyme: trypsin; variable modification: 
methionine oxidation; peptide tolerance: 50 ppm; MS/MS tolerance: 0.2 Da; maximal 
missed cleavages: 1 and ion-score cut off for peptides: 0.05 (95 %). The probability of 
an identification as a random event for proteins was set to 0.01 (99 %).  
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2.9 Data interpretation 
 
To categorize the identified proteins of the Glioblastoma multiforme tissue to gene 
ontologies GeneTrail software was used. Here, the subset of membrane proteins was 
selected for characterization of the retention behavior for intact proteins in the first 
dimension of the semi top-down approach. The following parameters were set: The 
chosen organism was human; identifier type: Swiss Prot; significance threshold: 99 % 
and the minimal genes of a category shown: 100. The GeneTrail software is based 
on gene functions of the Gene Ontology (GO) terms. PANTHER software was utilized 
to divide the identified proteins into main molecular functions based on their gene 
function.  
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3 Results and discussion 
 
3.1 The bottom-up approach as standard method in chromatography- and mass 
spectrometry-based  proteomics 
 
3.1.1 Two-dimensional fractionation of peptides 
 
In two-dimensional shotgun proteomics peptides are separated in both dimensions. 
The applied method in this study includes strong cation-exchange chromatography in 
the first dimension. Figure 39a provides the UV chromatogram of this separation. 
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Figure 39. Two-dimensional fractionation of peptides in the bottom-up approach. UV 
chromatogram (214 nm) of the first dimension (a) and BPCs of fraction 20-22 in the 
second dimension (b). Chromatographic conditions are given in the experimental 
section. 
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A shallow gradient with increasing ionic strength and pH was selected for the first 
dimension. No defined peaks are observable because the signal was recorded at  
214 nm and ammonium formate also shows UV activity at this wavelength. 
Fractions were collected in a time range of 80 min every second minute and the 40 
obtained fractions were evaporated to dryness before tryptic digestion. Subsequently 
peptides of every fraction were injected twice into the second dimension, 
concentrated and desalted on a monolithic trap column, and a monolithic column was 
also used for peptide separation. A shallow 50-min gradient was applied to perform 
peptide separation. The eluted peptides were analyzed employing the previousy 
optimized nano-flow HPLC-MALDI-TOF/TOF platform. Figure 39b illustrates the base 
peak chromatograms (BPC) of three adjacent fractions from obtained from the 
second dimension, acquired by MALDI-TOF/TOF. A time range of 50 minutes 
(minute 8-58) was analyzed including 600 spots. In the exemplary shown fractions 
(Figure 39b) peptide signals until spot 450 were observable which corresponds to an 
acetonitrile concentration of 27.3 % (including 0.05 % TFA). 
 
 
3.1.2 Protein identification 
 
The recorded mass spectrometric data were sent to the Mascot search engine which 
compares tandem mass spectra simulated from in silico digestion with the recorded 
mass spectra. Altogether, 2,056 proteins (Table 26) were identified in 34 fractions 
obtained from the first dimension peptide separation. As shown in Figure 40 the 
typical pattern for SCX separation in the first dimension is visible. In ion-exchange 
chromatography the analytes elute as clusters depending on their overall  
charge [249;250]. Only the proteins and peptides which appear for the first time in an 
individual fraction are included in the bar chart. Furthermore, the average peptides 
per protein are displayed in Figure 40. In fraction 19 the highest number of peptides 
(603) was observed, the highest number of proteins were identified in fraction 2 (190) 
followed by fraction 19 (184).  
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Figure 40. Non-redundant protein and peptide hits identified with the bottom-up 
approach. Distribution of identifications over the 34 protein- and peptide containing 
fractions (left scale) as well as average peptides per protein for these fractions (right 
scale). 
 
In Table 26 characteristic data for the bottom-up approach are given. Eight hundred-
eleven proteins, so-called one-hit wonders, were identified by only one peptide which 
correspondents to 39.4 % of the 2,056 identified proteins. There are various reasons 
for the appearance of one-hit wonders: the other peptides of one protein are too large 
or too small to be detected in the set mass range. This can be caused either by the 
protein sequence itself (high or low numbers of tryptic cleavage sites) or by 
incomplete digestion. Another reason for observing one-hit wonders are mass 
spectra of low quality due to sample contamination. Further a bad ionization 
efficiency caused by the amino acid composition of the peptide or its low abundance 
result in the appearance of one-hit wonders. Another well known phenomenon is that 
some peptides do not undergo sufficient fragmentation, hence not allowing sequence 
determination and identification (weak signal intensity). One-hit wonders were 
excluded from further evaluation. Although a significance threshold of 99 % for the 
proteins is given for this analysis one-hit wonders hold the highest probability to be 
false positive protein identifications. By excluding them, of course, a high number of 
correct peptide hits are excluded, too. It is even assumed that for one false positive 
identification 19 correct ones are eliminated [251]. A similar rate of one-hit wonders as 
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in this study was observed by Yates et al [252] in the proteomic study of a whole cell 
lysate of yeast. They reported a one-hit wonder rate of 34 %.  
As expected for human samples a high homology between the proteins is observed. 
As a result 594 peptides can be assigned to more than one protein. The percentage of 
annotated spectra (28.3 %) lies in the typical range for tandem mass spectra [253]. 
 
Table 26. Results from the bottom-up approach (Two replicates in the second 
separation dimension). 
 
parameter value 
identified proteins 6,883 
non-redundant proteins 2,056 
“one-hit wonders” 811 
identified proteins without “one-hit wonders” 1,245 
peptides in non-redundant proteins 7,122 
non-redundant peptides 6,528 
annotated spectra [%] 28.3 
false positives [%] 1.3 
average mass accuracy (MS mode) [ppm] 18 
average peptide score 66.5 
 
The remaining results revealed in Table 26 are discussed in detail for the semi top-
down approach in the paragraph 3.2.2 of this chapter. 
 
 
3.2 A semi top-down approach as alternative method for proteome analysis 
 
3.2.1 Two-dimensional fractionation of proteins and peptides 
 
Prior to first dimension separation for semi top-down approach disulfide bonds of the 
intact proteins were reduced with tributylphosphine to unfold protein structure and 
promote better interaction with the stationary phase of the monolithic separation 
column. In Figure 41 the UV chromatogram of the fractionation of the intact proteins is 
shown as well as the BPCs of three adjacent fractions of the second-dimension 
separation.  
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Figure 41. First dimension fractionation (280 nm) of intact proteins followed by 
peptide fractionation. UV chromatogram of first dimension (a) and BPCs of fraction 
20-22 in second dimension (b). Chromatographic conditions are given in the 
experimental section. 
 
Fractionation for further separation has always to cope with some aspects: 
conservation of the accomplished separation, dilution of the peptides or proteins 
gained in the individual fractions, time consumption for separation in the second 
dimension and carryover of peptides or proteins in contiguous fractions. 
Especially MALDI-TOF/TOF analyses after second-dimension separation are very 
time consuming. One analysis of a 50-min HPLC run can last up to 15 or even 20 
hours for complex samples. Therefore, two minute fractions were taken over a time 
range of 80 min and these 40 fractions were analyzed in the second dimension. 
However, the dilution of the proteins is still moderate and the high sensitivity of the 
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MALDI-TOF/TOF instrument still provides detection of low abundant proteins. 
Furthermore, the precursor selection procedure of the mass spectrometer supplies a 
pertinent decision for precursor selection: the spot with the highest intensity for the 
precursor ion of interest of the whole spotted HPLC run is chosen for fragmentation. 
The fraction-to-fraction carryover for proteins may be higher than for peptides due to 
the larger chromatographic peak width for proteins. This will be discussed later in 
detail (paragraph 3.4.3). For the fractionation of the intact proteins (Figure 41a) a 
shallow 60-minutes gradient was used to achieve high peak capacity resulting in 
observable discrete peaks containing numerous of different proteins. 
Into the second dimension the samples were injected in triplicate. Peptides were 
concentrated on a PS-DVB-based monolithic trap column. Subsequently the analytes 
were transferred for separation onto an equal monolithic capillary column and 
separated with the same gradient as used for the second separation dimension of the 
bottom-up approach. Typical base peak chromatograms (BPC) of three contiguous 
fractions are depicted in Figure 41b. In each case the first of the three replicates for 
one fraction is shown. In the fractions 20, 21 and 22, obtained from the first separation 
dimension 176, 174 and 178 proteins were identified, respectively. 
 
 
3.2.2 Protein identification 
 
The acquired mass spectrometric data were launched to the Mascot search engine 
using the same settings as for the previously discussed bottom-up approach. Proteins 
could be identified in the first 28 fractions as displayed in Figure 42.  
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Figure 42. Proteins and peptides identified with the semi top-down approach. 
Proteins and peptides which appear for the first time in a fraction are plotted (left 
scale) as well as average peptides per protein of the individual fractions (right scale). 
 
The highest number of proteins was identified in the first fraction which indicates that 
fragments of proteins and small hydrophilic proteins elute in this fraction because the 
gradient was started at a low concentration of acetonitrile (15 %) in 0.05 % aqueous 
TFA. The rest of the proteins was distributed over the remaining 27 fractions. Fraction 
9 contained the highest number of non-redundant proteins (159) beside fraction 1. In 
fraction 20 the highest number of peptide hits was obtained (417). The average 
number of identified peptides per protein for the individual fractions is also shown in 
Figure 42. In fraction 3, a very high protein/peptide ratio is observed because there 
was only one non-redundant protein identified, including eight peptides which is similar 
for fraction 2. An average peptide/protein ratio of 3.3 could be observed over all 
fractions as shown in Table 27. Altogether, 5,270 protein hits were obtained for the 28 
fractions analyzed using the Mascot search engine and the Swiss Prot database 
(release 54.7, same as for the bottom-up approach). After merging the raw data files 
of the triplicate analyses for all fractions, 1,642 non-redundant proteins  
(Table 27) were identified. With this semi top-down method altogether 5,439 peptides 
were assigned to the 1,642 proteins. After removal of redundant identifications, 4,945 
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unique peptides were identified. This means that 494 peptides occur in more than one 
protein. 
 
Table 27. Results from the semi top-down approach (Three replicates in the second 
separatioin dimension). 
 
parameter value 
identified proteins 5,270 
non-redundant proteins 1,642 
“one-hit wonders” 638 
identified proteins without “one-hit wonders” 1,004 
peptides in non-redundant proteins 5,439 
non-redundant peptides 4,945 
annotated spectra [%] 30.5 
false positives [%] 1.2 
average mass accuracy (MS mode) [ppm] 17 
average peptide score 70.3 
average protein/peptide ratio 3.3 
 
As expected, false-positives rate, average mass accuracy and average peptide score 
are similar to those of the bottom-up approach because the same instrumental setup 
and the same settings for the Mascot search engine were used. 
The percentage of 30.5 % annotated spectra lies in the typically reported range of  
25 % for tandem mass spectra. The relatively low percentage is caused either by poor 
quality of the spectra according to contamination of the sample or experimental noise. 
Another explanation for poor mass spectra assignment is searching with the incorrect 
sequence for the protein in the database. Protein sequence errors in the databases 
are caused generally by post translational modifications, polymorphisms or splice 
variants [254]. Then the peptide fragments can not be interpreted correctly by the 
search engine. 
The utilized Mascot version (2.2.2.) offers the automatic search in a decoy database. 
After browsing the database containing the protein sequences, a decoy database is 
applied for estimation of the false-positive identification rate. This decoy database is 
randomized which means that for the tested peptide or protein sequence a random 
sequence is generated with the same length of the sequences and probability of 
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average amino acid composition [255]. In that way the decoy database is built up and 
the containing sequences are browsed after generating the results for the “real” 
database. As given in Table 27 a false positives rate of 1.2 % is observed which is 
equivalent to the setting of a 99 % probability for correct protein identification. The 
peptide mass tolerance which was used to perform Mascot search was set to 50 ppm. 
The average obtained mass accuracy resulted in 17 ppm for MS mode (Table 27). By 
decreasing the value for mass tolerance in the search settings the average mass 
accuracy value would drop, too. The mass spectrometer was specified for 50 ppm 
employing default calibration and 5 ppm for internal calibration according to the 
manufacturer. Internal calibration was performed using glu1-fib in a concentration of  
15 fmol µL-1 resulting in a concentration of 3.9 fmol spot-1. However, this calibration 
peptide could not be recorded in every spectrum. Especially in spectra with high 
peptide signal intensity glu1-fib was subjected to peak suppression and hence was not 
detectable. For those spectra the default calibration was automatically applied 
resulting in a lower mass accuracy (50 ppm instead of 5 ppm). The Mowse Score 
developed with Mascot search algorithm is a scale for quality estimation of the 
identified peptides and proteins which means higher scores characterize more 
confident identification. The average Mowse Score for successful protein identification 
for this analysis was computed at 32. Table 27 shows 70.3 as average peptide score 
whereas 25.2 % of the peptides were identified with a score above 90 and 22.2 % with 
a score below 40.  
On the pie chart of Figure 43 the percental parts of peptides per protein for the 1,642 
identified proteins are depicted. 
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Figure 43. Peptides per protein of the 1,642 with the semi top-down approach in 
triplicate fraction analysis identified proteins. 
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3.3 Comparison of the semi top-down and the bottom-up approach 
 
3.3.1 Overlap of peptide and protein identifications 
 
Both methods of proteome analysis described above are based on two-dimensional 
chromatography and mass spectrometry. Whereas the bottom-up or shotgun 
approach is the most common method for proteome analysis utilizing 
chromatography and mass spectrometry, the semi top-down approach as shown 
here was newly established. In the following, a comparison of both methods is 
described to elaborate the advantages and disadvantages for both methods. To set 
both approaches in appropriate relation, for the semi top-down approach only two of 
the three technical replicates of the second separation dimension were considered 
because only two technical replicates were available for the classical bottom-up 
approach. This results in 920 instead of 1,004 protein hits with more than one peptide 
compared to 1,245 identified proteins obtained from the bottom-up approach. As 
depicted in Figure 44, 533 proteins were identified in both approaches.  
There are several possible explanations for the higher number of protein identification 
employing the bottom-up approach: In the semi top-down approach intact proteins 
are separated in the first dimension which can cause problems of solubility as they 
are much more complex in their structure than peptides. Furthermore large proteins 
can adsorb irreversibly at the stationary phase of the separation column which 
causes further protein losses. Another aspect to consider is the protein loss occurring 
during transfer of the analytes from the first- to the second dimension. Proteins can 
adsorb at the wall of the Eppendorf vials more probable than peptides during shaking 
and are then not available for the tryptic digest.  
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Figure 44. Venn diagram showing the the overlapping of both approaches. Identified 
proteins of the human Glioblastoma multiforme tissue with more than one peptide are 
considered. 
 
Altogether 1,632 proteins of the human Glioblastoma multiforme tumor tissue were 
identified with more than one peptide. In the overlapping area of the Venn diagram  
43 % of the proteins identified with bottom-up and 58 % of the proteins identified with 
semi top-down appeared. Hence, only about half of the identified proteins for one 
method were also identified with the other one. This may be caused inter alia by the 
extreme heterogeneity of the studied Glioblastoma multiforme tissue [256] since two 
different slices of the same tumor were used for the analysis. 
 
 
 
3.3.2 Coverage of mass and pI range 
 
An advantage of chromatographic methods in proteome analysis in comparison to 
gel-based approaches is the higher mass and pI range coverage of the identified 
proteins [3;257;258]. 
To investigate the covered mass and pI range for both chromatographic approaches, 
the logarithmic theoretical computed molecular protein mass was plotted as a 
function of the theoretical calculated pI value for each protein identified with more 
than one peptide (Figure 45). A wide pH and mass range could be covered with both 
methods as shown in Figure 45a+b. For the bottom-up approach 30.7 % proteins 
with a theoretical pI>7.5 were observed and for the semi top-down approach 26.5 %, 
respectively. As visible in Figure 45c, a similar distribution of pI and mass range as 
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for the single methods is obtained for the overlapping proteins. Here 26.5 % basic 
proteins with a pI value above 7.5 were observed. A large number of high molecular 
proteins were identified, for the bottom-up approach 18.3 % with a molecular weight 
>100 kDa, for the semi top-down approach 11.4 % and for the proteins identified in 
both approaches 12.4 %, respectively. Small proteins were also identified (semi top-
down approach 13.6 % < 20 kDa, bottom-up approach 9.0 % and intersection  
10.7 %, respectively). The insection at pH 7.5 is observable because this is the 
physiological pH of body fluids whereas the proteins have to be soluble. 
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Figure 45. LgMr/pI plots of the identified proteins with at least two peptides of (a) 
bottom-up, (b) semi top-down approach and (c) prorteins identified with both 
methods. BU = bottom-up; STD = semi top-down. 
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In Figure 46a and Figure 46b the percentage of the theoretical computed pI and 
mass of the proteins is depicted. As far as the semi top-down approach is concerned 
slightly more acidic proteins were identified, consequently the bottom-up approach 
provided more basic ones (Figure 46a). A trend was also observed for the small 
proteins (below 70 kDa) in Figure 46b. Smaller proteins are more presented by the 
semi top-down approach whereas with the bottom-up method more high-molecular 
proteins are observable. All in all the small acidic proteins are higher represented in 
the semi top-down approach and the high molecular basic proteins by utilizing the 
bottom-up method. 
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Figure 46. Comparison of the semi top-down and the bottom-up approach according 
to (a) the theoretical calculated pI for the proteins and (b) the computed molecular 
weight of the intact proteins. 
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3.3.3 Characterization of retention behavior 
 
3.3.3.1 First dimension separation of peptides or proteins 
 
In strong cation-exchange chromatography peptides should elute as function of their 
net charge, and their separation is influenced by the charge distribution. In order to 
retain a peptide on a cation-exchange column, the pH of the eluent needs to be lower 
than the isoelectric point of the peptide. A pH gradient was applied in SCX-HPLC 
additional to a gradient of ionic strength to perform peptide separation in the bottom-
up approach. Furthermore, 25 % acetonitrile were added to both eluents to suppress 
unspecific secondary hydrophobic interactions of the peptides with the stationary 
phase. The range of the calculated theoretical pI values for the peptides (computed 
with MW/pI tool on www.expasy.org) eluting in the different fractions of the first 
separation dimension is shown in Figure 47a. The values were arithmetically averaged 
for every individual fraction. Only unique peptides were included for one fraction. 
There is no linear correlation observable because of the isocratic step at the beginning 
of elution. However, the computed pI of the eluting peptides increases with the ionic 
strength during gradient elution (fraction 10 to 33). A similar effect was recognized 
before in a proteome study of C. glutamicum [259]. 
The retention of proteins in the first dimension for the semi top-down approach is 
achieved by solvophobic interactions between the hydrophobic stationary phase and 
the hydrophobic moieties of the proteins as well as electrostatic effects. Thus, the 
hydrophobicity of the eluted proteins should rise with increasing fraction number. To 
investigate the retention behavior the Grand Average of Hydropathy (GRAVY) Index 
was calculated [260;261] for every protein identified in the 28 fractions (Protein GRAVY 
tool on www.bioinformatics.org) and was then arithmetically averaged. Figure 47b 
shows the distribution of the computed average GRAVY Indices  as a function of the 
fraction number in the first dimension. 
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Figure 47. Retention behavior of first-dimension analytes. (a) pI as a function of 
peptide retention in the first dimension. (b) GRAVY Index as a function of protein 
retention in first dimension. 
 
In the first eight fractions the GRAVY Indices range between -0.7 and -0.6. From 
fraction 9 to 20 a slight increase of GRAVY values was observed. This means, as 
expected, that more hydrophobic proteins elute in later fractions. However, the 
dependency was not highly significant. Potentially, this indicates that the 
hydrophobicity of a protein is not sufficiently described by calculating the GRAVY 
Index from the primary structure. Moreover, electrostatic interactions also have to be 
considered due to the effect of the ion-pair modifier (0.05 % TFA) which was added 
to both eluents. In the case of working under acidic conditions with  
0.05 % TFA at pH 2.1 the alkaline amino-acid residues histidine, arginine, lysine and 
the N-termini are protonated. This means that not only hydrophobic amino-acid 
residues can interact with the stationary phase, but also charged moieties leading to 
an increase of selectivity for the protein separation [262]. These secondary interactions 
are favored (in contrast to unspecific solvophobic interactions in ion-exchange HPLC) 
because they abet multi-point adsorption of the proteins. 
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3.3.3.2 Second dimension separation of peptides 
 
For both chromatographic approaches the same nano-flow HPLC system with the 
same column dimensions and equal gradient (0-30 % acetonitrile in 0.05 % aqueous 
TFA within 50 min) was used. In the second dimension the retention behavior for 
both methods is characterized by computing the GRAVY Indices  for the individual 
peptides. The principle of separation is the same as for proteins eluting in the first 
dimension of the semi top-down approach. Solvophobic interactions and electrostatic 
effects contribute to the elution of the peptides. To investigate the correlation of 
hydrophobicity and retention time one protein from fraction 9 of the semi top-down 
approach, which is represented by six peptides, was chosen (Figure 48). The most 
hydrophilic peptide HQTNSELK elutes first, the most hydrophobic peptide 
LMDGSEIFSLLESAR last and the moderate hydrophobic peptide WQETVLVEER 
between them, as expected. However, the peptides of moderate hydrophobicity do 
not follow this concept strictly. For peptide QEEQSAAIHISETLEQKPHFESSTVK a 
GRAVY Index of -0.96 was computed which is more hydrophilic than the peptide 
KPTEFIGGVTSTSQSWVQK (GRAVY Index -0.55), but the former peptide elutes 
later. 
 
HQTNISELK 9.9 - 1.20
VVQETVLVEER 19.4 + 0.13
LMDGSEIFSLLESAR 40.6 + 0.31
KPTEFIGGVTSTSQSWVQK 25.7 - 0.55
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Figure 48. Elution of six peptides of the human protein E41L3 (band 4.1-like 
 protein 3) in fraction 9 of the semi top-down approach. 
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The ionic interactions which also contribute to peptide retention prevent a linear 
increase of the GRAVY Index as a function of retention time. This is illustrated further 
by plotting the average GRAVY Index of all unique peptides of fraction 9 as a 
function of their retention times in the second dimension (Figure 49a). The indices 
are summarized to two-minute sets of peptides to emphasize the slightly increase of 
GRAVY Indices  with the retention time. However, no linear correlation is observable. 
The separated peptides in the second dimension are more likely to be hydrophobic 
than the intact proteins separated in the first dimension of the semi top-down 
approach. In the aqueous medium surrounding the proteins in the cell (and later in 
the vial), the majority of the hydrophobic moieties are situated in the inner part of the 
protein whereas at the surface mainly hydrophilic residues are positioned. When 
proteins are digested, hydrophobic as well as hydrophilic peptides are present in the 
digest. The cumulative appearance of hydrophilic or hydrophobic amino acids in a 
short sequence (= peptide) is more probable while in proteins the GRAVY Index is 
averaged for plenty of amino acids. Actually, higher GRAVY Indices  were observed 
for the peptides than for the proteins. In Figure 49b GRAVY Indices  up to a value of 
1.88 are obtained for the peptides whereas the highest computed GRAVY Index for a 
protein in fraction 9 is 0.209.  
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Figure 49. GRAVY Indices  for unique peptides in fraction 09 of the semi top-down 
approach. (a) Peptides were summarized every two minutes and (b) all peptides of 
fraction 09 were plotted. 
 
In Figure 49a the summarized GRAVY Indices  emphasize the trend of increasing 
hydrophobicity of the peptides with the concentration of organic solvent, and the 
GRAVY Indices  of the unique peptides are revealed in Figure 49b to show their 
individual distribution. 
 
 
3.3.4 Sequence coverage 
 
For the semi top-down and the bottom-up approach the sequence coverage of the 
individual proteins was examined. Only proteins identified with more than one peptide 
were considered for this study. The sequence coverage of a protein is computed by 
multiplying the ratio of identified and possible amino-acid residues with 100 %. 
Referring to Figure 50a for the bottom-up approach 10.6 % more proteins with a 
sequence coverage of less than 10 % were found. This induces a 3.2 % higher 
protein coverage for proteins identified with more than 40 % sequence coverage for 
the semi top-down approach in comparison to the bottom-up method (Figure 50).  
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Figure 50. Sequence coverage for the identified proteins of (a) the bottom-up 
approach and (b) the semi top-down approach. 
 
To get a more accurate comparison, not only the sequence coverage for individual 
proteins was ascertained but also the average sequence coverage of the identified 
proteins to prove the higher sequence coverage for the established semi top-down 
approach. For this, the sum of all amino acids listed in the database protein 
sequences of the identified proteins was set to 100 %. Then the number of amino 
acids of the identified peptides was summed and the percentage of them was 
computed to the total number of amino acids in the identified peptides. Again, only 
proteins identified with more than one peptide were included in this computation. For 
the semi top-down approach an average sequence coverage of 11.4 % and for the 
bottom-up approach of 9.9 % were obtained. This means that 11.4 % (and 9.9 %, 
respectively) of the possibly identifiable amino acids of the observed proteins (without 
one-hit wonders) were found. Still, the semi top-down approach offers a slightly 
increased average sequence coverage of 1.5 %.  
Furthermore, the distribution of the peptide length was considered (Figure 51). For 
both methods the maximum of the obtained distribution is 11 amino acids per 
peptide. For the semi top-down approach more peptides with higher amino acid 
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numbers were identified resulting in the slightly higher sequence coverage for the 
identified proteins. 
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Figure 51. Distribution of peptide length for the semi top-down and the bottom-up 
approach. 
 
 
3.3.5 Dimension orthogonality and peak capacity 
 
It is important for a two-dimensional chromatographic separation scheme that both 
dimensions follow orthogonal separation mechanisms. This means that almost the 
entire separation space should be covered. The orthogonality of a two-dimensional 
separation system for proteome analysis can be proven by plotting each hit as a 
function of the retention times for both dimensions. The abscissa represents the 
retention time in the first dimension whereas the ordinate shows the retention time in 
the second dimension. Only non-redundant peptides within one fraction were 
included. Proteins were identified in 34 fractions (fraction 2 to 35) of the bottom-up 
approach and in 28 fractions of the first dimension of the semi top-down approach. 
Therefore, in Figure 52a 70 min are plotted and in Figure 52b 56 min, respectively.  
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Figure 52. Orthogonality of separation dimensions in both two-dimensional 
separation schemes tested. The retention time of the second dimension is plotted as 
a function of the retention time of the first dimension for (a) the bottom-up approach 
(= BU) and (b) the semi top-down approach (= STD). 
 
As seen in Figure 52, nearly the whole separation space for both methods is covered. 
It seems that for the semi top-down approach the coverage is even higher. For this 
method intact proteins were separated in the first dimension and peptides in the 
second dimension. This implies that one data point in the first dimension (= one 
protein) results in several data points in the second dimension when the protein is 
identified by more than one peptide. This is why for the semi top-down approach the 
term “pseudo”-orthogonality is more suitable. In contrast, for the bottom-up approach 
peptides are separated in both dimensions. As a result one data point in the first 
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dimension corresponds to one data point in the second dimension. In Figure 52b the 
charge-dependent distribution of the eluted peptides is visible. Peptides are quasi not 
individually separated but clusters of peptides with similar charges (+1, +2, +3, +4) 
are separated in SCX-HPLC. 
A further important parameter to characterize a two-dimensional separatioin system 
is the theoretical peak capacity (P) (Chapter I, paragraph 3.1.2). The total peak 
capacity of a multi-dimensional chromatographic system is estimated by multiplying 
the peak capacities from the single dimensions [263;264]. The peak capacities of both 
tested approaches have been computed as shown in Table 28. Here, the peak 
capacities for the first dimension were not computed but determined by the number of 
fractions in which proteins were identified. 
 
Table 28. Theoretical peak capacity for both two-dimensional chromatographic 
separation systems. BU = bottom-up, STD = semi top-down, tG = gradient time. 
 
approach tG average wb P 
1st dimension SCX 
of peptides = BU 
(a) 
50  34 
1st dimension IP-RP 
of intact proteins = 
STD 
(b) 
60  28 
2nd dimension IP-RP 
peptides 50 0.26 190 
2D-HPLC (a)   6,460 
2D-HPLC (b)   5,320 
 
The peak capacities for both methods of 6,460 and 5,320, respectively, lay within the 
range of previously described peak capacities for 2D-HPLC systems [224].  
The second dimension peak capacity was calculated using the average peak width at 
4σ (=13.4 % of peak height) for four standard peptides at the same 50-min gradient 
as for the second dimension of the proteome analysis (0-30 % acetonitrile in 0.05 % 
aqueous TFA). A 17.5 % higher peak capacity was accomplished using the classical 
bottom-up approach, resulting in an increased protein identification of 26 % (1,245 
vs. 920 proteins). By comprising three replicates for the semi top-down method,  
19.4 % more proteins were identified with the bottom-up method (1,240 vs. 1,004).  
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A higher peak capacity of the 2D-HPLC system was achieved for the bottom-up 
approach because in more fractions of the first dimension proteins were identified  
(34 vs. 28). The number of protein- and peptide containing fractions is determined by 
the gradient time and the time interval for fractionation as well as the final fraction 
volume (after evaporation to dryness and dissolving) due to dilution of the analytes. 
To increase the peak capacity for the semi top-down approach the following 
experimental changes or a combination of them could be applied: 
 
1. increased gradient time 
2. shorter collection inteval for one fraction 
3. dissolving the analytes in less solvent volume  
 
Aspect 1. and 2. can only be applied at the cost of time consumed for the proteome 
analysis. The last point however, could be employed with the risk of precipitation of 
proteins. Furthermore, the replicate injection is limited due to reduced sample 
volume. 
 
 
3.4 Biological relevance of the identified proteins in the human brain tumor 
tissue 
 
3.4.1 Validation of the obtained protein identifications 
 
For further validation of Mascot search results the software Scaffold 2.0 was applied 
to the obtained protein identifications. Peptide Prophet and Protein Prophet are the 
underlying validation algorithms. Additionally X!tandem search engine was run to 
obtain extra information.  
By validating the Mascot result files with Scaffold for the semi top-down approach 
802 proteins could be identified instead of 1,004 and for the bottom-up approach 
1,065 instead of 1,245. The reduction in identifications is caused by the sorting 
principle of Protein Prophet. Proteins that contained the identical set of identified 
peptides could not be differentiated based on MS/MS analysis alone and were 
grouped utilizing the expectation-maximization algorithm. Then one group with an 
identical subset of identified peptides is counted as one hit. 
Figure 53 demonstrates exemplary for the semi top-down approach the necessity of 
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eliminating proteins identified by only one peptide. Even with a peptide probability of 
95 % the protein probability does not rise above 78 %, whereas for two identified 
peptides per protein already with 95 % peptide probability a protein probability of 
almost 100 % can be achieved. Proteins identified with five peptides need only 65 % 
peptide probability to achieve close to 100 % protein probability. 
 
0
20
40
60
80
100
0 10 20 30 40 50 60 70 80 90 100
1 peptide
2 peptides
3 peptides
4 peptides
5 peptides
pr
ot
ei
n 
pr
ob
ab
ili
ty
peptide probability
pr
ot
ei
n 
pr
ob
ab
ili
ty
 
 
Figure 53. Protein probability plotted as function of peptide probability for the semi 
top-down approach. 
 
The distribution of the discriminant scores computed for the peptides of the semi top-
down approach are shown in Figure 54. The black distribution shows the incorrect 
assignments and the white one the correctly identified peptides with a probability 
equal to or higher than 95 %. In the overlapping area the probability of a false 
assignment declines with the increase of the discriminant score. Peptides which are 
identified with a discriminant score above 2.8 in this case are counted as positive 
identification.  
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Figure 54. Histogram of discriminant scores of the identified peptides for the pool of 
both approaches. 
 
By pooling the results of both chromatographic methods 1,401 proteins were 
identified with more than one peptide instead of 1,670 with Mascot only. In this case 
all three replicates for the semi top-down approach were included because now the 
total proteins of the investigated tumor tissue are of interest and not only those suited 
for a comparison between the methods. Thus, 466 proteins were identified with both 
methods which is equal to 44 % of the bottom-up identifications and 58 % of the semi 
top-down identifications, respectively (Figure 55).  
 
466599 336
semi top-down
approach
bottom-up
approach  
 
Figure 55. Venn diagram of the semi top-down and bottom-up identifications 
validated with the Scaffold proteome software. 
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3.4.2 Molecular function of the identified proteins 
 
The molecular function of the 1,401 protein hits confirmed with the Scaffold proteome 
software was disposed using the PANTHER classification system. Dissolving the 
Scaffold grouping of proteins including the same subset of identified peptides 
resulted in 1,429 protein hits which were uploaded to PANTHER. To these proteins 
1,761 molecular functions were allotted. For 186 hits the molecular function was 
unknown (10.6 %). These were eliminated as well as the 85 hits with miscellaneous 
function (4.8 %). The distribution of the remaining 1,490 molecular function hits is 
depicted in Figure 56.  
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Figure 56. Molecular function of the 1, 429 proteins identified in the pool of the semi 
top-down and the bottom-up approach (unknown and miscellanous function 
excluded). 
 
More than one third (35.8 %) of the molecular function hits were assigned to 
enzymes. These are shown in Figure 56 as an extra chart. Altogether 10 different 
classes of enzymes could be identified in which the oxidoreductases with 24.2 % are 
most highly represented.  
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3.4.3 Protein retention behavior in the first separation dimension 
 
To characterize the retention pattern of the intact proteins in the first dimension of the 
semi top-down approach, the subset of identified membrane proteins was chosen. 
Identifying high amounts of membrane proteins normally demands detergent-based 
methods including a strong denaturant applied for dissolving the membrane proteins. 
However, the main drawback of those methods is the necessity to remove the 
detergents prior to mass spectrometric analysis which comes along with sample 
losses. To prevent this effect TFE was added in the sample preparation method 
instead of detergents. This organic co-solvent enhances protein solubility and 
contributes to protein denaturation. It easily evaporates during the sample 
concentration process; hence no cleanup step is required prior to HPLC-MS/MS 
analysis. Furthermore a high concentration of TFE (40-50 % v/v) probably decreases 
the dielectric constant of the solubilization medium resulting in superior protein 
extraction performance [265]. In this study the focus was not on the identification of 
membrane proteins strictly. However, due to their poor solubility, membrane proteins 
are usually underrepresented, especially in top-down approaches. To investigate 
these proteins exclusively, sedimentation or partition techniques are required to 
separate membrane components from the cytosolic bulk [266]. 
The retention behavior of the proteins in the first dimension is discussed with the 
membrane protein subset of the identified proteins. Altogether, 290 membrane 
proteins were identified for the pool of both chromatographic methods, of which 236 
were confirmed with Scaffold. Here, the retention pattern of the intact proteins in the 
first dimension is discussed. Thus, only the semi top-down results are taken in 
account. For this method 142 intrinsic membrane proteins were identified utilizing the 
Mascot search engine with the parameters given in the experimental section. All of 
them were integral, no anchored membrane proteins were observed. Of the 142 
membrane proteins identified with Mascot, 104 proteins were confirmed with the 
Scaffold proteome software. Forty-two percent of the 104 proteins eluted in one or 
two fractions and 58 % were distributed over more than two fractions. Figure 57 
shows the retention behavior of six selected membrane proteins on which the 
retention pattern will be discussed. The retention behavior of all membrane proteins 
matched with the semi top-down approach is listed in the appendix. 
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Three different elution patterns will be considered: the elution of proteins over more 
than two fractions, over two fractions and in one fraction. The latter case is 
represented by protein five and six of Figure 57. Twenty-three of the 104 membrane 
proteins eluted in one fraction with two to four peptides per protein. Protein 5 is a 
relatively small protein including only 142 amino acids (15.5 kDa). With the five 
identified peptides, already 62 % of the protein sequence is covered and none of the 
five identified peptides corresponds to another protein. However, not only small 
proteins elute in only one fraction. Protein 6 is a larger protein consisting of 416 
amino acids (46.5 kDa). All of the four peptides identified also appear in no other 
protein. No isoforms are known of both proteins (www.expasy.org). This retention 
behavior is ideal and such proteins are best suitable for further investigations by 
micropreparation. 
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Figure 57. Exemplary retention behavior of six selected membrane proteins. 
Numbered proteins represent different retention behavior: 1+2 over more than two 
fractions, 3+4 over two fractions and 4+5 in one fraction. 
 
Protein 3 and 4 are both distributed over two fractions. Protein 3 consists of 240 
amino acids resulting in a molecular mass of 25.5 kDa. This protein elutes in two 
adjacent fractions which is reasonable as the peak of the protein begins in one 
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fraction and ends in the next one. Though protein 4 with 586 amino acids (62.3 kDa) 
is also a moderate protein in size as well as protein 3, it is distributed over two 
isolated fractions. It is very likely that the heavy and the light chain of this heterodimer 
were separated or the protein was degraded by proteases of the cell prior to 
fractionation.  
Two exemplary proteins were also chosen for proteins which are dispersed over 
more than two fractions. Protein 1, a protein of medium size (592 amino acids and 
67.6 kDa), is distributed over seven consecutive fractions. Protein 2 however, a large 
protein composed of 1,347 amino acids resulting in a molecular mass of  
150 kDa, is distributed over nine fractions, not all contiguous. There are some 
reasonable explanations for this behavior. At first the proteins 1 and 2 are highly 
abundant as can be estimated from their spectrum count. For protein 1 a spectrum 
count of 118 was computed and 89 for protein 2, respectively. As for only 9.9 % of 
the 802 proteins identified with the semi top-down approach a spectrum count >80 
was computed these proteins are highly abundant ones. For such highly abundant 
proteins the separation column may have been overloaded and therefore the proteins 
spread over different fractions. This could explain why the proteins elute over more 
than two fractions. The distribution over isolated fractions could be explained as 
before for protein 4 with rest proteases activity. Furthermore, the very high sequence 
homology of many human proteins is an important factor. Especially polymorphisms, 
alternative splicing and post-translational modifications are increasing the complexity 
of the sample. It is estimated that 40 to 60 % of the human genes are alternatively 
spliced [267]. In fact, for protein 2 thirteen isoforms are known (www.expasy.org). It is 
possible that by identifying one protein in several isolated or even adjacent fractions 
rather different isoforms with the same subset of peptides are identified. The 
presence of highly abundant, degraded and highly homologous proteins likely 
explains the distribution over more than two fractions of the first chromatographic 
separation dimension. 
 
 
3.4.4 Confirmation of previously identified potential biomarkers 
 
Serological identification of antigens by recombinant expression screening (SEREX) 
was developed to identify human tumor antigens. In this approach molecular cloning 
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techniques are implemented into serological analysis [268]. By applying SEREX to 
pooled Glioblastoma multiforme patient’s sera 13 potential antigens were  
obtained [205]. Now it should be proven, if these proteins indirectly identified in the 
patient serum based on antibodies directed against them, are also present in 
molecular form in the Glioblastoma multiforme tissue. Table 29 shows the 13 
antigens indirectly identified with SEREX and those which were confirmed by 
chromatography- and mass spectrometry-based proteome analysis.  
 
Table 29. Detection for five of 13 potential antigens for Glioblastoma multiforme 
directly identified with 2D-HPLC-MALDI-MS/MS. BU = bottom-up; STD = semi top-
down. For GO annotations see appendix. 
 
antigen description 
detected 
with 
STD        BU   
ACTN4 actinin, alpha 4  x 
ING4 inhibitor of growth family, member 4   
RTN4 reticulon 4 x x 
CLIP2 cytoplasmic linker 2 x  
HCLS1 hematopoietic lineage cell-specific protein x  
U2AFL U2(RNU2) small nuclear RNA auxiliary factor 1-like 1   
ZN232 zinc finger protein 232   
HS105 heat-shock protein 105 kDa  x x 
PHF3 PHD finger protein 3   
PHF20 PHD finger protein 20   
TPR translocated promoter region (to activated MET oncogene)   
CYTSA cytospin-A (NY-REN-22 antigen)   
GOGA1 golgi autoantigen, golgin subfamily a   
 
According to their spectrum count ACTN4, RTN4 and HCLS are relatively high 
abundant proteins whereas CLIP2 and HS105 are represented by a low spectrum 
count. ACTN4 also was identified by Mascot in the semi top-down approach, but 
categorized to ACTN1 in Scaffold, following the expectation-maximization algorithm. 
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In Table 30, the distribution of the identified SEREX peptides is displayed. Only the 
proteins confirmed with the Scaffold software are shown in the table. The annotation 
of peptide distribution was performed with Mascot. The protein HS105 in the table is 
represented by just one peptide in Mascot. Caused by this fact it has to be excluded 
from the list following strictly proteomics identification rules or at least discussed 
critical [269].  
 
Table 30. Distribution of peptides observed for SEREX proteins. White numbers 
belong to bottom-up and black numbers to semi top-down results. 
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As Table 30 demonstrates clearly, the advantage of the semi top-down method rests 
within the possibility to focus on potential tumor markers found in selected fractions of 
intact protein separation without the need to analyze the entire set of fractions again. 
Moreover, identified tumor antigens may be isolated micropreparatively for further 
investigations. 
The narrower retention window for one protein applying the semi top-down approach 
becomes especially clear by looking at the protein reticulon 4 (RTN4). This potential 
biomarker is identified by both methods. Its observed peptides are distributed over 13 
fractions employing the bottom-up approach while for the semi top-down method the 
peptides elute in just three fractions. It is very likely that isoforms are present. 
Actually four isoforms are known for reticulon 4 (www.expasy.org). This could explain 
why the peptides elute in isolated fractions identified with the semi top-down 
approach. Another reason could be a degradation of the protein prior to fractionation 
as discussed for the membrane proteins before. 
The hematopoietic lineage cell-specific protein (HS105) was identified by three 
peptides for the semi top-down approach. These peptides were distributed over three 
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fractions. However, this protein was identified by only one peptide in the bottom-up 
approach and has to be excluded from the protein identification list as one-hit wonder 
for this method. 
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4 Summary 
 
It was shown by comparison to the classical bottom-up approach that the developed 
semi top-down platform is suitable for proteome research. First, the classical bottom-
up approach was validated using a human Glioblastoma multiforme tissue sample. 
The extracted proteome was tryptic digested and then separated using strong cation- 
exchange chromatography. Then the fractions were injected into the second 
dimension: the previously established off-line nano-flow IP-RP-HPLC MALDI-
TOF/TOF platform. Here, peptides were flushed after injection onto a monolithic trap 
column for concentration and desalting and then in back-flush mode onto the 
monolithic separation column. The eluting analytes were mixed with α-cyano-4-
hydroxycinnamic acid employed as matrix and spotted onto a stainless steel target 
automatically. The target subsequently was transferred off-line into the MALDI-
TOF/TOF system and there the intact peptide mass as well as the mass of the 
peptide fragment ions were analyzed. With this method 1,245 proteins were identified 
using the Mascot search engine. By validation with the Scaffold proteome software, 
using Peptide- and Protein Prophet to filter peptide and protein hits, 1,065 proteins 
still passed acceptance.  
This classical bottom-up method was compared to the new semi top-down approach. 
In this approach intact proteins were first separated using IP-RP-HPLC and then 
each fraction was digested and separated in the second dimension in the same 
chromatographic system as the classical bottom-up approach. We called this method 
semi top-down approach. Here, applying the Mascot search engine 1,004 protein hits 
for three and 920 for two replicates, respectively, were obtained. As a comparison 
with the bottom-up approach should be performed, only two replicates of the second 
separation dimension were considered first. Validation of this method with Scaffold 
resulted in a protein acceptance of 763 instead of 920 for two replicates and 802 
instead of 1,004 hits for three replicates, respectively. 
With both approaches 533 proteins of 1,632 total hits were identified (Mascot) which 
is not surprising due to the high heterogeneity of the used tumor tissue sample. With 
each method a broad pH (4-12) and mass range (6.4-628.7 kDa) could be covered. 
Interestingly, with the bottom-up approach more basic proteins were identified 
whereas a higher level of acidic proteins was detected with the semi top-down 
method. Moreover, the retention modes for the first and the second dimension of both 
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methods were discussed. A slight increase of the GRAVY Index with the retention 
time in IP-RP-HPLC was observed for the proteins identified with the semi top-down 
approach. The same was valid for peptides separated with IP-RP-HPLC with both 
methods in the second dimension. For the pI of the peptides separated with SCX-
HPLC in the first dimension of the bottom-up approach also a slight increase was 
observed with the retention time. 
Furthermore, to mirror the entire protein hits for this brain tumor, the results of both 
methods were pooled comprising three second-dimension replicates for the semi top-
down approach. In this pool 1,401 proteins were confirmed with Scaffold proteome 
software. These proteins were classified using PANTHER software according to their 
functions. This software categorized the most highly part (35.8 %) of the proteins to 
be enzymes.  
Finally, the set of identified tumor proteins was compared to a set of biomarkers 
previously discovered with SEREX. Of 13 with this indirect method detected 
biomarkers, five were identified as molecular proteins. A clear advantage was shown 
for the semi top-down approach in terms of focused protein elution in few or ideally 
one fraction. Thus, this new nethod is suitable for biomarker isolation circumventing 
the analysis of the whole set of fractions obtained from the first dimension in further 
experiments. 
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5 Conclusions 
 
By applying the established proteomic platforms to a highly complex protein mixture 
(proteins of a human Glioblastoma multiforme tissue) a comprehensive protein 
overview could be obtained. Moreover, the presence of biomarkers which were 
identified indirectly utilizing SEREX was now confirmed directly. 
Obviously, more proteins were identified with the classical bottom-up approach; 
nevertheless advantages of the alternative approach could be demonstrated:  
 
1. The sequence coverage for proteins with > 40 % sequence coverage was 
3.2 % higher for the semi top-down approach. As different proteins were 
identified for both methods the average sequence coverage was computed for 
a more adequate comparison. So all amino acids in the sequence of the 
identified proteins were summed for each method and set to 100 %. For the 
semi top-down approach a 1.5 % higher average sequence coverage was 
obtained. 
2. The semi top-down approach offered a higher orthogonality than the  
bottom-up method, although it is more a “pseudo”-orthogonality because every 
data point of the first dimension results in several data points for the second 
dimension when the protein is identified with more than one peptide. 
3. For further analyses there is no need to analyze the entire set of fractions from 
first dimension, but only those fractions which contain the demanded proteins. 
 
The gradient time could be extended or the fraction collection time interval could be 
shortened for further optimization in terms of peak capacity for the semi top-down 
approach. Moreover, the final volume of the fractions after evaporating and refilling 
could be reduced. To prevent problems with the solubility of the proteins a detergent 
could be added which would be removed by the chromatographic separation. 
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  proteins identified in a human  
  Glioblastoma multiforme tissue  
  with more than one peptide 
- membrane proteins 
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XXV
identified proteins of Glioblastoma multiforme # 1-52 
nr. protein description accession numbers mass [Da]
1 Hemoglobin subunit beta HBB_HUMAN 15,980 
2 Glial fibrillary acidic protein GFAP_HUMAN 49,863 
3 Serum albumin precursor ALBU_HUMAN 69,349 
4 Tubulin beta-2C chain TBB2C_HUMAN 49,813 
5 Actin, cytoplasmic 2 ACTB_HUMAN, ACTG_HUMAN 41,776 
6 Keratin, type II cytoskeletal 1 K2C1_HUMAN 66,001 
7 Tubulin alpha-1B chain TBA1B_HUMAN 50,134 
8 ATP synthase subunit beta, mitochondrial precursor ATPB_HUMAN 56,543 
9 Hemoglobin subunit alpha HBA_HUMAN 15,240 
10 Creatine kinase B-type KCRB_HUMAN 42,627 
11 Myelin basic protein MBP_HUMAN 33,100 
12 Vimentin VIME_HUMAN 53,635 
13 Keratin, type I cytoskeletal 9 K1C9_HUMAN 62,113 
14 Spectrin alpha chain, brain SPTA2_HUMAN 284,525 
15 Heat shock cognate 71 kDa protein HSP7C_HUMAN 70,882 
16 Dihydropyrimidinase-related protein 2 DPYL2_HUMAN 62,276 
17 Synapsin-1 SYN1_HUMAN 74,093 
18 14-3-3 protein epsilon 1433E_HUMAN 29,157 
19 Keratin, type I cytoskeletal 10 K1C10_HUMAN 59,494 
20 Alpha-enolase ENOA_HUMAN 47,152 
21 14-3-3 protein zeta/delta 1433Z_HUMAN 27,728 
22 Fructose-bisphosphate aldolase A ALDOA_HUMAN 39,403 
23 Spectrin beta chain, brain 1 SPTB2_HUMAN 274,595 
24 Brain acid soluble protein 1 BASP_HUMAN 22,675 
25 Annexin A5 ANXA5_HUMAN 35,921 
26 Synaptosomal-associated protein 25 SNP25_HUMAN 23,297 
27 Stress-70 protein, mitochondrial precursor GRP75_HUMAN 73,663 
28 Ferritin light chain FRIL_HUMAN 20,003 
29 78 kDa glucose-regulated protein precursor GRP78_HUMAN 72,317 
30 Microtubule-associated protein 2 MAP2_HUMAN 199,523 
31 Annexin A2 ANXA2_HUMAN 38,588 
32 Alpha-1-antichymotrypsin precursor AACT_HUMAN 47,635 
33 Serotransferrin precursor TRFE_HUMAN 77,032 
34 Calnexin precursor CALX_HUMAN 67,552 
35 Keratin, type II cytoskeletal 2 epidermal K22E_HUMAN 65,848 
36 Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN 36,035 
37 Tenascin-R precursor TENR_HUMAN 149,528 
38 Tubulin beta-2B chain TBB2B_HUMAN 49,935 
39 Gamma-enolase ENOG_HUMAN 47,252 
40 Microtubule-associated protein tau TAU_HUMAN 78,860 
41 Malate dehydrogenase, mitochondrial precursor MDHM_HUMAN 35,514 
42 Ferritin heavy chain FRIH_HUMAN 21,208 
43 2',3'-cyclic-nucleotide 3'-phosphodiesterase CN37_HUMAN 47,563 
44 Carbonic anhydrase 1 CAH1_HUMAN 28,852 
45 Guanine nucleotide-binding protein G(o) subunit alpha 2 
GNAO1_HUMAN, 
GNAO2_HUMAN 40,070 
46 Phosphoglycerate mutase 1 PGAM1_HUMAN 28,787 
47 Phosphoglycerate kinase 1 PGK1_HUMAN 44,597 
48 Neurofilament medium polypeptide NFM_HUMAN 102,429 
49 L-lactate dehydrogenase B chain LDHB_HUMAN 36,621 
50 Alpha-1-antitrypsin precursor A1AT_HUMAN 46,720 
51 Clathrin coat assembly protein AP180 AP180_HUMAN 92,486 
52 Fibrinogen beta chain precursor [Contains: Fibrinopeptide B] FIBB_HUMAN 55,911 
                   Appendix 
   
XXVI
identified proteins of Glioblastoma multiforme # 53-97 
nr. protein description accession numbers mass [Da]
53 Microtubule-associated protein 1B MAP1B_HUMAN 270,602 
54 Clathrin heavy chain 1 CLH1_HUMAN 191,601 
55 Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A] FIBA_HUMAN 94,955 
56 Triosephosphate isomerase TPIS_HUMAN 26,651 
57 Catalase CATA_HUMAN 59,739 
58 Endophilin-A1 SH3G2_HUMAN 39,945 
59 Annexin A1 ANXA1_HUMAN 38,698 
60 Ankyrin-2 ANK2_HUMAN 430,319 
61 Sodium/potassium-transporting ATPase subunit beta-1 AT1B1_HUMAN 35,045 
62 60 kDa heat shock protein, mitochondrial precursor CH60_HUMAN 61,038 
63 Dynamin-1 DYN1_HUMAN 97,392 
64 Fructose-bisphosphate aldolase C ALDOC_HUMAN 39,438 
65 Myelin-associated glycoprotein precursor MAG_HUMAN 69,050 
66 Fibronectin precursor FINC_HUMAN 262,581 
67 14-3-3 protein gamma 1433G_HUMAN 28,285 
68 Phosphatidylethanolamine-binding protein 1 PEBP1_HUMAN 21,039 
69 Superoxide dismutase [Mn], mitochondrial precursor SODM_HUMAN 24,705 
70 Tubulin beta-4 chain TBB4_HUMAN 49,567 
71 Plectin-1 PLEC1_HUMAN 531,708 
72 Apolipoprotein A-I precursor APOA1_HUMAN 30,761 
73 Neuromodulin NEUM_HUMAN 24,784 
74 Protein disulfide-isomerase A3 precursor PDIA3_HUMAN 56,767 
75 Visinin-like protein 1 VISL1_HUMAN 22,125 
76 Peroxiredoxin-1 PRDX1_HUMAN 22,093 
77 Pyruvate kinase isozymes M1/M2 KPYM_HUMAN 57,920 
78 Clusterin precursor CLUS_HUMAN 52,477 
79 14-3-3 protein beta/alpha 1433B_HUMAN 28,065 
80 ATP synthase subunit alpha, mitochondrial precursor ATPA_HUMAN 59,734 
81 Actin, alpha cardiac muscle 1 ACTC_HUMAN 42,002 
82 Microtubule-associated protein 1A MAP1A_HUMAN 306,456 
83 Heat shock protein HSP 90-alpha HS90A_HUMAN 84,645 
84 Haptoglobin precursor [Contains: Haptoglobin alpha chain; Haptoglobin beta chain] HPT_HUMAN 45,187 
85 Neurofascin precursor NFASC_HUMAN 150,010 
86 Filamin-A FLNA_HUMAN 280,711 
87 Vacuolar ATP synthase subunit B, brain isoform VATB2_HUMAN 56,484 
88 Versican core protein precursor CSPG2_HUMAN 372,795 
89 Hornerin HORN_HUMAN 282,355 
90 Septin-11 SEP11_HUMAN 49,381 
91 Heterogeneous nuclear ribonucleoproteins A2/B1 ROA2_HUMAN 37,412 
92 Protein bassoon BSN_HUMAN 416,480 
93 Neuroblast differentiation-associated protein AHNAK AHNK_HUMAN 629,086 
94 Protein S100-A9 S10A9_HUMAN 13,224 
95 Hemoglobin subunit delta HBD_HUMAN 16,037 
96 Myosin-9 MYH9_HUMAN 226,520 
97 Ubiquitin carboxyl-terminal hydrolase isozyme L1 UCHL1_HUMAN 24,806 
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98 Glutaminase kidney isoform, mitochondrial precursor GLSK_HUMAN 73,444 
99 Talin-1 TLN1_HUMAN 269,747 
100 Contactin-1 precursor CNTN1_HUMAN 113,305 
101 Fibrinogen gamma chain precursor FIBG_HUMAN 51,495 
102 Dynein heavy chain, cytosolic DYHC_HUMAN 532,388 
103 Tyrosine-protein phosphatase non-receptor type substrate 1 precursor SHPS1_HUMAN 54,793 
104 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial precursor IDH3A_HUMAN 39,575 
105 Cofilin-1 COF1_HUMAN 18,485 
106 Sodium/potassium-transporting ATPase subunit alpha-1 precursor AT1A1_HUMAN 112,882 
107 Beta-soluble NSF attachment protein SNAB_HUMAN 33,540 
108 Thy-1 membrane glycoprotein precursor THY1_HUMAN 17,917 
109 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 DDAH1_HUMAN 31,104 
110 Neuron-specific calcium-binding protein hippocalcin HPCA_HUMAN 22,411 
111 Syntaxin-1B STX1B_HUMAN 33,227 
112 Aspartate aminotransferase, cytoplasmic AATC_HUMAN 46,230 
113 Band 4.1-like protein 3 E41L3_HUMAN 120,662 
114 14-3-3 protein theta 1433T_HUMAN 27,747 
115 Collagen alpha-1(I) chain precursor CO1A1_HUMAN 138,893 
116 Alpha-crystallin B chain CRYAB_HUMAN 20,141 
117 Glutamine synthetase GLNA_HUMAN 42,047 
118 Alpha-actinin-1 ACTN1_HUMAN 103,043 
119 Spectrin alpha chain, erythrocyte SPTA1_HUMAN 279,903 
120 Calmodulin CALM_HUMAN 16,820 
121 Band 3 anion transport protein B3AT_HUMAN 101,778 
122 Rab GDP dissociation inhibitor alpha GDIA_HUMAN 50,566 
123 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 2AAA_HUMAN 65,292 
124 Dihydropyrimidinase-related protein 3 DPYL3_HUMAN 61,946 
125 Neural cell adhesion molecule L1 precursor L1CAM_HUMAN 139,985 
126 Glutathione S-transferase P GSTP1_HUMAN 23,339 
127 Peptidyl-prolyl cis-trans isomerase A PPIA_HUMAN 17,995 
128 A-kinase anchor protein 12 AKA12_HUMAN 191,457 
129 Acyl-CoA-binding protein ACBP_HUMAN 10,027 
130 Syntaxin-binding protein 1 STXB1_HUMAN 67,554 
131 Ubiquitin UBIQ_HUMAN 8,547 
132 NAD-dependent deacetylase sirtuin-2 SIRT2_HUMAN 43,166 
133 Protein FAM49B FA49B_HUMAN 36,731 
134 Nucleoside diphosphate kinase B NDKB_HUMAN 17,280 
135 Annexin A6 ANXA6_HUMAN 75,860 
136 Glutamate dehydrogenase 1, mitochondrial precursor DHE3_HUMAN 61,382 
137 Heat shock protein beta-1 HSPB1_HUMAN 22,765 
138 Vesicle-fusing ATPase NSF_HUMAN 82,545 
139 Tubulin beta-3 chain TBB3_HUMAN 50,415 
140 Aconitate hydratase, mitochondrial precursor ACON_HUMAN 85,410 
141 Alpha-internexin AINX_HUMAN 55,374 
142 Amphiphysin AMPH_HUMAN 76,239 
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identified proteins of Glioblastoma multiforme # 143-185 
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143 Isocitrate dehydrogenase [NADP], mitochondrial precursor IDHP_HUMAN 50,892 
144 Heat shock 70 kDa protein 1 HSP71_HUMAN 70,036 
145 Peroxiredoxin-6 PRDX6_HUMAN 25,018 
146 Protein S100-A8 S10A8_HUMAN 10,817 
147 Cadherin-2 precursor CADH2_HUMAN 99,794 
148 14-3-3 protein eta 1433F_HUMAN 28,202 
149 CD44 antigen precursor CD44_HUMAN 81,535 
150 Heterogeneous nuclear ribonucleoprotein K HNRPK_HUMAN 50,961 
151 Tubulin polymerization-promoting protein TPPP_HUMAN 23,676 
152 Histone H4 H4_HUMAN 11,350 
153 Endoplasmin precursor ENPL_HUMAN 92,454 
154 4F2 cell-surface antigen heavy chain 4F2_HUMAN 57,929 
155 ATP synthase subunit b, mitochondrial precursor AT5F1_HUMAN 28,891 
156 Vesicle-associated membrane protein-associated protein A VAPA_HUMAN 27,876 
157 Spectrin beta chain, erythrocyte SPTB1_HUMAN 246,307 
158 Keratin, type I cytoskeletal 16 K1C16_HUMAN 51,251 
159 Protein disulfide-isomerase precursor PDIA1_HUMAN 57,100 
160 Collagen alpha-2(I) chain precursor CO1A2_HUMAN 129,271 
161 Aldehyde dehydrogenase, mitochondrial precursor ALDH2_HUMAN 56,363 
162 L-lactate dehydrogenase A chain LDHA_HUMAN 36,671 
163 Thioredoxin-dependent peroxide reductase, mitochondrial precursor PRDX3_HUMAN 27,675 
164 Carbonic anhydrase 2 CAH2_HUMAN 29,229 
165 Acid ceramidase precursor ASAH1_HUMAN 44,633 
166 Synapsin-2 SYN2_HUMAN 62,951 
167 Ig gamma-1 chain C region IGHG1_HUMAN 36,087 
168 Large proline-rich protein BAT3 BAT3_HUMAN 119,389 
169 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform PP2BA_HUMAN 58,672 
170 Carbonyl reductase [NADPH] 1 CBR1_HUMAN 30,357 
171 Vacuolar ATP synthase catalytic subunit A VATA_HUMAN 68,287 
172 Sideroflexin-1 SFXN1_HUMAN 35,602 
173 Mitochondrial inner membrane protein IMMT_HUMAN 83,661 
174 Histone H2B type 1-B 
H2B1B_HUMAN, 
H2B1J_HUMAN, 
H2B1O_HUMAN, 
H2B2E_HUMAN, 
H2B3B_HUMAN 
13,933 
175 Myoglobin MYG_HUMAN 17,166 
176 Septin-7 SEPT7_HUMAN 50,662 
177 Ig alpha-1 chain C region IGHA1_HUMAN 37,636 
178 Ankyrin-1 ANK1_HUMAN 206,246 
179 Citrate synthase, mitochondrial precursor CISY_HUMAN 51,696 
180 10 kDa heat shock protein, mitochondrial CH10_HUMAN 10,914 
181 Tubulin alpha-4A chain TBA4A_HUMAN 49,907 
182 Calcineurin subunit B isoform 1 CANB1_HUMAN 19,282 
183 Vacuolar proton pump subunit d 1 VA0D1_HUMAN 40,313 
184 Lysosome membrane protein 2 SCRB2_HUMAN 54,274 
185 Serine/threonine-protein phosphatase 2A regulatory subunit B' PTPA_HUMAN 40,650 
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186 Myristoylated alanine-rich C-kinase substrate MARCS_HUMAN 31,536 
187 Ermin ERMIN_HUMAN 32,765 
188 Astrocytic phosphoprotein PEA-15 PEA15_HUMAN 15,023 
189 Limbic system-associated membrane protein precursor LSAMP_HUMAN 37,375 
190 Adenylate kinase isoenzyme 1 KAD1_HUMAN 21,617 
191 
Complement C3 precursor [Contains: Complement 
C3 beta chain; Complement C3 alpha chain; C3a 
anaphylatoxin; Complement C3b alpha' chain; 
Complement C3c alpha' chain fragment 1; 
Complement C3dg fragment; Complemen... 
CO3_HUMAN 187,131 
192 T-complex protein 1 subunit beta TCPB_HUMAN 57,472 
193 Histone H2AV H2AV_HUMAN, H2AZ_HUMAN 13,491 
194 Ubiquitin-like modifier-activating enzyme 1 UBA1_HUMAN 117,832 
195 Malate dehydrogenase, cytoplasmic MDHC_HUMAN 36,409 
196 Brevican core protein precursor PGCB_HUMAN 99,100 
197 Myosin-10 MYH10_HUMAN 228,927 
198 Ubiquitin thioesterase OTUB1 OTUB1_HUMAN 31,267 
199 Profilin-1 PROF1_HUMAN 15,036 
200 Myc box-dependent-interacting protein 1 BIN1_HUMAN 64,681 
201 Receptor-type tyrosine-protein phosphatase zeta precursor PTPRZ_HUMAN 254,512 
202 Protein NDRG2 NDRG2_HUMAN 40,781 
203 Protein S100-B S100B_HUMAN 10,695 
204 Neurogranin NEUG_HUMAN 7,601 
205 Tubulin beta chain TBB5_HUMAN 49,653 
206 Neutral alpha-glucosidase AB precursor GANAB_HUMAN 106,858 
207 Keratin, type I cytoskeletal 14 K1C14_HUMAN 51,605 
208 Contactin-associated protein 1 precursor CNTP1_HUMAN 156,250 
209 Fumarate hydratase, mitochondrial precursor FUMH_HUMAN 54,620 
210 Cathepsin D precursor CATD_HUMAN 44,535 
211 Ig kappa chain C region KAC_HUMAN 11,591 
212 Sodium/potassium-transporting ATPase subunit beta-3 AT1B3_HUMAN 31,496 
213 Voltage-dependent calcium channel subunit alpha-2/delta-1 precursor CA2D1_HUMAN 123,169 
214 Protein DJ-1 PARK7_HUMAN 19,873 
215 Transthyretin precursor TTHY_HUMAN 15,869 
216 Ectonucleotide pyrophosphatase/phosphodiesterase family member 6 precursor ENPP6_HUMAN 50,225 
217 Superoxide dismutase [Cu-Zn] SODC_HUMAN 15,917 
218 Cytosol aminopeptidase AMPL_HUMAN 56,150 
219 Neuronal cell adhesion molecule precursor NRCAM_HUMAN 143,877 
220 Nicotinamide phosphoribosyltransferase NAMPT_HUMAN 55,505 
221 Myosin light polypeptide 6 MYL6_HUMAN 16,912 
222 ADP/ATP translocase 2 ADT2_HUMAN 32,879 
223 Aspartate aminotransferase, mitochondrial precursor AATM_HUMAN 47,459 
224 Dematin DEMA_HUMAN 45,498 
225 Vitronectin precursor VTNC_HUMAN 54,288 
226 Stress-induced-phosphoprotein 1 STIP1_HUMAN 62,624 
227 Protein kinase C and casein kinase substrate in neurons protein 1 PACN1_HUMAN 50,948 
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228 Creatine kinase, ubiquitous mitochondrial precursor KCRU_HUMAN 47,020 
229 Hepatocyte cell adhesion molecule precursor HECAM_HUMAN 46,010 
230 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial precursor AL4A1_HUMAN 61,702 
231 Tripeptidyl-peptidase 1 precursor TPP1_HUMAN 61,230 
232 ATP synthase-coupling factor 6, mitochondrial precursor ATP5J_HUMAN 12,570 
233 Reticulon-1 RTN1_HUMAN 83,602 
234 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial precursor NDUS3_HUMAN 30,224 
235 Syntaxin-1A STX1A_HUMAN 33,006 
236 Reticulon-4 RTN4_HUMAN 129,917 
237 Membrane-associated progesterone receptor component 1 PGRC1_HUMAN 21,654 
238 Galectin-3-binding protein precursor LG3BP_HUMAN 65,314 
239 Septin-8 SEPT8_HUMAN 55,738 
240 Synaptotagmin-1 SYT1_HUMAN 47,556 
241 Tropomyosin alpha-1 chain TPM1_HUMAN 32,692 
242 Lysosomal alpha-glucosidase precursor LYAG_HUMAN 105,321 
243 HLA class I histocompatibility antigen, Cw-12 alpha chain precursor 1C12_HUMAN 40,867 
244 Lysosome-associated membrane glycoprotein 2 precursor LAMP2_HUMAN 44,943 
245 Filamin-C FLNC_HUMAN 290,934 
246 AP-2 complex subunit beta-1 AP2B1_HUMAN 104,537 
247 Ezrin EZRI_HUMAN 69,397 
248 Peroxiredoxin-2 PRDX2_HUMAN 21,874 
249 Alpha-1-acid glycoprotein 1 precursor A1AG1_HUMAN 23,494 
250 Acetyl-CoA acetyltransferase, mitochondrial precursor THIL_HUMAN 45,182 
251 Elongation factor Tu, mitochondrial precursor EFTU_HUMAN 49,524 
252 Myelin proteolipid protein MYPR_HUMAN 30,060 
253 Nestin NEST_HUMAN 177,419 
254 Glucose-6-phosphate isomerase G6PI_HUMAN 63,130 
255 Rho GDP-dissociation inhibitor 1 GDIR_HUMAN 23,190 
256 Alpha-synuclein SYUA_HUMAN 14,441 
257 Integrin alpha-V precursor ITAV_HUMAN 116,023 
258 Protein-L-isoaspartate(D-aspartate) O-methyltransferase PIMT_HUMAN 24,633 
259 Sorcin SORCN_HUMAN 21,659 
260 Ras-related protein Rab-11B RB11B_HUMAN 24,471 
261 Microtubule-associated protein 4 MAP4_HUMAN 121,003 
262 Basement membrane-specific heparan sulfate proteoglycan core protein precursor PGBM_HUMAN 468,788 
263 Keratin, type II cytoskeletal 6A K2C6A_HUMAN 60,028 
264 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial precursor COX41_HUMAN 19,559 
265 Calreticulin precursor CALR_HUMAN 48,125 
266 Sodium/potassium-transporting ATPase subunit beta-2 AT1B2_HUMAN 33,349 
267 Excitatory amino acid transporter 1 EAA1_HUMAN 59,556 
268 Protein disulfide-isomerase A4 precursor PDIA4_HUMAN 72,916 
269 Trifunctional enzyme subunit alpha, mitochondrial precursor ECHA_HUMAN 82,984 
270 Collagen alpha-3(VI) chain precursor CO6A3_HUMAN 343,532 
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271 Breast carcinoma-amplified sequence 1 BCAS1_HUMAN 61,691 
272 Enoyl-CoA hydratase, mitochondrial precursor ECHM_HUMAN 31,370 
273 Heterogeneous nuclear ribonucleoprotein H HNRH1_HUMAN 49,212 
274 Beta-adducin ADDB_HUMAN 80,836 
275 Basigin precursor BASI_HUMAN 42,182 
276 Myeloperoxidase precursor PERM_HUMAN 83,853 
277 Neural cell adhesion molecule 1, 140 kDa isoform precursor NCA11_HUMAN 93,343 
278 Heat shock protein HSP 90-beta HS90B_HUMAN 83,249 
279 Cytochrome b-c1 complex subunit 7 QCR7_HUMAN 13,513 
280 Cysteine and glycine-rich protein 1 CSRP1_HUMAN 20,549 
281 Calumenin precursor CALU_HUMAN 37,090 
282 Heterogeneous nuclear ribonucleoprotein A3 ROA3_HUMAN 39,577 
283 Cell cycle control protein 50A CC50A_HUMAN 40,668 
284 HLA class I histocompatibility antigen, Cw-7 alpha chain precursor 1C07_HUMAN 40,630 
285 Mitochondrial 28S ribosomal protein S36 RT36_HUMAN 11,448 
286 3-hydroxyacyl-CoA dehydrogenase type-2 HCD2_HUMAN 26,905 
287 Septin-9 SEPT9_HUMAN 65,384 
288 Band 4.1-like protein 1 E41L1_HUMAN 98,487 
289 Ras-related protein Rab-7a RAB7A_HUMAN 23,472 
290 Toll-interacting protein TOLIP_HUMAN 30,263 
291 2-oxoglutarate dehydrogenase E1 component, mitochondrial precursor ODO1_HUMAN 115,919 
292 Rho GTPase-activating protein 1 RHG01_HUMAN 50,420 
293 Cytochrome b-c1 complex subunit 2, mitochondrial precursor QCR2_HUMAN 48,425 
294 T-complex protein 1 subunit theta TCPQ_HUMAN 59,603 
295 S-phase kinase-associated protein 1A SKP1_HUMAN 18,640 
296 Beta-synuclein SYUB_HUMAN 14,269 
297 Stathmin STMN1_HUMAN 17,285 
298 Neuronal-specific septin-3 SEPT3_HUMAN 40,687 
299 Secretogranin-2 precursor SCG2_HUMAN 70,925 
300 Peroxiredoxin-5, mitochondrial precursor PRDX5_HUMAN 22,008 
301 Alpha-adducin ADDA_HUMAN 80,938 
302 Peptidyl-prolyl cis-trans isomerase B precursor PPIB_HUMAN 22,725 
303 Sulfatase-modifying factor 2 precursor SUMF2_HUMAN 33,839 
304 D-3-phosphoglycerate dehydrogenase SERA_HUMAN 56,633 
305 Lactotransferrin precursor TRFL_HUMAN 78,164 
306 SH3 domain-binding glutamic acid-rich-like protein SH3L1_HUMAN 12,757 
307 Plasma protease C1 inhibitor precursor IC1_HUMAN 55,138 
308 Transitional endoplasmic reticulum ATPase TERA_HUMAN 89,307 
309 Neurofilament light polypeptide NFL_HUMAN 61,500 
310 Splicing factor, proline- and glutamine-rich SFPQ_HUMAN 76,132 
311 Alpha-aminoadipic semialdehyde dehydrogenase AL7A1_HUMAN 55,349 
312 Cytosolic non-specific dipeptidase CNDP2_HUMAN 52,862 
313 Serum amyloid P-component precursor SAMP_HUMAN 25,370 
314 ATP synthase subunit e, mitochondrial ATP5I_HUMAN 7,916 
315 Histidine triad nucleotide-binding protein 1 HINT1_HUMAN 13,784 
316 ATP synthase subunit g, mitochondrial ATP5L_HUMAN 11,411 
317 Elongation factor 1-alpha 1 EF1A1_HUMAN 50,123 
318 Vesicle-associated membrane protein 3 VAMP3_HUMAN 11,291 
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319 Brain-specific angiogenesis inhibitor 1-associated protein 2 BAIP2_HUMAN 60,851 
320 Apolipoprotein E precursor APOE_HUMAN 36,136 
321 HLA class I histocompatibility antigen, A-69 alpha chain 1A69_HUMAN 40,958 
322 Reticulocalbin-1 precursor RCN1_HUMAN 38,873 
323 Vacuolar proton pump subunit E 1 VATE1_HUMAN 26,128 
324 Protein NDRG1 NDRG1_HUMAN 42,817 
325 Dihydropyrimidinase-related protein 1 DPYL1_HUMAN 62,167 
326 Neuroplastin precursor NPTN_HUMAN 31,274 
327 Macrophage migration inhibitory factor MIF_HUMAN 12,459 
328 cAMP-regulated phosphoprotein 19 ARP19_HUMAN 12,305 
329 Mitogen-activated protein kinase 1 MK01_HUMAN 41,374 
330 Transgelin-2 TAGL2_HUMAN 22,374 
331 Calcium/calmodulin-dependent protein kinase type II alpha chain KCC2A_HUMAN 54,013 
332 Ig gamma-2 chain C region IGHG2_HUMAN 35,865 
333 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas GNAS1_HUMAN 111,008 
334 Gelsolin precursor GELS_HUMAN 85,680 
335 Chromogranin-A precursor CMGA_HUMAN 50,712 
336 Nucleophosmin NPM_HUMAN 32,557 
337 Catenin delta-2 CTND2_HUMAN 132,641 
338 Protein S100-A13 S10AD_HUMAN 11,454 
339 Ig lambda chain C regions LAC_HUMAN 11,218 
340 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial precursor NDUS6_HUMAN 13,693 
341 Vacuolar proton translocating ATPase 116 kDa subunit a isoform 1 VPP1_HUMAN 96,399 
342 Amine oxidase [flavin-containing] B AOFB_HUMAN 58,746 
343 Neurosecretory protein VGF precursor VGF_HUMAN 67,269 
344 Antithrombin-III precursor ANT3_HUMAN 52,586 
345 Cytochrome b-c1 complex subunit Rieske, mitochondrial precursor UCRI_HUMAN 29,650 
346 Sideroflexin-3 SFXN3_HUMAN 35,486 
347 Rabphilin-3A RP3A_HUMAN 76,856 
348 Programmed cell death protein 6 PDCD6_HUMAN 21,851 
349 Myosin regulatory light chain 2, nonsarcomeric MLRM_HUMAN 19,777 
350 ATP synthase subunit d, mitochondrial ATP5H_HUMAN 18,474 
351 UMP-CMP kinase KCY_HUMAN 22,205 
352 Hypoxia up-regulated protein 1 precursor HYOU1_HUMAN 111,319 
353 Protein phosphatase 1 regulatory subunit 1B PPR1B_HUMAN 22,945 
354 Glycogen phosphorylase, brain form PYGB_HUMAN 96,680 
355 NADH-cytochrome b5 reductase 3 NB5R3_HUMAN 34,218 
356 Annexin A11 ANX11_HUMAN 54,374 
357 Programmed cell death 6-interacting protein PDC6I_HUMAN 96,007 
358 Protein disulfide-isomerase A6 precursor PDIA6_HUMAN 48,104 
359 Ubiquitin carboxyl-terminal hydrolase 5 UBP5_HUMAN 95,770 
360 Cell adhesion molecule 2 precursor CADM2_HUMAN 47,536 
361 Src substrate cortactin SRC8_HUMAN 61,617 
362 Monoglyceride lipase MGLL_HUMAN 33,244 
363 Elongation factor 1-alpha 2 EF1A2_HUMAN 50,453 
364 Septin-2 SEPT2_HUMAN 41,470 
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365 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit precursor RIB1_HUMAN 68,553 
366 Sodium/potassium-transporting ATPase subunit alpha-2 precursor AT1A2_HUMAN 112,251 
367 Serine/threonine-protein kinase PAK 1 PAK1_HUMAN 60,630 
368 LIM and SH3 domain protein 1 LASP1_HUMAN 29,699 
369 Sodium channel subunit beta-3 precursor SCN3B_HUMAN 24,684 
370 Heterogeneous nuclear ribonucleoprotein A1 ROA1_HUMAN 38,828 
371 TOM1-like protein 2 TM1L2_HUMAN 55,539 
372 Inorganic pyrophosphatase IPYR_HUMAN 32,643 
373 Synaptojanin-1 SYNJ1_HUMAN 173,332 
374 Matrin-3 MATR3_HUMAN 94,609 
375 Acetyl-CoA acetyltransferase, cytosolic THIC_HUMAN 41,332 
376 Aquaporin-4 AQP4_HUMAN 34,812 
377 Synaptic vesicle glycoprotein 2A SV2A_HUMAN 82,679 
378 Heterogeneous nuclear ribonucleoprotein U HNRPU_HUMAN 90,496 
379 Inter-alpha-trypsin inhibitor heavy chain H2 precursor ITIH2_HUMAN 106,421 
380 Angiotensinogen precursor ANGT_HUMAN 53,137 
381 Prohibitin PHB_HUMAN 29,787 
382 Alpha-soluble NSF attachment protein SNAA_HUMAN 33,216 
383 Neurocan core protein precursor CSPG3_HUMAN 143,072 
384 Flavin reductase BLVRB_HUMAN 22,101 
385 Immunoglobulin superfamily member 8 precursor IGSF8_HUMAN 65,015 
386 Protein NDRG4 NDRG4_HUMAN 38,440 
387 Opioid-binding protein/cell adhesion molecule precursor OPCM_HUMAN 37,990 
388 Tropomyosin alpha-4 chain TPM4_HUMAN 28,504 
389 Tubulin alpha-1A chain TBA1A_HUMAN 50,118 
390 Osteopontin precursor OSTP_HUMAN 35,405 
391 Clathrin light chain B CLCB_HUMAN 25,173 
392 Ezrin-radixin-moesin-binding phosphoprotein 50 NHERF_HUMAN 38,850 
393 Heat shock-related 70 kDa protein 2 HSP72_HUMAN 70,005 
394 PH and SEC7 domain-containing protein 3 PSD3_HUMAN 116,018 
395 Galectin-3 LEG3_HUMAN 26,171 
396 Glutathione transferase omega-1 GSTO1_HUMAN 27,549 
397 Erlin-2 precursor ERLN2_HUMAN 37,822 
398 Synaptic vesicle membrane protein VAT-1 homolog VAT1_HUMAN 41,902 
399 Plasma membrane calcium-transporting ATPase 4 AT2B4_HUMAN 137,906 
400 Microtubule-associated protein RP/EB family member 2 MARE2_HUMAN 37,014 
401 Transgelin-3 TAGL3_HUMAN 22,455 
402 Plasminogen activator inhibitor 1 RNA-binding protein PAIRB_HUMAN 44,948 
403 ADP-ribosylation factor 1 ARF1_HUMAN, ARF3_HUMAN 20,680 
404 AP-2 complex subunit alpha-2 AP2A2_HUMAN 103,945 
405 Annexin A7 ANXA7_HUMAN 52,723 
406 Synaptopodin SYNPO_HUMAN 99,446 
407 Cytochrome c1, heme protein, mitochondrial precursor CY1_HUMAN 35,373 
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408 Hepatoma-derived growth factor HDGF_HUMAN 26,771 
409 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 NDUBA_HUMAN 20,759 
410 Cystatin-B CYTB_HUMAN 11,121 
411 Protein TFG TFG_HUMAN 43,416 
412 Pyruvate carboxylase, mitochondrial precursor PYC_HUMAN 129,617 
413 Phosphate carrier protein, mitochondrial precursor MPCP_HUMAN 40,078 
414 Cytochrome b-c1 complex subunit 1, mitochondrial precursor QCR1_HUMAN 52,628 
415 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial precursor 
ODO2_HUMAN 48,622 
416 S-formylglutathione hydrolase ESTD_HUMAN 31,446 
417 Transforming protein RhoA precursor RHOA_HUMAN 21,750 
418 Calpain small subunit 1 CPNS1_HUMAN 28,299 
419 ATP-dependent RNA helicase A DHX9_HUMAN 140,944 
420 Importin subunit beta-1 IMB1_HUMAN 97,153 
421 Calpastatin ICAL_HUMAN 76,557 
422 Ras GTPase-activating-like protein IQGAP1 IQGA1_HUMAN 189,241 
423 Protein NipSnap2 NIPS2_HUMAN 33,725 
424 Nebulette NEBL_HUMAN 116,438 
425 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial precursor MMSA_HUMAN 57,822 
426 Drebrin DREB_HUMAN 71,407 
427 Chitinase-3-like protein 1 precursor CH3L1_HUMAN 42,609 
428 Cell adhesion molecule 3 precursor CADM3_HUMAN 43,283 
429 FK506-binding protein 3 FKBP3_HUMAN 25,159 
430 Integrin beta-1 precursor ITB1_HUMAN 88,447 
431 4-aminobutyrate aminotransferase, mitochondrial precursor GABT_HUMAN 56,423 
432 Serpin H1 precursor SERPH_HUMAN 46,424 
433 Apolipoprotein C-III precursor APOC3_HUMAN 10,834 
434 Plastin-2 PLSL_HUMAN 70,274 
435 Alpha-actinin-4 ACTN4_HUMAN 104,839 
436 MAP6 domain-containing protein 1 MA6D1_HUMAN 20,987 
437 WAS/WASL-interacting protein family member 2 WIPF2_HUMAN 46,272 
438 6-phosphogluconolactonase 6PGL_HUMAN 27,530 
439 Prolargin precursor PRELP_HUMAN 43,794 
440 Tropomodulin-2 TMOD2_HUMAN 39,578 
441 Adenylate kinase isoenzyme 4, mitochondrial KAD4_HUMAN 25,251 
442 GTP:AMP phosphotransferase mitochondrial KAD3_HUMAN 25,548 
443 Transaldolase TALDO_HUMAN 37,524 
444 Vacuolar proton pump subunit G 2 VATG2_HUMAN 13,586 
445 Lactoylglutathione lyase LGUL_HUMAN 20,761 
446 NSFL1 cofactor p47 NSF1C_HUMAN 40,555 
447 GTP-binding nuclear protein Ran RAN_HUMAN 24,405 
448 Gamma-synuclein SYUG_HUMAN 13,312 
449 Voltage-dependent anion-selective channel protein 1 VDAC1_HUMAN 30,756 
450 Endoplasmic reticulum protein ERp29 precursor ERP29_HUMAN 28,977 
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451 Ras-related protein Rap-1b precursor RAP1B_HUMAN 20,807 
452 Lambda-crystallin homolog CRYL1_HUMAN 35,401 
453 Mannose-6-phosphate isomerase MANA_HUMAN 46,639 
454 Cytochrome b5 type B precursor CYB5B_HUMAN 16,314 
455 Trifunctional enzyme subunit beta, mitochondrial precursor ECHB_HUMAN 51,278 
456 Neuronal growth regulator 1 precursor NEGR1_HUMAN 38,701 
457 Drebrin-like protein DBNL_HUMAN 48,188 
458 Fatty acid synthase FAS_HUMAN 273,382 
459 Pyridoxal kinase PDXK_HUMAN 35,084 
460 F-actin-capping protein subunit beta CAPZB_HUMAN 31,334 
461 Dipeptidyl-peptidase 2 precursor DPP2_HUMAN 54,311 
462 Proactivator polypeptide precursor [Contains: Saposin-A SAP_HUMAN 58,094 
463 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 PIN1_HUMAN 18,226 
464 Glutathione S-transferase Mu 3 GSTM3_HUMAN 26,543 
465 Spectrin beta chain, brain 2 SPTN2_HUMAN 271,278 
466 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial precursor DHSB_HUMAN 31,613 
467 Far upstream element-binding protein 2 FUBP2_HUMAN 73,129 
468 EH domain-containing protein 3 EHD3_HUMAN 61,881 
469 Nuclease sensitive element-binding protein 1 YBOX1_HUMAN 35,906 
470 Excitatory amino acid transporter 2 EAA2_HUMAN 62,088 
471 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial precursor NDUV1_HUMAN 50,800 
472 BAG family molecular chaperone regulator 3 BAG3_HUMAN 61,575 
473 Sodium/potassium-transporting ATPase subunit alpha-3 AT1A3_HUMAN 111,734 
474 Adenylyl cyclase-associated protein 1 CAP1_HUMAN 51,838 
475 Vesicular integral-membrane protein VIP36 precursor LMAN2_HUMAN 40,212 
476 Cytochrome c oxidase subunit 5B, mitochondrial precursor COX5B_HUMAN 13,678 
477 Secernin-1 SCRN1_HUMAN 46,364 
478 Actin-related protein 2/3 complex subunit 4 ARPC4_HUMAN 19,649 
479 Crk-like protein CRKL_HUMAN 33,759 
480 Dynamin-1-like protein DNM1L_HUMAN 81,861 
481 Transketolase TKT_HUMAN 67,861 
482 Glucosidase 2 subunit beta precursor GLU2B_HUMAN 59,408 
483 Actin-related protein 3 ARP3_HUMAN 47,354 
484 Protein enabled homolog ENAH_HUMAN 66,493 
485 FK506-binding protein 2 precursor FKBP2_HUMAN 15,632 
486 Transmembrane protein 65 TMM65_HUMAN 25,526 
487 Protein S100-A10 S10AA_HUMAN 11,186 
488 Paralemmin PALM_HUMAN 42,057 
489 SH3-containing GRB2-like protein 3-interacting protein 1 SGIP1_HUMAN 89,093 
490 SRA stem-loop-interacting RNA-binding protein, mitochondrial precursor SLIRP_HUMAN 12,331 
491 26S proteasome non-ATPase regulatory subunit 2 PSMD2_HUMAN 100,184 
492 Hexokinase-1 HXK1_HUMAN 102,470 
493 Puromycin-sensitive aminopeptidase PSA_HUMAN 103,261 
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494 Calcium-binding mitochondrial carrier protein Aralar1 CMC1_HUMAN 74,740 
495 Hematopoietic lineage cell-specific protein HCLS1_HUMAN 53,979 
496 Vacuolar protein sorting-associated protein 35 VPS35_HUMAN 91,692 
497 Hippocalcin-like protein 4 HPCL4_HUMAN 22,186 
498 Cytochrome c oxidase subunit 2 COX2_HUMAN 25,548 
499 Nidogen-2 precursor NID2_HUMAN 151,377 
500 Elongation factor 1-gamma EF1G_HUMAN 50,101 
501 Mitochondrial precursor proteins import receptor TOM70_HUMAN 67,439 
502 Heterogeneous nuclear ribonucleoprotein D0 HNRPD_HUMAN 38,417 
503 Mannose-6-phosphate receptor-binding protein 1 M6PBP_HUMAN 47,028 
504 Sorbin and SH3 domain-containing protein 1 SRBS1_HUMAN 142,441 
505 Succinyl-CoA ligase [ADP-forming] beta-chain, mitochondrial precursor SUCB1_HUMAN 50,300 
506 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial precursor NDUB8_HUMAN 21,748 
507 Microtubule-associated protein RP/EB family member 1 MARE1_HUMAN 29,982 
508 ES1 protein homolog, mitochondrial precursor ES1_HUMAN 28,152 
509 Talin-2 TLN2_HUMAN 271,535 
510 Eukaryotic translation initiation factor 5A-1 IF5A1_HUMAN 16,815 
511 Glucose-6-phosphate 1-dehydrogenase G6PD_HUMAN 59,240 
512 Cholecystokinins precursor CCKN_HUMAN 12,652 
513 Heat shock 70 kDa protein 12A HS12A_HUMAN 74,962 
514 Neurocalcin-delta NCALD_HUMAN 22,228 
515 6-phosphofructokinase, muscle type K6PF_HUMAN 85,166 
516 Epoxide hydrolase 1 HYEP_HUMAN 52,933 
517 Mimitin, mitochondrial precursor MIMIT_HUMAN 19,839 
518 Endonuclease domain-containing 1 protein precursor ENDD1_HUMAN 55,000 
519 Ribonuclease inhibitor RINI_HUMAN 49,956 
520 Aquaporin-1 AQP1_HUMAN 28,509 
521 Catenin beta-1 CTNB1_HUMAN 85,479 
522 High mobility group protein B1 HMGB1_HUMAN 24,877 
523 Endophilin-B2 SHLB2_HUMAN 43,957 
524 Heat shock protein 105 kDa HS105_HUMAN 96,848 
525 Carbonic anhydrase 4 precursor CAH4_HUMAN 35,015 
526 26S protease regulatory subunit 6B PRS6B_HUMAN 47,350 
527 Septin-5 SEPT5_HUMAN 42,760 
528 Alpha-1B-glycoprotein precursor A1BG_HUMAN 54,254 
529 Dynactin subunit 2 DCTN2_HUMAN 44,214 
530 Glycolipid transfer protein GLTP_HUMAN 23,833 
531 Neuronal membrane glycoprotein M6-a GPM6A_HUMAN 31,192 
532 Calcium/calmodulin-dependent protein kinase type II delta chain KCC2D_HUMAN 56,353 
533 14 kDa phosphohistidine phosphatase PHP14_HUMAN 13,815 
534 Plasminogen precursor PLMN_HUMAN 90,549 
535 Prolow-density lipoprotein receptor-related protein 1 precursor LRP1_HUMAN 504,543 
536 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial precursor DHSA_HUMAN 72,674 
537 Tubulin polymerization-promoting protein family member 3 TPPP3_HUMAN 18,968 
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538 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial precursor NDUA9_HUMAN 42,492 
539 Lysosomal acid phosphatase precursor PPAL_HUMAN 48,327 
540 Guanine nucleotide-binding protein G(i), alpha-2 subunit GNAI2_HUMAN 40,434 
541 Flotillin-1 FLOT1_HUMAN 47,337 
542 Collagen alpha-2(VI) chain precursor CO6A2_HUMAN 108,563 
543 Lamina-associated polypeptide 2, isoforms beta/gamma 
LAP2A_HUMAN, 
LAP2B_HUMAN 50,653 
544 Alcohol dehydrogenase [NADP+] AK1A1_HUMAN 36,556 
545 Protein FAM123A F123A_HUMAN 69,532 
546 ATPase inhibitor, mitochondrial precursor ATIF1_HUMAN 12,231 
547 Vacuolar proton pump subunit F VATF_HUMAN 13,353 
548 Membrane-associated progesterone receptor component 2 PGRC2_HUMAN 23,801 
549 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial precursor ODPB_HUMAN 39,215 
550 Platelet-activating factor acetylhydrolase IB subunit beta PA1B2_HUMAN 25,552 
551 Nucleosome assembly protein 1-like 1 NP1L1_HUMAN 45,357 
552 26S proteasome non-ATPase regulatory subunit 13 PSD13_HUMAN 42,901 
553 Ubiquitin-conjugating enzyme E2 N UBE2N_HUMAN 17,121 
554 Palmitoyl-protein thioesterase 1 precursor PPT1_HUMAN 34,176 
555 LanC-like protein 1 LANC1_HUMAN 45,267 
556 Cytochrome c oxidase polypeptide VIIa-liver/heart, mitochondrial precursor CX7A2_HUMAN 9,379 
557 Lumican precursor LUM_HUMAN 38,414 
558 Galectin-1 LEG1_HUMAN 14,698 
559 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 NDUAC_HUMAN 17,096 
560 PC4 and SFRS1-interacting protein PSIP1_HUMAN 60,086 
561 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial precursor NDUS8_HUMAN 23,688 
562 Myelin-oligodendrocyte glycoprotein precursor MOG_HUMAN 28,162 
563 Uncharacterized protein C10orf35 CJ035_HUMAN 13,220 
564 10-formyltetrahydrofolate dehydrogenase FTHFD_HUMAN 98,812 
565 Ubiquilin-2 UBQL2_HUMAN 65,679 
566 Cytoskeleton-associated protein 4 CKAP4_HUMAN 66,004 
567 6-phosphofructokinase, liver type K6PL_HUMAN 85,001 
568 Vacuolar ATP synthase subunit S1 precursor VAS1_HUMAN 52,009 
569 Phospholipid transfer protein precursor PLTP_HUMAN 54,723 
570 Polypyrimidine tract-binding protein 1 PTBP1_HUMAN 57,205 
571 UTP--glucose-1-phosphate uridylyltransferase UGPA_HUMAN 56,924 
572 Tenascin precursor TENA_HUMAN 240,845 
573 Sodium/calcium exchanger 2 precursor NAC2_HUMAN 100,351 
574 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial precursor NDUS1_HUMAN 79,451 
575 Alpha-centractin ACTZ_HUMAN 42,597 
576 Ras-related protein Rab-31 RAB31_HUMAN 21,551 
577 ATP synthase subunit O, mitochondrial precursor ATPO_HUMAN 23,259 
578 Heterogeneous nuclear ribonucleoprotein G HNRPG_HUMAN 42,316 
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579 Melanoma inhibitory activity protein 3 precursor MIA3_HUMAN 213,687 
580 Protein RUFY3 RUFY3_HUMAN 52,949 
581 Protein ERGIC-53 precursor LMAN1_HUMAN 57,531 
582 Dipeptidyl aminopeptidase-like protein 6 DPP6_HUMAN 97,573 
583 Beta-hexosaminidase alpha chain precursor HEXA_HUMAN 60,672 
584 Mitochondrial import receptor subunit TOM22 homolog TOM22_HUMAN 15,504 
585 Hepatoma-derived growth factor-related protein 3 HDGR3_HUMAN 22,603 
586 Cation-dependent mannose-6-phosphate receptor precursor MPRD_HUMAN 30,975 
587 Casein kinase II subunit alpha CSK21_HUMAN 45,127 
588 T-complex protein 1 subunit zeta TCPZ_HUMAN 58,007 
589 Thrombospondin-1 precursor TSP1_HUMAN 129,364 
590 Ganglioside-induced differentiation-associated protein 1 GDAP1_HUMAN 41,235 
591 Serine/threonine-protein kinase DCLK2 DCLK2_HUMAN 83,595 
592 Cathepsin B precursor CATB_HUMAN 37,803 
593 Synapsin-3 SYN3_HUMAN 63,285 
594 Mitochondrial carrier homolog 2 MTCH2_HUMAN 33,314 
595 Adipocyte plasma membrane-associated protein APMAP_HUMAN 46,464 
596 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial precursor ACADM_HUMAN 46,572 
597 Lysosomal Pro-X carboxypeptidase precursor PCP_HUMAN 55,783 
598 Sorting nexin-3 SNX3_HUMAN 18,745 
599 Gamma-soluble NSF attachment protein SNAG_HUMAN 34,729 
600 D-dopachrome decarboxylase DOPD_HUMAN 12,694 
601 Galectin-related protein LEGL_HUMAN 18,968 
602 La-related protein 1 LARP1_HUMAN 123,495 
603 Selenium-binding protein 1 SBP1_HUMAN 52,374 
604 Neuronal calcium sensor 1 NCS1_HUMAN 21,862 
605 Kininogen-1 precursor KNG1_HUMAN 71,940 
606 Ras-related protein Rab-10 RAB10_HUMAN 22,524 
607 Thioredoxin domain-containing protein 4 precursor TXND4_HUMAN 46,955 
608 PDZ and LIM domain protein 5 PDLI5_HUMAN 63,953 
609 SH3 and multiple ankyrin repeat domains protein 3 SHAN3_HUMAN 186,282 
610 Emerin EMD_HUMAN 28,977 
611 Dynamin-like 120 kDa protein, mitochondrial precursor OPA1_HUMAN 111,643 
612 Elongation factor 2 EF2_HUMAN 95,322 
613 WD repeat-containing protein 1 WDR1_HUMAN 66,175 
614 NAD(P) transhydrogenase, mitochondrial precursor NNTM_HUMAN 113,881 
615 Neural cell adhesion molecule 2 precursor NCAM2_HUMAN 92,916 
616 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial precursor ACADV_HUMAN 70,374 
617 60S ribosomal protein L15 RL15_HUMAN 24,129 
618 Complement C4-B precursor CO4A_HUMAN, CO4B_HUMAN 192,777 
619 60S ribosomal protein L10 RL10_HUMAN 24,587 
620 Estradiol 17-beta-dehydrogenase 12 DHB12_HUMAN 34,307 
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621 Major vault protein MVP_HUMAN 99,308 
622 Dystroglycan precursor DAG1_HUMAN 97,563 
623 Rab GDP dissociation inhibitor beta GDIB_HUMAN 50,648 
624 Kinectin KTN1_HUMAN 156,258 
625 Serine/threonine-protein kinase DCLK1 DCLK1_HUMAN 82,208 
626 Growth factor receptor-bound protein 2 GRB2_HUMAN 25,189 
627 Cytochrome c oxidase polypeptide VIc precursor COX6C_HUMAN 8,764 
628 2,4-dienoyl-CoA reductase, mitochondrial precursor DECR_HUMAN 36,051 
629 Proto-oncogene C-crk CRK_HUMAN 33,813 
630 Heat shock protein beta-6 HSPB6_HUMAN 17,117 
631 Splicing factor, arginine/serine-rich 1 SFRS1_HUMAN 27,727 
632 Metaxin-2 MTX2_HUMAN 29,745 
633 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 NDUA2_HUMAN 10,904 
634 Neurabin-2 NEB2_HUMAN 89,174 
635 Dual specificity mitogen-activated protein kinase kinase 1 MP2K1_HUMAN 43,422 
636 Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform PP2BB_HUMAN 59,007 
637 Plasma membrane calcium-transporting ATPase 1 AT2B1_HUMAN 138,741 
638 Poliovirus receptor-related protein 1 precursor PVRL1_HUMAN 57,140 
639 Copine-3 CPNE3_HUMAN 60,114 
640 p130Cas-associated protein SNIP_HUMAN 112,450 
641 Nucleoside diphosphate kinase A NDKA_HUMAN 17,131 
642 Adenine phosphoribosyltransferase APT_HUMAN 19,591 
643 RNA-binding protein FUS FUS_HUMAN 53,408 
644 Nicastrin precursor NICA_HUMAN 78,394 
645 Syntaxin-7 STX7_HUMAN 29,798 
646 ADP-ribosylation factor GTPase-activating protein 1 ARFG1_HUMAN 44,649 
647 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 NDUS5_HUMAN 12,500 
648 SH3 domain-binding glutamic acid-rich-like protein 3 SH3L3_HUMAN 10,420 
649 Uncharacterized protein C2orf32 CB032_HUMAN 18,630 
650 Dynein light chain 1, cytoplasmic DYL1_HUMAN, DYL2_HUMAN 10,348 
651 Guanine nucleotide-binding protein G(q) subunit alpha GNAQ_HUMAN 41,451 
652 T-complex protein 1 subunit alpha TCPA_HUMAN 60,327 
653 Target of Myb protein 1 TOM1_HUMAN 53,801 
654 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial precursor SCOT_HUMAN 56,141 
655 Mannosyl-oligosaccharide glucosidase GCS1_HUMAN 91,901 
656 Phospholipase D3 PLD3_HUMAN 54,688 
657 Leucine-rich PPR motif-containing protein, mitochondrial precursor LPPRC_HUMAN 157,894 
658 Integrin alpha-IIb precursor ITA2B_HUMAN 113,373 
659 Protein kinase C alpha type KPCA_HUMAN 76,747 
660 Ras-related protein Rab-27B RB27B_HUMAN 24,591 
661 Voltage-dependent anion-selective channel protein 2 VDAC2_HUMAN 31,549 
662 Cold-inducible RNA-binding protein CIRBP_HUMAN 18,630 
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663 Oligodendrocyte-myelin glycoprotein precursor OMGP_HUMAN 49,592 
664 Chloride intracellular channel protein 4 CLIC4_HUMAN 28,756 
665 Solute carrier family 12 member 5 S12A5_HUMAN 126,168 
666 Cytoplasmic dynein 1 light intermediate chain 1 DC1L1_HUMAN 56,562 
667 Platelet-activating factor acetylhydrolase IB subunit gamma PA1B3_HUMAN 25,716 
668 Single-stranded DNA-binding protein, mitochondrial precursor SSB_HUMAN 17,242 
669 Leukocyte elastase inhibitor ILEU_HUMAN 42,726 
670 Heterogeneous nuclear ribonucleoproteins C1/C2 HNRPC_HUMAN 33,653 
671 Synaptophysin SYPH_HUMAN 33,827 
672 SPARC-like protein 1 precursor SPRL1_HUMAN 75,198 
673 5'(3')-deoxyribonucleotidase, cytosolic type NT5C_HUMAN 23,365 
674 Heterogeneous nuclear ribonucleoprotein A0 ROA0_HUMAN 30,823 
675 Band 4.1-like protein 2 E41L2_HUMAN 112,570 
676 HLA class II histocompatibility antigen, DRB1-1 beta chain precursor 
2B11_HUMAN, 
2B14_HUMAN, 
2B1A_HUMAN, 
HB2C_HUMAN 
29,896 
677 Protein NipSnap1 NIPS1_HUMAN 33,293 
678 Gamma-glutamyltransferase 5 precursor GGT5_HUMAN 62,243 
679 FXYD domain-containing ion transport regulator 6 precursor FXYD6_HUMAN 10,525 
680 Erythrocyte band 7 integral membrane protein STOM_HUMAN 31,714 
681 Sorting and assembly machinery component 50 homolog SAM50_HUMAN 51,960 
682 DmX-like protein 2 DMXL2_HUMAN 339,740 
683 Transmembrane protein 43 TMM43_HUMAN 44,859 
684 Immunity-related GTPase family Q protein IRGQ_HUMAN 62,701 
685 40S ribosomal protein S4, X isoform RS4X_HUMAN 29,581 
686 NADH-cytochrome b5 reductase 1 NB5R1_HUMAN 34,078 
687 UV excision repair protein RAD23 homolog B RD23B_HUMAN 43,153 
688 Cell cycle exit and neuronal differentiation protein 1 CEND_HUMAN 14,936 
689 Dihydrolipoyl dehydrogenase, mitochondrial precursor DLDH_HUMAN 54,132 
690 ADP/ATP translocase 1 ADT1_HUMAN 33,047 
691 Cdc42 effector protein 4 BORG4_HUMAN 37,963 
692 Renin receptor precursor RENR_HUMAN 38,991 
693 Heme oxygenase 1 HMOX1_HUMAN 32,801 
694 Gap junction alpha-1 protein CXA1_HUMAN 42,991 
695 Nucleobindin-1 precursor NUCB1_HUMAN 53,862 
696 Tryptophanyl-tRNA synthetase, cytoplasmic SYWC_HUMAN 53,150 
697 COP9 signalosome complex subunit 6 CSN6_HUMAN 36,145 
698 Integrin beta-2 precursor ITB2_HUMAN 84,764 
699 Polyadenylate-binding protein 1 PABP1_HUMAN 70,653 
700 Arsenical pump-driving ATPase ARSA1_HUMAN 38,776 
701 Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic GPDA_HUMAN 37,550 
702 Proline synthetase co-transcribed bacterial homolog protein PROSC_HUMAN 30,326 
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703 3-hydroxyisobutyrate dehydrogenase, mitochondrial precursor 3HIDH_HUMAN 35,312 
704 Chloride intracellular channel protein 1 CLIC1_HUMAN 26,905 
705 Gamma-adducin ADDG_HUMAN 79,138 
706 Alpha-2-antiplasmin precursor A2AP_HUMAN 54,549 
707 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 
PP1A_HUMAN, 
PP1G_HUMAN 36,968 
708 Aflatoxin B1 aldehyde reductase member 2 ARK72_HUMAN 39,571 
709 Ubiquitin carboxyl-terminal hydrolase 14 UBP14_HUMAN 56,052 
710 Protein piccolo PCLO_HUMAN 566,639 
711 26S protease regulatory subunit 6A PRS6A_HUMAN 49,187 
712 Alpha-2-macroglobulin precursor A2MG_HUMAN 163,259 
713 ADP-ribosylation factor-like protein 3 ARL3_HUMAN 20,438 
714 Collagen alpha-1(VI) chain precursor CO6A1_HUMAN 108,513 
715 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial precursor NDUS2_HUMAN 52,529 
716 3-ketoacyl-CoA thiolase, mitochondrial THIM_HUMAN 41,906 
717 AP-2 complex subunit alpha-1 AP2A1_HUMAN 107,540 
718 Neurofilament heavy polypeptide NFH_HUMAN 112,463 
719 Translationally-controlled tumor protein TCTP_HUMAN 19,578 
720 Centrosomal protein of 170 kDa CE170_HUMAN 175,278 
721 Activated RNA polymerase II transcriptional coactivator p15 TCP4_HUMAN 14,378 
722 Hemopexin precursor HEMO_HUMAN 51,659 
723 Beta-2-microglobulin precursor [Contains: Beta-2-microglobulin form pI 5.3] B2MG_HUMAN 13,697 
724 Cysteine-rich protein 2 CRIP2_HUMAN 22,475 
725 Nitrilase homolog 1 NIT1_HUMAN 35,879 
726 Heterogeneous nuclear ribonucleoprotein H3 HNRH3_HUMAN 36,910 
727 Syntaxin-12 STX12_HUMAN 31,625 
728 Apolipoprotein B-100 precursor APOB_HUMAN 515,554 
729 Lamin-A/C LMNA_HUMAN 74,123 
730 Disks large homolog 4 DLG4_HUMAN 80,479 
731 Protein KIAA0284 K0284_HUMAN 171,671 
732 Junctional adhesion molecule C precursor JAM3_HUMAN 35,002 
733 DNA-dependent protein kinase catalytic subunit PRKDC_HUMAN 469,078 
734 Guanine nucleotide-binding protein alpha-13 subunit GNA13_HUMAN 44,033 
735 Beta-Ala-His dipeptidase precursor CNDP1_HUMAN 56,675 
736 6-phosphofructokinase type C K6PP_HUMAN 85,579 
737 Fascin FSCN1_HUMAN 54,512 
738 COP9 signalosome complex subunit 7a CSN7A_HUMAN 30,259 
739 Acylphosphatase-2 ACYP2_HUMAN 11,121 
740 Ubiquitin-associated protein 2-like UBP2L_HUMAN 114,516 
741 AP-2 complex subunit mu-1 AP2M1_HUMAN 49,638 
742 LanC-like protein 2 LANC2_HUMAN 50,838 
743 Myosin light chain kinase, smooth muscle MYLK_HUMAN 210,754 
744 40S ribosomal protein S8 RS8_HUMAN 24,188 
745 NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial precursor NDUV3_HUMAN 11,923 
746 Ras GTPase-activating protein-binding protein 2 G3BP2_HUMAN 54,102 
747 Cytoplasmic dynein 1 light intermediate chain 2 DC1L2_HUMAN 54,082 
748 ProSAAS precursor PCSK1_HUMAN 27,355 
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749 Interferon-inducible double stranded RNA-dependent protein kinase activator A PRKRA_HUMAN 34,387 
750 Secretory carrier-associated membrane protein 1 SCAM1_HUMAN 37,903 
751 Heterogeneous nuclear ribonucleoprotein L HNRPL_HUMAN 60,169 
752 Tubulin folding cofactor B TBCB_HUMAN 27,308 
753 Transcription elongation factor A protein-like 5 TCAL5_HUMAN 23,289 
754 Transcription intermediary factor 1-beta TIF1B_HUMAN 88,531 
755 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 GBB1_HUMAN 37,360 
756 T-complex protein 1 subunit epsilon TCPE_HUMAN 59,654 
757 Protein FAM49A FA49A_HUMAN 37,296 
758 Receptor-type tyrosine-protein phosphatase-like N precursor PTPRN_HUMAN 105,830 
759 Heterogeneous nuclear ribonucleoprotein M HNRPM_HUMAN 77,499 
760 Poly(rC)-binding protein 1 PCBP1_HUMAN 37,480 
761 Tropomyosin alpha-3 chain TPM3_HUMAN 32,802 
762 Cytochrome b5 CYB5_HUMAN 15,312 
763 Dihydropyrimidinase-related protein 4 DPYL4_HUMAN 61,859 
764 Tyrosine-protein phosphatase non-receptor type 11 PTN11_HUMAN 68,418 
765 40S ribosomal protein S19 RS19_HUMAN 16,043 
766 E2-induced gene 5 protein E2IG5_HUMAN 17,325 
767 Splicing factor, arginine/serine-rich 3 SFRS3_HUMAN 19,312 
768 T-complex protein 1 subunit delta TCPD_HUMAN 57,908 
769 26S proteasome non-ATPase regulatory subunit 8 PSMD8_HUMAN 29,989 
770 Ras GTPase-activating protein-binding protein 1 G3BP1_HUMAN 52,145 
771 Hydroxyacylglutathione hydrolase GLO2_HUMAN 28,842 
772 Electron transfer flavoprotein subunit alpha, mitochondrial precursor ETFA_HUMAN 35,062 
773 TATA-binding protein-associated factor 2N RBP56_HUMAN 61,813 
774 Glutathione S-transferase theta-2 GSTT2_HUMAN 27,490 
775 Zinc-alpha-2-glycoprotein precursor ZA2G_HUMAN 33,854 
776 Isoamyl acetate-hydrolyzing esterase 1 homolog IAH1_HUMAN 27,582 
777 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 NDUA5_HUMAN 13,441 
778 Prostaglandin E synthase 3 TEBP_HUMAN 18,680 
779 Caldesmon CALD1_HUMAN 93,233 
780 Collagen alpha-2(IV) chain precursor [Contains: Canstatin] CO4A2_HUMAN 167,540 
781 Zyxin ZYX_HUMAN 61,258 
782 General transcription factor II-I GTF2I_HUMAN 112,400 
783 Pyridoxine-5'-phosphate oxidase PNPO_HUMAN 29,970 
784 60S ribosomal protein L6 RL6_HUMAN 32,711 
785 Thymidine phosphorylase precursor TYPH_HUMAN 49,938 
786 Leucine zipper-EF-hand-containing transmembrane protein 1, mitochondrial precursor LETM1_HUMAN 83,338 
787 Laminin subunit gamma-1 precursor LAMC1_HUMAN 177,587 
788 Glycerol-3-phosphate dehydrogenase, mitochondrial precursor GPDM_HUMAN 80,818 
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789 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial precursor HCDH_HUMAN 34,260 
790 Acyl-coenzyme A thioesterase 1 ACOT1_HUMAN 46,260 
791 Alanyl-tRNA synthetase, cytoplasmic SYAC_HUMAN 106,795 
792 Armadillo repeat-containing protein 10 ARM10_HUMAN 37,523 
793 T-cell immunomodulatory protein precursor TIP_HUMAN 68,092 
794 60S ribosomal protein L19 RL19_HUMAN 23,449 
795 Solute carrier family 2, facilitated glucose transporter member 3 GTR3_HUMAN 53,908 
796 Protachykinin 1 precursor TKN1_HUMAN 14,986 
797 Vitamin D-binding protein precursor VTDB_HUMAN 52,947 
798 Filamin-B FLNB_HUMAN 278,172 
799 Protein tyrosine kinase 2 beta FAK2_HUMAN 115,860 
800 Adenylate kinase isoenzyme 2, mitochondrial KAD2_HUMAN 26,461 
801 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial precursor NDUV2_HUMAN 27,374 
802 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform 
PP2AA_HUMAN, 
PP2AB_HUMAN 35,577 
803 Solute carrier family 12 member 2 S12A2_HUMAN 131,434 
804 COP9 signalosome complex subunit 3 CSN3_HUMAN 47,857 
805 Proteasome activator complex subunit 2 PSME2_HUMAN 27,344 
806 Intercellular adhesion molecule 1 precursor ICAM1_HUMAN 57,807 
807 Inter-alpha-trypsin inhibitor heavy chain H1 precursor ITIH1_HUMAN 101,372 
808 Ceruloplasmin precursor CERU_HUMAN 122,190 
809 Cytochrome c oxidase subunit 5A, mitochondrial precursor COX5A_HUMAN 16,757 
810 Proline-rich transmembrane protein 2 PRRT2_HUMAN 34,926 
811 Heterogeneous nuclear ribonucleoprotein H2 HNRH2_HUMAN 49,246 
812 Cytochrome b-c1 complex subunit 8 QCR8_HUMAN 9,889 
813 3-mercaptopyruvate sulfurtransferase THTM_HUMAN 33,161 
814 Heme-binding protein 1 HEBP1_HUMAN 21,079 
815 Neuronal pentraxin-1 precursor NPTX1_HUMAN 47,105 
816 Serum deprivation-response protein SDPR_HUMAN 47,155 
817 Sodium/hydrogen exchanger 6 SL9A6_HUMAN 74,146 
818 Neuropeptide Y precursor [Contains: Neuropeptide Y NPY_HUMAN 10,834 
819 Diablo homolog, mitochondrial precursor DBLOH_HUMAN 27,113 
820 Hypoxanthine-guanine phosphoribosyltransferase HPRT_HUMAN 24,562 
821 Radixin RADI_HUMAN 68,548 
822 Splicing factor 1 SF01_HUMAN 68,313 
823 Isochorismatase domain-containing protein 1 ISOC1_HUMAN 32,219 
824 UDP-glucose:glycoprotein glucosyltransferase 1 precursor UGGG1_HUMAN 174,965 
825 26S protease regulatory subunit 4 PRS4_HUMAN 49,168 
826 Lethal(2) giant larvae protein homolog 1 L2GL1_HUMAN 115,024 
827 Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial precursor IDH3B_HUMAN 42,166 
828 Ubiquilin-1 UBQL1_HUMAN 62,502 
829 Interleukin enhancer-binding factor 2 ILF2_HUMAN 43,045 
830 DnaJ homolog subfamily C member 5 DNJC5_HUMAN 22,131 
831 Acylphosphatase-1 ACYP1_HUMAN 11,243 
832 Obg-like ATPase 1 OLA1_HUMAN 44,727 
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833 Actin-related protein 2/3 complex subunit 2 ARPC2_HUMAN 34,316 
834 ATP-dependent DNA helicase 2 subunit 2 KU86_HUMAN 82,689 
835 TBC1 domain family member 13 TBC13_HUMAN 32,143 
836 ATP-binding cassette sub-family D member 3 ABCD3_HUMAN 75,461 
837 Transforming growth factor-beta-induced protein ig-h3 precursor BGH3_HUMAN 74,665 
838 ATP-citrate synthase ACLY_HUMAN 120,825 
839 28 kDa heat- and acid-stable phosphoprotein HAP28_HUMAN 20,613 
840 B-cell receptor-associated protein 31 BAP31_HUMAN 27,975 
841 Complexin-2 CPLX2_HUMAN 15,377 
842 Neutrophil defensin 1 precursor DEF1_HUMAN, DEF3_HUMAN 10,183 
843 Hematological and neurological expressed 1 protein HN1_HUMAN 15,997 
844 Plasma membrane calcium-transporting ATPase 2 AT2B2_HUMAN 136,862 
845 Reticulon-3 RTN3_HUMAN 112,595 
846 Tight junction protein ZO-1 ZO1_HUMAN 195,442 
847 DnaJ homolog subfamily B member 2 DNJB2_HUMAN 35,563 
848 Contactin-associated protein-like 2 precursor CNTP2_HUMAN 148,151 
849 Serum paraoxonase/arylesterase 2 PON2_HUMAN 39,381 
850 Na(+)/H(+) exchange regulatory cofactor NHE-RF2 NHRF2_HUMAN 37,395 
851 Ig kappa chain V-III region SIE KV302_HUMAN, KV305_HUMAN 11,757 
852 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial precursor 
ODP2_HUMAN 65,764 
853 Actin-binding LIM protein 2 ABLM2_HUMAN 67,795 
854 Protein 4.1 41_HUMAN 97,000 
855 Ubiquitin-conjugating enzyme E2 variant 2 UB2V2_HUMAN 16,345 
856 IQ motif and Sec7 domain-containing protein 1 IQEC1_HUMAN 108,300 
857 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 NDUA4_HUMAN 9,352 
858 Delta-aminolevulinic acid dehydratase HEM2_HUMAN 36,277 
859 Tripartite motif-containing protein 2 TRIM2_HUMAN 81,513 
860 Beta-hexosaminidase beta chain precursor HEXB_HUMAN 63,095 
861 G-protein coupled receptor 56 precursor GPR56_HUMAN 77,721 
862 Laminin subunit beta-1 precursor LAMB1_HUMAN 198,045 
863 Dynactin subunit 1 DCTN1_HUMAN 141,680 
864 Ubiquitin-conjugating enzyme E2 L3 UB2L3_HUMAN 17,844 
865 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial precursor ODPA_HUMAN 43,279 
866 Arfaptin-2 ARFP2_HUMAN 37,839 
867 ERO1-like protein alpha precursor ERO1A_HUMAN 54,377 
868 Amyloid beta A4 protein precursor A4_HUMAN 86,923 
869 Apolipoprotein C-I precursor APOC1_HUMAN 9,314 
870 Integrin-linked protein kinase ILK_HUMAN 51,402 
871 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial precursor ECH1_HUMAN 35,798 
872 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 MACF1_HUMAN 620,397 
873 LIM domain and actin-binding protein 1 LIMA1_HUMAN 85,208 
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874 Proteasome activator complex subunit 1 PSME1_HUMAN 28,706 
875 C-terminal-binding protein 1 CTBP1_HUMAN 47,517 
876 AP-3 complex subunit sigma-1 AP3S1_HUMAN 21,715 
877 Neurotrimin precursor NTRI_HUMAN 37,953 
878 COP9 signalosome complex subunit 4 CSN4_HUMAN 46,252 
879 E3 ubiquitin-protein ligase HUWE1 HUWE1_HUMAN 481,874 
880 Afadin AFAD_HUMAN 205,592 
881 Vacuolar proton pump subunit G 1 VATG1_HUMAN 13,740 
882 GDH/6PGL endoplasmic bifunctional protein precursor [Includes: Glucose 1-dehydrogenase G6PE_HUMAN 88,876 
883 Exportin-1 XPO1_HUMAN 123,371 
884 Eukaryotic initiation factor 4A-I IF4A1_HUMAN 46,137 
885 Atlastin-3 ATLA3_HUMAN 60,525 
886 Peroxisomal multifunctional enzyme type 2 DHB4_HUMAN 79,670 
887 Calretinin CALB2_HUMAN 31,524 
888 Purine nucleoside phosphorylase PNPH_HUMAN 32,100 
889 Extended-synaptotagmin-1 ESYT1_HUMAN 122,841 
890 cAMP-dependent protein kinase, alpha-catalytic subunit KAPCA_HUMAN 40,573 
891 Protein tyrosine phosphatase-like protein PTPLAD1 PTAD1_HUMAN 43,143 
892 ATP-dependent DNA helicase 2 subunit 1 KU70_HUMAN 69,828 
893 Ubiquitin carboxyl-terminal hydrolase 7 UBP7_HUMAN 128,257 
894 Presequence protease, mitochondrial precursor PREP_HUMAN 117,439 
895 Keratin, type II cytoskeletal 5 K2C5_HUMAN 62,362 
896 Tricarboxylate transport protein, mitochondrial precursor TXTP_HUMAN 33,995 
897 Solute carrier family 2, facilitated glucose transporter member 1 GTR1_HUMAN 54,067 
898 Calcium-regulated heat stable protein 1 CHSP1_HUMAN 15,874 
899 Nicotinate phosphoribosyltransferase PNCB_HUMAN 57,561 
900 F-actin-capping protein subunit alpha-2 CAZA2_HUMAN 32,931 
901 Importin subunit alpha-3 IMA3_HUMAN 57,793 
902 FK506-binding protein 1A FKB1A_HUMAN 11,933 
903 Histone H1.4 
H12_HUMAN, 
H13_HUMAN, 
H14_HUMAN 
21,849 
904 Putative RNA-binding protein 3 RBM3_HUMAN 17,153 
905 Bisphosphoglycerate mutase PMGE_HUMAN 29,988 
906 40S ribosomal protein SA RSSA_HUMAN 32,836 
907 3-ketoacyl-CoA thiolase, peroxisomal precursor THIK_HUMAN 44,274 
908 Metaxin-1 MTX1_HUMAN 35,760 
909 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor D3D2_HUMAN 32,799 
910 Desmuslin DMN_HUMAN 172,747 
911 Charged multivesicular body protein 4b CHM4B_HUMAN 24,933 
912 Protein phosphatase 1F PPM1F_HUMAN 49,812 
913 Thioredoxin domain-containing protein 5 precursor TXND5_HUMAN 47,611 
914 Ig kappa chain V-IV region Len KV402_HUMAN 12,622 
915 Probable serine carboxypeptidase CPVL precursor CPVL_HUMAN 54,148 
916 Catenin delta-1 CTND1_HUMAN 108,154 
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917 Fatty acid-binding protein, brain FABPB_HUMAN 14,871 
918 Apolipoprotein A-IV precursor APOA4_HUMAN 45,381 
919 Calponin-3 CNN3_HUMAN 36,397 
920 Vasodilator-stimulated phosphoprotein VASP_HUMAN 39,811 
921 Caskin-1 CSKI1_HUMAN 149,797 
922 Acyl-coenzyme A oxidase 1, peroxisomal ACOX1_HUMAN 74,407 
923 Putative tyrosine-protein phosphatase auxilin AUXI_HUMAN 99,980 
924 Actin-related protein 2/3 complex subunit 1A ARC1A_HUMAN 41,551 
925 Double-stranded RNA-specific adenosine deaminase DSRAD_HUMAN 135,981 
926 Interleukin enhancer-binding factor 3 ILF3_HUMAN 95,321 
927 Phosphoserine phosphatase SERB_HUMAN 24,990 
928 DnaJ homolog subfamily A member 1 DNJA1_HUMAN 44,851 
929 F-actin-capping protein subunit alpha-1 CAZA1_HUMAN 32,905 
930 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 NDUA6_HUMAN 15,118 
931 Muscleblind-like protein 1 MBNL1_HUMAN 41,799 
932 Mitochondrial glutamate carrier 2 GHC2_HUMAN 33,832 
933 Histidine triad nucleotide-binding protein 2 HINT2_HUMAN 17,144 
934 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 NDUA8_HUMAN 20,087 
935 DCN1-like protein 1 DCNL1_HUMAN 30,108 
936 PDZ and LIM domain protein 4 PDLI4_HUMAN 35,380 
937 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 DDAH2_HUMAN 29,626 
938 Small glutamine-rich tetratricopeptide repeat-containing protein A SGTA_HUMAN 34,046 
939 Translocon-associated protein subunit alpha precursor SSRA_HUMAN 32,218 
940 Farnesyl pyrophosphate synthetase FPPS_HUMAN 40,516 
941 Mu-crystallin homolog CRYM_HUMAN 33,757 
942 Ras-related protein Rab-1B RAB1B_HUMAN 22,154 
943 Histidine-rich glycoprotein precursor HRG_HUMAN 59,559 
944 26S protease regulatory subunit S10B PRS10_HUMAN 44,157 
945 Cytosolic acyl coenzyme A thioester hydrolase BACH_HUMAN 41,777 
946 Heat shock protein 75 kDa, mitochondrial precursor TRAP1_HUMAN 80,095 
947 Actin-related protein 2 ARP2_HUMAN 44,744 
948 Nuclear mitotic apparatus protein 1 NUMA1_HUMAN 238,242 
949 Poly [ADP-ribose] polymerase 1 PARP1_HUMAN 113,070 
950 Protein phosphatase methylesterase 1 PPME1_HUMAN 42,298 
951 ATP synthase subunit f, mitochondrial ATPK_HUMAN 10,900 
952 Vigilin VIGLN_HUMAN 141,424 
953 Adipophilin ADFP_HUMAN 48,057 
954 Tubulin-specific chaperone A TBCA_HUMAN 12,837 
955 Plastin-3 PLST_HUMAN 70,421 
956 Amine oxidase [flavin-containing] A AOFA_HUMAN 59,665 
957 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 63 kDa subunit precursor RIB2_HUMAN 69,267 
958 Vacuolar proton pump subunit H VATH_HUMAN 55,865 
959 Arylacetamide deacetylase-like 1 ADCL1_HUMAN 45,791 
960 Prohibitin-2 PHB2_HUMAN 33,280 
961 Biglycan precursor PGS1_HUMAN 41,638 
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962 Aspartyl/asparaginyl beta-hydroxylase ASPH_HUMAN 85,845 
963 Aspartyl-tRNA synthetase, cytoplasmic SYDC_HUMAN 57,119 
964 Mitochondrial 2-oxoglutarate/malate carrier protein M2OM_HUMAN 34,045 
965 Myosin-Va MYO5A_HUMAN 215,411 
966 Vesicle-trafficking protein SEC22b SC22B_HUMAN 24,723 
967 Glutathione synthetase GSHB_HUMAN 52,368 
968 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 AT2A2_HUMAN 114,741 
969 MAP7 domain-containing protein 1 MA7D1_HUMAN 92,802 
970 Protein BAT5 BAT5_HUMAN 63,226 
971 Monocyte differentiation antigen CD14 precursor CD14_HUMAN 40,059 
972 Uncharacterized protein KIAA1671 K1671_HUMAN 196,693 
973 60S ribosomal protein L7a RL7A_HUMAN 29,978 
974 PRA1 family protein 3 PRAF3_HUMAN 21,598 
975 Misshapen-like kinase 1 MINK1_HUMAN 149,793 
976 Synaptotagmin-7 SYT7_HUMAN 45,547 
977 CDGSH iron sulfur domain-containing protein 1 CISD1_HUMAN 12,181 
978 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 NDUA3_HUMAN 9,261 
979 Protein dpy-30 homolog DPY30_HUMAN 11,232 
980 Phytanoyl-CoA hydroxylase-interacting protein PHYIP_HUMAN 37,555 
981 CD63 antigen CD63_HUMAN 25,618 
982 Abl interactor 1 ABI1_HUMAN 55,064 
983 Glucosamine-6-phosphate isomerase GNPI_HUMAN 32,651 
984 UPF0424 protein C1orf128 CA128_HUMAN 24,160 
985 Stomatin-like protein 2 STML2_HUMAN 38,517 
986 Complexin-1 CPLX1_HUMAN 15,013 
987 Dystrobrevin alpha DTNA_HUMAN 83,917 
988 Trans-2-enoyl-CoA reductase, mitochondrial precursor MECR_HUMAN 40,410 
989 60S acidic ribosomal protein P2 RLA2_HUMAN 11,647 
990 Probable oxidoreductase KIAA1576 K1576_HUMAN 45,882 
991 Haloacid dehalogenase-like hydrolase domain-containing protein 3 HDHD3_HUMAN 27,982 
992 Interferon-induced guanylate-binding protein 2 GBP2_HUMAN 67,167 
993 Protein canopy homolog 2 precursor CNPY2_HUMAN 20,635 
994 Actin-related protein 2/3 complex subunit 3 ARPC3_HUMAN 20,530 
995 Importin subunit beta-3 IMB3_HUMAN 123,614 
996 Transmembrane emp24 domain-containing protein 9 precursor TMED9_HUMAN 25,087 
997 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial precursor HIBCH_HUMAN 43,466 
998 Glutathione S-transferase kappa 1 GSTK1_HUMAN 25,480 
999 Transmembrane protein 126A T126A_HUMAN 21,511 
1,000 Fatty acid-binding protein, heart FABPH_HUMAN 14,841 
1,001 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial precursor NDUS4_HUMAN 20,090 
1,002 HLA class I histocompatibility antigen, alpha chain H precursor HLAH_HUMAN 40,831 
1,003 Bifunctional aminoacyl-tRNA synthetase SYEP_HUMAN 170,632 
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1,004 Epidermal growth factor receptor precursor EGFR_HUMAN 134,261 
1,005 FK506-binding protein 4 FKBP4_HUMAN 51,788 
1,006 Phosphatidylinositol 4-kinase alpha PI4KA_HUMAN 231,282 
1,007 Synaptosomal-associated protein 29 SNP29_HUMAN 28,953 
1,008 26S proteasome non-ATPase regulatory subunit 7 PSD7_HUMAN 37,008 
1,009 Suppressor of G2 allele of SKP1 homolog SUGT1_HUMAN 41,007 
1,010 Glycogen phosphorylase, muscle form PYGM_HUMAN 97,077 
1,011 ATP-dependent RNA helicase DDX1 DDX1_HUMAN 82,415 
1,012 Carnitine O-acetyltransferase CACP_HUMAN 70,909 
1,013 Isoleucyl-tRNA synthetase, mitochondrial precursor SYIM_HUMAN 113,776 
1,014 Staphylococcal nuclease domain-containing protein 1 SND1_HUMAN 101,981 
1,015 Guanine nucleotide-binding protein G(z) subunit alpha GNAZ_HUMAN 40,908 
1,016 Serine/threonine-protein kinase PAK 2 PAK2_HUMAN 58,026 
1,017 Cytoplasmic FMR1-interacting protein 2 CYFP2_HUMAN 148,385 
1,018 ATPase family AAA domain-containing protein 3A ATD3A_HUMAN 71,352 
1,019 Isoleucyl-tRNA synthetase, cytoplasmic SYIC_HUMAN 144,944 
1,020 40S ribosomal protein S9 RS9_HUMAN 22,575 
1,021 C-1-tetrahydrofolate synthase, cytoplasmic C1TC_HUMAN 101,544 
1,022 Vacuolar proton pump subunit C 1 VATC1_HUMAN 43,925 
1,023 Pre-mRNA-processing-splicing factor 8 PRP8_HUMAN 273,591 
1,024 Core histone macro-H2A.1 H2AY_HUMAN 39,601 
1,025 Lymphocyte-specific protein 1 LSP1_HUMAN 37,173 
1,026 Platelet-activating factor acetylhydrolase IB subunit alpha LIS1_HUMAN 46,619 
1,027 Erythrocyte membrane protein band 4.2 EPB42_HUMAN 76,956 
1,028 Retinaldehyde-binding protein 1-like protein 2 RLBL2_HUMAN 37,984 
1,029 Protein FAM114A2 F1142_HUMAN 56,255 
1,030 Agrin precursor AGRIN_HUMAN 214,820 
1,031 T-complex protein 1 subunit eta TCPH_HUMAN 59,350 
1,032 ATP-dependent RNA helicase DDX3X DDX3X_HUMAN 73,228 
1,033 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial precursor MCCC2_HUMAN 61,317 
1,034 Glycogen [starch] synthase, muscle GYS1_HUMAN 83,769 
1,035 
Bifunctional purine biosynthesis protein PURH 
[Includes: Phosphoribosylaminoimidazolecarboxamide 
formyltransferase 
PUR9_HUMAN 64,599 
1,036 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 precursor PLOD1_HUMAN 83,535 
1,037 Exportin-2 XPO2_HUMAN 110,404 
1,038 G protein-regulated inducer of neurite outgrowth 1 GRIN1_HUMAN 102,353 
1,039 Protein CREG1 precursor CREG1_HUMAN 24,057 
1,040 40S ribosomal protein S13 RS13_HUMAN 17,205 
1,041 Synaptogyrin-3 SNG3_HUMAN 24,537 
1,042 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-1 PLCB1_HUMAN 138,553 
1,043 Cathepsin L1 precursor CATL1_HUMAN 37,546 
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1,044 Complement component 1 Q subcomponent-binding protein, mitochondrial precursor C1QBP_HUMAN 31,345 
1,045 Glyoxalase domain-containing protein 4 GLOD4_HUMAN 34,776 
1,046 Rap1 GTPase-activating protein 1 RPGP1_HUMAN 73,374 
1,047 cAMP-dependent protein kinase type II-alpha regulatory subunit KAP2_HUMAN 45,501 
1,048 Bullous pemphigoid antigen 1, isoforms 6/9/10 BPAEA_HUMAN 590,974 
1,049 Fibromodulin precursor FMOD_HUMAN 43,230 
1,050 Catenin alpha-2 CTNA2_HUMAN 105,296 
1,051 Tyrosyl-tRNA synthetase, cytoplasmic SYYC_HUMAN 59,127 
1,052 Twinfilin-2 TWF2_HUMAN 39,531 
1,053 Calcium/calmodulin-dependent protein kinase type II beta chain KCC2B_HUMAN 72,710 
1,054 Putative adenosylhomocysteinase 3 SAHH2_HUMAN, SAHH3_HUMAN 66,703 
1,055 STIP1 homology and U box-containing protein 1 STUB1_HUMAN 34,839 
1,056 Reticulocalbin-2 precursor RCN2_HUMAN 36,860 
1,057 AP-2 complex subunit sigma-1 AP2S1_HUMAN 17,000 
1,058 Nuclear protein localization protein 4 homolog NPL4_HUMAN 68,103 
1,059 Coatomer subunit epsilon COPE_HUMAN 34,465 
1,060 Sodium/hydrogen exchanger 1 SL9A1_HUMAN 90,748 
1,061 Acyl carrier protein, mitochondrial precursor ACPM_HUMAN 17,400 
1,062 60S ribosomal protein L17 RL17_HUMAN 21,379 
1,063 Protein FAM3C precursor FAM3C_HUMAN 24,663 
1,064 Casein kinase II subunit beta CSK2B_HUMAN 24,925 
1,065 Kinesin light chain 1 KLC1_HUMAN 64,769 
1,066 Paraspeckle component 1 PSPC1_HUMAN 58,727 
1,067 WW domain-binding protein 2 WBP2_HUMAN 28,069 
1,068 Serine racemase SRR_HUMAN 36,548 
1,069 Thioredoxin domain-containing protein 12 precursor TXD12_HUMAN 19,188 
1,070 Calpain-1 catalytic subunit CAN1_HUMAN 81,875 
1,071 Synembryn-A RIC8A_HUMAN 59,595 
1,072 NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial precursor NDUC1_HUMAN 8,717 
1,073 Actin-binding LIM protein 1 ABLM1_HUMAN 87,628 
1,074 Probable ubiquitin carboxyl-terminal hydrolase FAF-X USP9X_HUMAN 289,527 
1,075 Vitamin K-dependent protein S precursor PROS_HUMAN 75,105 
1,076 Nuclear pore complex protein Nup205 NU205_HUMAN 227,909 
1,077 Neuroblastoma-amplified gene protein NAG_HUMAN 268,573 
1,078 Carboxypeptidase E precursor CBPE_HUMAN 53,134 
1,079 Import inner membrane translocase subunit TIM50, mitochondrial precursor TIM50_HUMAN 39,630 
1,080 Abhydrolase domain-containing protein 14B ABHEB_HUMAN 22,328 
1,081 T-complex protein 1 subunit gamma TCPG_HUMAN 60,517 
1,082 Choline dehydrogenase, mitochondrial precursor CHDH_HUMAN 65,383 
1,083 Eukaryotic translation initiation factor 3 subunit A EIF3A_HUMAN 166,557 
1,084 Signal transducer and activator of transcription 1-alpha/beta STAT1_HUMAN 87,319 
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1,085 Coatomer subunit beta COPB_HUMAN 107,128 
1,086 Heterogeneous nuclear ribonucleoprotein Q HNRPQ_HUMAN 69,586 
1,087 Coatomer subunit alpha COPA_HUMAN 138,317 
1,088 Heme oxygenase 2 HMOX2_HUMAN 36,016 
1,089 Sorting nexin-18 SNX18_HUMAN 68,863 
1,090 Thioredoxin domain-containing protein 1 precursor TXND1_HUMAN 31,774 
1,091 Protein phosphatase inhibitor 2 IPP2_HUMAN 22,998 
1,092 Pentraxin-related protein PTX3 precursor PTX3_HUMAN 42,002 
1,093 Fructosamine-3-kinase FN3K_HUMAN 35,154 
1,094 Nucleosome assembly protein 1-like 4 NP1L4_HUMAN 42,806 
1,095 Ras-related protein Rab-2A RAB2A_HUMAN 23,528 
1,096 Factor VIII intron 22 protein F8I2_HUMAN 39,086 
1,097 Golgi-associated plant pathogenesis-related protein 1 GAPR1_HUMAN 17,200 
1,098 Moesin MOES_HUMAN 67,804 
1,099 N-terminal EF-hand calcium-binding protein 1 NECA1_HUMAN 40,554 
1,100 40S ribosomal protein S16 RS16_HUMAN 16,428 
1,101 Inter-alpha-trypsin inhibitor heavy chain H3 precursor ITIH3_HUMAN 99,833 
1,102 Electrogenic sodium bicarbonate cotransporter 1 S4A4_HUMAN 121,449 
1,103 Collagen alpha-1(III) chain precursor CO3A1_HUMAN 138,547 
1,104 Tubulin gamma-2 chain TBG1_HUMAN, TBG2_HUMAN 51,075 
1,105 Thiosulfate sulfurtransferase THTR_HUMAN 33,411 
1,106 Glycogen debranching enzyme GDE_HUMAN 174,750 
1,107 Transmembrane protein 16F TM16F_HUMAN 106,151 
1,108 Pre-B-cell leukemia transcription factor-interacting protein 1 PBIP1_HUMAN 80,625 
1,109 Eukaryotic translation initiation factor 3 subunit F EIF3F_HUMAN 37,546 
1,110 Coronin-1A COR1A_HUMAN 51,008 
1,111 Eukaryotic initiation factor 4A-III IF4A3_HUMAN 46,854 
1,112 Dynamin-3 DYN3_HUMAN 96,667 
1,113 Monocarboxylate transporter 1 MOT1_HUMAN 53,942 
1,114 E3 ubiquitin-protein ligase UBR4 UBR4_HUMAN 573,825 
1,115 Secretogranin-1 precursor SCG1_HUMAN 78,228 
1,116 Adaptin ear-binding coat-associated protein 1 NECP1_HUMAN 29,720 
1,117 Ras-related protein Rab-3C RAB3C_HUMAN 25,935 
1,118 Apoptosis-inducing factor 1, mitochondrial precursor AIFM1_HUMAN 66,884 
1,119 Protein TBRG4 TBRG4_HUMAN 70,722 
1,120 Calcyclin-binding protein CYBP_HUMAN 26,192 
1,121 Ectonucleoside triphosphate diphosphohydrolase 2 ENTP2_HUMAN 53,648 
1,122 Histone H3.1t 
H31T_HUMAN, 
H31_HUMAN, 
H32_HUMAN, 
H33_HUMAN 
15,491 
1,123 Signal transducer and activator of transcription 3 STAT3_HUMAN 88,052 
1,124 Potassium voltage-gated channel subfamily A member 3 
KCNA2_HUMAN, 
KCNA3_HUMAN 58,287 
1,125 C4b-binding protein alpha chain precursor C4BP_HUMAN 67,015 
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identified proteins of Glioblastoma multiforme # 1,126-1,167 
nr. protein description accession numbers mass [Da]
1,126 Atlastin-1 ATLA1_HUMAN 63,528 
1,127 Succinate-semialdehyde dehydrogenase, mitochondrial precursor SSDH_HUMAN 57,197 
1,128 Uncharacterized protein C1orf198 CA198_HUMAN 36,329 
1,129 Brain protein 44 BR44_HUMAN 14,262 
1,130 40S ribosomal protein S26 RS26_HUMAN 12,998 
1,131 Guanine nucleotide-binding protein subunit alpha-11 GNA11_HUMAN 42,107 
1,132 Retinol dehydrogenase 11 RDH11_HUMAN 35,369 
1,133 Proteasome subunit alpha type-5 PSA5_HUMAN 26,393 
1,134 Low molecular weight phosphotyrosine protein phosphatase PPAC_HUMAN 18,025 
1,135 Nicotinate-nucleotide pyrophosphorylase [carboxylating] NADC_HUMAN 30,797 
1,136 Peroxisomal biogenesis factor 19 PEX19_HUMAN 32,789 
1,137 Transmembrane protein 109 precursor TM109_HUMAN 26,193 
1,138 40S ribosomal protein S23 RS23_HUMAN 15,790 
1,139 Prenylcysteine oxidase 1 precursor PCYOX_HUMAN 56,624 
1,140 BTB/POZ domain-containing protein KCTD16 KCD16_HUMAN 49,121 
1,141 Isocitrate dehydrogenase [NADP] cytoplasmic IDHC_HUMAN 46,643 
1,142 FK506-binding protein 10 precursor FKB10_HUMAN 64,228 
1,143 Glucosylceramidase precursor GLCM_HUMAN 59,700 
1,144 Vacuolar protein sorting-associating protein 4B VPS4B_HUMAN 49,286 
1,145 F-box only protein 2 FBX2_HUMAN 33,309 
1,146 Calcium/calmodulin-dependent protein kinase type 1 KCC1A_HUMAN 41,320 
1,147 Tapasin precursor TPSN_HUMAN 47,609 
1,148 Protein FAM98A FA98A_HUMAN 55,383 
1,149 Macrophage-capping protein CAPG_HUMAN 38,500 
1,150 Serine/threonine-protein kinase PAK 3 PAK3_HUMAN 62,293 
1,151 Ubiquinone biosynthesis protein COQ9, mitochondrial precursor COQ9_HUMAN 35,491 
1,152 Alpha-1-acid glycoprotein 2 precursor A1AG2_HUMAN 23,585 
1,153 Lin-7 homolog C LIN7C_HUMAN 21,816 
1,154 Eukaryotic translation initiation factor 4B IF4B_HUMAN 69,209 
1,155 Coiled-coil domain-containing protein 56 CCD56_HUMAN 11,714 
1,156 Serine/threonine-protein kinase TAO1 TAOK1_HUMAN 116,054 
1,157 Dihydropteridine reductase DHPR_HUMAN 25,772 
1,158 Ubiquitin-like modifier-activating enzyme 6 UBA6_HUMAN 117,955 
1,159 AP2-associated protein kinase 1 AAK1_HUMAN 93,560 
1,160 Plexin-B2 precursor PLXB2_HUMAN 205,109 
1,161 NAD-dependent malic enzyme, mitochondrial precursor MAOM_HUMAN 65,428 
1,162 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUC2_HUMAN 14,171 
1,163 Uncharacterized protein C2orf55 CB055_HUMAN 102,145 
1,164 Vesicle-associated membrane protein-associated protein B/C VAPB_HUMAN 27,211 
1,165 Valyl-tRNA synthetase SYV_HUMAN 140,460 
1,166 ATP-dependent RNA helicase DDX39 DDX39_HUMAN, UAP56_HUMAN 49,112 
1,167 60S ribosomal protein L3 RL3_HUMAN 46,092 
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identified proteins of Glioblastoma multiforme # 1,168-1,209 
nr. protein description accession numbers mass [Da]
1,168 Lon protease homolog, mitochondrial precursor LONM_HUMAN 106,473 
1,169 AP-3 complex subunit delta-1 AP3D1_HUMAN 130,144 
1,170 Ephrin-B3 precursor EFNB3_HUMAN 35,818 
1,171 Ras-related protein Rab-5C RAB5C_HUMAN 23,465 
1,172 Hematological and neurological expressed 1-like protein HN1L_HUMAN 20,046 
1,173 ADP-ribosylation factor-like protein 8B ARL8B_HUMAN 21,522 
1,174 Fatty aldehyde dehydrogenase AL3A2_HUMAN 54,832 
1,175 Cytochrome c oxidase subunit VIb isoform 1 CX6B1_HUMAN 10,174 
1,176 EH domain-containing protein 1 EHD1_HUMAN 60,611 
1,177 ATP synthase subunit gamma, mitochondrial precursor ATPG_HUMAN 32,980 
1,178 60S ribosomal protein L4 RL4_HUMAN 47,681 
1,179 Phosphatidate cytidylyltransferase 2 CDS2_HUMAN 51,402 
1,180 26S proteasome non-ATPase regulatory subunit 1 PSMD1_HUMAN 105,821 
1,181 Annexin A3 ANXA3_HUMAN 36,359 
1,182 KH domain-containing, RNA-binding, signal transduction-associated protein 1 KHDR1_HUMAN 48,210 
1,183 ADP-ribose pyrophosphatase, mitochondrial precursor NUDT9_HUMAN 39,108 
1,184 Acylglycerol kinase, mitochondrial precursor AGK_HUMAN 47,120 
1,185 UBX domain-containing protein 8 UBXD8_HUMAN 52,606 
1,186 Extended synaptotagmin-2 ESYT2_HUMAN 102,343 
1,187 Tubulin beta-1 chain TBB1_HUMAN 50,309 
1,188 Mitochondrial carrier homolog 1 MTCH1_HUMAN 41,527 
1,189 S-adenosylmethionine synthetase isoform type-2 METK2_HUMAN 43,643 
1,190 Phenylalanyl-tRNA synthetase beta chain SYFB_HUMAN 66,115 
1,191 26S proteasome non-ATPase regulatory subunit 6 PSMD6_HUMAN 45,515 
1,192 40S ribosomal protein S3a RS3A_HUMAN 29,927 
1,193 Bcl-2-like 13 protein B2L13_HUMAN 52,705 
1,194 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A STT3A_HUMAN 80,457 
1,195 Long-chain-fatty-acid--CoA ligase 3 ACSL3_HUMAN 80,405 
1,196 von Willebrand factor A domain-containing protein 1 precursor VWA1_HUMAN 46,786 
1,197 Tetratricopeptide repeat protein 1 TTC1_HUMAN 33,509 
1,198 Brain-specific polypeptide PEP-19 PEP19_HUMAN 6,773 
1,199 Transgelin TAGL_HUMAN 22,593 
1,200 Laminin subunit alpha-5 precursor LAMA5_HUMAN 399,725 
1,201 TSC22 domain family protein 4 T22D4_HUMAN 41,009 
1,202 Parvalbumin alpha PRVA_HUMAN 12,042 
1,203 Microsomal glutathione S-transferase 3 MGST3_HUMAN 16,499 
1,204 Histone H1x H1X_HUMAN 22,470 
1,205 BRO1 domain-containing protein BROX BROX_HUMAN 46,460 
1,206 Guanylate kinase KGUA_HUMAN 21,708 
1,207 Ubiquitin fusion degradation protein 1 homolog UFD1_HUMAN 34,483 
1,208 Intracellular hyaluronan-binding protein 4 HABP4_HUMAN 45,767 
1,209 Coiled-coil-helix-coiled-coil-helix domain-containing protein 6 CHCH6_HUMAN 26,439 
                   Appendix 
   
LIII
identified proteins of Glioblastoma multiforme # 1,210-1,253 
nr. protein description accession numbers mass [Da]
1,210 Protein unc-84 homolog B UN84B_HUMAN 80,294 
1,211 Retinal dehydrogenase 1 AL1A1_HUMAN 54,845 
1,212 NudC domain-containing protein 3 NUDC3_HUMAN 40,804 
1,213 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 
SMCA1_HUMAN, 
SMCA5_HUMAN 121,893 
1,214 Protein phosphatase 1 regulatory subunit 7 PP1R7_HUMAN 41,548 
1,215 60S ribosomal protein L18a RL18A_HUMAN 20,745 
1,216 Proteasome subunit alpha type-7 PSA7_HUMAN 27,869 
1,217 Vacuolar protein sorting-associated protein 18 homolog VPS18_HUMAN 110,170 
1,218 Pirin PIR_HUMAN 32,096 
1,219 Pigment epithelium-derived factor precursor PEDF_HUMAN 46,326 
1,220 CAP-Gly domain-containing linker protein 2 CLIP2_HUMAN 115,821 
1,221 Growth arrest-specific protein 7 GAS7_HUMAN 47,249 
1,222 Intercellular adhesion molecule 5 precursor ICAM5_HUMAN 97,311 
1,223 COP9 signalosome complex subunit 8 CSN8_HUMAN 23,208 
1,224 Sorting nexin-5 SNX5_HUMAN 46,800 
1,225 Protein S100-A11 S10AB_HUMAN 11,723 
1,226 Leucine-rich repeat-containing protein 57 LRC57_HUMAN 26,738 
1,227 Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial precursor IDH3G_HUMAN 42,776 
1,228 60S ribosomal protein L26 RL26_HUMAN 17,240 
1,229 Homer protein homolog 1 HOME1_HUMAN 40,260 
1,230 Acyl-coenzyme A thioesterase 9 ACOT9_HUMAN 46,337 
1,231 ARF GTPase-activating protein GIT1 GIT1_HUMAN 84,324 
1,232 Galactokinase GALK1_HUMAN 42,254 
1,233 Clathrin interactor 1 EPN4_HUMAN 68,243 
1,234 40S ribosomal protein S7 RS7_HUMAN 22,110 
1,235 Propionyl-CoA carboxylase alpha chain, mitochondrial precursor PCCA_HUMAN 77,336 
1,236 Unc-112-related protein 2 URP2_HUMAN 75,937 
1,237 Calcium-binding protein 39 CAB39_HUMAN 39,853 
1,238 Spectrin beta chain, brain 3 SPTN4_HUMAN 288,966 
1,239 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit precursor OST48_HUMAN 48,793 
1,240 Serine hydroxymethyltransferase, mitochondrial precursor GLYM_HUMAN 55,977 
1,241 Tubulin-specific chaperone D TBCD_HUMAN 132,513 
1,242 Apolipoprotein A-I-binding protein precursor AIBP_HUMAN 31,657 
1,243 Flotillin-2 FLOT2_HUMAN 41,667 
1,244 N-terminal EF-hand calcium-binding protein 2 NECA2_HUMAN 43,176 
1,245 Ras-related protein Rab-32 RAB32_HUMAN 24,979 
1,246 Prolyl 4-hydroxylase subunit alpha-1 precursor P4HA1_HUMAN 61,034 
1,247 Orphan sodium- and chloride-dependent neurotransmitter transporter NTT4 S6A17_HUMAN 80,986 
1,248 26S proteasome non-ATPase regulatory subunit 11 PSD11_HUMAN 47,448 
1,249 Myeloid leukemia factor 2 MLF2_HUMAN 28,130 
1,250 Pre-mRNA-processing factor 19 PRP19_HUMAN 55,163 
1,251 Glycyl-tRNA synthetase SYG_HUMAN 83,124 
1,252 THO complex subunit 4 THOC4_HUMAN 26,871 
1,253 Exocyst complex component 7 EXOC7_HUMAN 83,367 
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nr. protein description accession numbers mass [Da]
1,254 Abhydrolase domain-containing protein 12 ABD12_HUMAN 45,080 
1,255 Phosphofurin acidic cluster sorting protein 1 PACS1_HUMAN 104,881 
1,256 Tubulin--tyrosine ligase-like protein 12 TTL12_HUMAN 74,386 
1,257 Copine-1 CPNE1_HUMAN 59,041 
1,258 Endoplasmic reticulum aminopeptidase 1 ERAP1_HUMAN 107,220 
1,259 40S ribosomal protein S15a RS15A_HUMAN 14,822 
1,260 NADPH:adrenodoxin oxidoreductase, mitochondrial precursor ADRO_HUMAN 53,819 
1,261 Regulator of nonsense transcripts 1 RENT1_HUMAN 124,329 
1262 Probable phospholipid-transporting ATPase IA AT8A1_HUMAN 131,356 
1,263 Matrix metalloproteinase-9 precursor MMP9_HUMAN 78,411 
1,264 Phosphatidylinositol-5-phosphate 4-kinase type-2 beta PI42B_HUMAN 47,361 
1265 ADP-dependent glucokinase ADPGK_HUMAN 54,071 
1,266 Triple functional domain protein TRIO_HUMAN 341,600 
1,267 Collagen alpha-1(XIV) chain precursor COEA1_HUMAN 193,498 
1,268 Opioid growth factor receptor-like protein 1 OGRL1_HUMAN 51,235 
1,269 40S ribosomal protein S14 RS14_HUMAN 16,255 
1,270 Protein-glutamine gamma-glutamyltransferase 2 TGM2_HUMAN 77,311 
1,271 Prolactin regulatory element-binding protein PREB_HUMAN 45,450 
1,272 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 NDUB6_HUMAN 15,472 
1,273 RalBP1-associated Eps domain-containing protein 1 REPS1_HUMAN 80,751 
1,274 COMM domain-containing protein 9 COMD9_HUMAN 21,802 
1,275 Cleft lip and palate transmembrane protein 1 CLPT1_HUMAN 76,080 
1,276 40S ribosomal protein S15 RS15_HUMAN 17,023 
1,277 Heterogeneous nuclear ribonucleoprotein D-like HNRDL_HUMAN 46,421 
1,278 Copine-5 CPNE5_HUMAN 65,717 
1279 Sulfide:quinone oxidoreductase, mitochondrial precursor SQRD_HUMAN 49,944 
1,280 Programmed cell death protein 5 PDCD5_HUMAN 14,267 
1,281 Mitochondrial 39S ribosomal protein L4 RM04_HUMAN 34,902 
1,282 60S ribosomal protein L5 RL5_HUMAN 34,346 
1,283 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 precursor PLOD3_HUMAN 84,769 
1,284 RuvB-like 1 RUVB1_HUMAN 50,211 
1,285 Thioredoxin-like protein 1 TXNL1_HUMAN 32,233 
1,286 Copine-6 CPNE6_HUMAN 61,973 
1,287 Ras-related protein Rab-21 RAB21_HUMAN 24,330 
1,288 Methyltransferase-like protein 7B precursor MET7B_HUMAN 27,757 
1,289 SEC14-like protein 2 S14L2_HUMAN 46,128 
1,290 DnaJ homolog subfamily B member 6 DNJB6_HUMAN 36,070 
1,291 Microtubule-associated protein 1S MAP1S_HUMAN 112,195 
1,292 Quinone oxidoreductase QOR_HUMAN 35,189 
1,293 Surfeit locus protein 4 SURF4_HUMAN 30,377 
1,294 Methyl-CpG-binding protein 2 MECP2_HUMAN 52,423 
1,295 Cathepsin H precursor CATH_HUMAN 37,360 
1,296 Ribose-phosphate pyrophosphokinase 2 PRPS2_HUMAN 34,752 
1,297 60 kDa SS-A/Ro ribonucleoprotein RO60_HUMAN 60,654 
1,298 MAP7 domain-containing protein 2 MA7D2_HUMAN 81,945 
1,299 Ribonuclease T2 precursor RNT2_HUMAN 29,463 
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identified proteins of Glioblastoma multiforme # 1,300-1,341 
nr. protein description accession numbers mass [Da]
1,300 40S ribosomal protein S27 RS27_HUMAN 9,443 
1,301 Succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial precursor SUCA_HUMAN 35,030 
1,302 Peripheral plasma membrane protein CASK CSKP_HUMAN 105,106 
1,303 Metabotropic glutamate receptor 5 precursor GRM5_HUMAN 132,454 
1,304 Transcriptional activator protein Pur-alpha PURA_HUMAN 34,893 
1,305 Calcium-dependent secretion activator 1 CAPS1_HUMAN 152,771 
1,306 Ephrin-B2 precursor EFNB2_HUMAN 36,906 
1,307 PDZ domain-containing protein 11 PDZ11_HUMAN 16,114 
1,308 Rap1 GTPase-GDP dissociation stimulator 1 GDS1_HUMAN 66,386 
1,309 Autophagy-related protein 3 ATG3_HUMAN 35,846 
1,310 CaM kinase-like vesicle-associated protein CAMKV_HUMAN 54,336 
1,311 Exonuclease 3'-5' domain-like-containing protein 2 EXDL2_HUMAN 56,329 
1,312 Tetratricopeptide repeat protein 9C TTC9C_HUMAN 19,995 
1,313 NADH-cytochrome b5 reductase 2 NB5R2_HUMAN 31,442 
1,314 Proliferation-associated protein 2G4 PA2G4_HUMAN 43,769 
1,315 Phosphoglucomutase-2-like 1 PGM2L_HUMAN 70,439 
1,316 Ribosomal protein S6 kinase alpha-3 KS6A3_HUMAN 83,721 
1,317 Lupus La protein LA_HUMAN 46,821 
1,318 Oxysterol-binding protein-related protein 8 OSBL8_HUMAN 101,181 
1,319 Heparin-binding growth factor 1 precursor FGF1_HUMAN 17,442 
1,320 Zinc-binding alcohol dehydrogenase domain-containing protein 1 ZADH1_HUMAN 38,481 
1,321 Ankyrin repeat and FYVE domain-containing protein 1 ANFY1_HUMAN 128,384 
1,322 Casein kinase II subunit alpha' CSK22_HUMAN 41,197 
1,323 rRNA 2'-O-methyltransferase fibrillarin FBRL_HUMAN 33,766 
1,324 Alpha-aminoadipic semialdehyde synthase, mitochondrial precursor AASS_HUMAN 102,117 
1,325 UPF0368 protein Cxorf26 CX026_HUMAN 26,040 
1,326 Catechol O-methyltransferase COMT_HUMAN 30,020 
1,327 Coatomer subunit beta' COPB2_HUMAN 102,471 
1,328 Active breakpoint cluster region-related protein ABR_HUMAN 97,682 
1,329 Transferrin receptor protein 1 TFR1_HUMAN 84,856 
1,330 Succinyl-CoA ligase [GDP-forming] beta-chain, mitochondrial precursor SUCB2_HUMAN 46,494 
1,331 SH3 domain-binding glutamic acid-rich-like protein 2 SH3L2_HUMAN 12,308 
1,332 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial precursor NDUBB_HUMAN 17,299 
1,333 Translin TSN_HUMAN 26,165 
1,334 Coiled-coil domain-containing protein 47 precursor CCD47_HUMAN 55,857 
1,335 Glycine dehydrogenase [decarboxylating], mitochondrial precursor GCSP_HUMAN 112,697 
1,336 Zinc finger CCCH type antiviral protein 1 ZCC2_HUMAN 101,428 
1,337 ADP-ribosyl cyclase 1 CD38_HUMAN 34,310 
1,338 Coronin-1C COR1C_HUMAN 53,232 
1,339 Torsin-1A-interacting protein 2 TOIP2_HUMAN 51,245 
1,340 Signal recognition particle 68 kDa protein SRP68_HUMAN 70,714 
1,341 Amyloid-like protein 1 precursor APLP1_HUMAN 72,158 
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nr. protein description accession numbers mass [Da]
1,342 Twinfilin-1 TWF1_HUMAN 42,192 
1,343 Kinesin-like protein KIF3A KIF3A_HUMAN 80,370 
1,344 Enhancer of rudimentary homolog ERH_HUMAN 12,241 
1,345 Transportin-1 TNPO1_HUMAN 101,296 
1,346 Mitochondrial import inner membrane translocase subunit Tim13 TIM13_HUMAN 10,482 
1,347 BTB/POZ domain-containing protein KCTD12 KCD12_HUMAN 35,684 
1,348 Mesoderm development candidate 2 MESD2_HUMAN 26,060 
1,349 Importin-7 IPO7_HUMAN 119,502 
1,350 Oligopeptide transporter, kidney isoform S15A2_HUMAN 81,925 
1,351 Retinol-binding protein I, cellular RET1_HUMAN 15,832 
1,352 Serine/threonine-protein kinase WNK1 WNK1_HUMAN 250,732 
1,353 SAPK substrate protein 1 SAKS1_HUMAN 33,307 
1,354 NADP-dependent leukotriene B4 12-hydroxydehydrogenase LTB4D_HUMAN 35,853 
1,355 GRB2-associated-binding protein 1 GAB1_HUMAN 76,599 
1,356 Choline transporter-like protein 2 CTL2_HUMAN 80,138 
1,357 Leucine-rich repeat-containing protein 8A LRC8A_HUMAN 94,186 
1,358 Tripartite motif-containing protein 47 TRI47_HUMAN 69,513 
1,359 Eukaryotic translation initiation factor 3 subunit E-interacting protein IF3EI_HUMAN 66,711 
1,360 ETHE1 protein, mitochondrial precursor ETHE1_HUMAN 27,855 
1,361 Rho-related GTP-binding protein RhoG precursor RHOG_HUMAN 21,290 
1,362 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon PLCE_HUMAN 42,056 
1,363 OTU domain-containing protein 7B OTU7B_HUMAN 92,509 
1,364 Aspartoacylase ACY2_HUMAN 35,718 
1,365 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta-1 PLCD1_HUMAN 85,747 
1,366 Gamma-butyrobetaine dioxygenase BODG_HUMAN 44,698 
1,367 Derlin-1 DERL1_HUMAN 28,785 
1,368 Thyroid hormone receptor-associated protein 3 TR150_HUMAN 108,651 
1,369 Nuclear pore complex protein Nup107 NU107_HUMAN 106,359 
1,370 Multiple coagulation factor deficiency protein 2 precursor MCFD2_HUMAN 16,373 
1,371 39S ribosomal protein L12, mitochondrial precursor RM12_HUMAN 21,330 
1,372 Phenylalanyl-tRNA synthetase alpha chain SYFA_HUMAN 57,547 
1,373 Integrin beta-5 precursor ITB5_HUMAN 88,037 
1,374 Bifunctional coenzyme A synthase COASY_HUMAN 62,312 
1,375 Peptidyl-prolyl cis-trans isomerase G PPIG_HUMAN 88,602 
1,376 
Multifunctional protein ADE2 [Includes: 
Phosphoribosylaminoimidazole-succinocarboxamide 
synthase 
PUR6_HUMAN 47,062 
1,377 HLA class II histocompatibility antigen, DQ(5) alpha chain precursor HA25_HUMAN 27,982 
1,378 Asparaginyl-tRNA synthetase, cytoplasmic SYNC_HUMAN 62,926 
1,379 40S ribosomal protein S18 RS18_HUMAN 17,701 
1,380 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 DHX15_HUMAN 90,917 
1,381 Vacuolar protein sorting-associated protein 11 homolog VPS11_HUMAN 107,821 
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nr. protein description accession numbers mass [Da]
1,382 Protein phosphatase 1A PPM1A_HUMAN 42,429 
1,383 Tescalcin TESC_HUMAN 24,733 
1,384 Adenosylhomocysteinase SAHH_HUMAN 47,699 
1,385 Vacuolar protein sorting-associated protein 41 homolog VPS41_HUMAN 98,521 
1,386 Calcium-independent phospholipase A2-gamma PLPL8_HUMAN 88,462 
1,387 D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor BDH_HUMAN 38,140 
1,388 WD repeat-containing protein 7 WDR7_HUMAN 163,795 
1,389 ATP-dependent RNA helicase DDX19A DD19A_HUMAN, DD19B_HUMAN 53,958 
1,390 Dihydropyrimidinase-related protein 5 DPYL5_HUMAN 61,403 
1,391 Glutathione reductase, mitochondrial precursor GSHR_HUMAN 56,239 
1,392 Heat shock 70 kDa protein 4 HSP74_HUMAN 94,283 
1,393 Alpha-actinin-2 ACTN2_HUMAN 103,840 
1,394 Gamma-aminobutyric acid receptor subunit gamma-2 precursor GBRG2_HUMAN 54,146 
1,395 Myosin-11 MYH11_HUMAN 227,327 
1,396 [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 3, mitochondrial precursor PDK3_HUMAN 46,923 
1,397 Double-strand break repair protein MRE11A MRE11_HUMAN 80,577 
1,398 Arylsulfatase A precursor ARSA_HUMAN 53,571 
1,399 Myosin-Ic MYO1C_HUMAN 118,024 
1,400 Beta-glucuronidase precursor BGLR_HUMAN 74,715 
1,401 Spartin SPG20_HUMAN 72,815 
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Retention behavior of all 142 membrane proteins identified with the semi top-down 
approach. Proteins in bold and italic are not confirmed with Scaffold proteome 
software. KCNA2 and KCNA 3 were grouped by Scaffold. 
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different 
peptides
sequence 
coverage 
[%]
28272625242322212019181716151413121110987654321
fraction
protein
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LX
38.7OPCM96
317.6RSSA95
32.1MIA394
25.5IGSF893
34.8MVP92
37.2PVRL191
24.6ENTP290
415.31C1789
57.6NICA88
24.4SAP87
211.6STX1286
523.3ARM1085
35.2ITB284
28.0SSRA83
314.2TIM5082
521.2APMAP81
47.2TOM7080
43.8TIP79
614.1PLD378
22.0CHL177
313.2PHB76
213.2VAPB75
314.6EMD74
34.0DAG173
different 
peptides
sequence 
coverage 
[%]
28272625242322212019181716151413121110987654321
fraction
protein
 
23.6PRRT3120
217.9CCD56119
212.0CXA1118
29.0NTRI117
241.7NDUA3116
221.3COX6C115
310.9B2L13114
22.3KCD16113
28.6NPDC1112
227.5NDUBB111
24.2KCNA3110
24.4KCNA2109
211.7MTX1108
25.4APLP1107
34.8AT2B1106
417.8MTCH2105
210.3BCLX104
34.2S12A5103
311.0JAM3102
24.9GPR56101
43.6RPGF2100
34.0KTN199
35.4DCLK198
412.0LANC197
different
peptides
sequence
coverage
[%]
28272625242322212019181716151413121110987654321
fraction
protein
 
                   Appendix 
   
LXI
21.3LPHN1142
30.3SYNE1141
24.5HNRPM140
26.4NPTXR139
20.7CAD23138
21.7CNTP2137
22.7ICAM5136
29.3EFNB2135
29.6CT103134
29.0HA25133
22.6S12A2132
27.1EFNB3131
24.3RTN3130
25.0CADM1129
25.5RANB3128
23.4PCDH1127
22.7AT2B2126
311.7CY1125
22.1S12A4124
314.4K0152123
28.6NSDHL122
214.9T126A121
different
peptides
sequence
coverage
[%]
28272625242322212019181716151413121110987654321
fraction
protein
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LXII
Distribution of peptides observed for SEREX proteins. Not for all 13 proteins GO 
annotations are available (www.expasy.org). 
Gene ontology term anti-
gen name cellular component molecular function biological process 
ACTN4 actinin, alpha 4 
nucleus, 
perinuclear 
region of 
cytoplasm, 
protein complex, 
pseudopodium 
actin filament binding, 
integrin binding, 
nucleoside binding, 
protein 
homodimerization 
activity 
positive regulation of cell 
motility, positive 
regulation of 
sodium:hydrogen 
antiporter activity, 
regulation of apoptosis 
ING4 
inhibitor of 
growth family, 
member 4 
nucleus protein binding 
apoptosis, cell cycle 
arrest, negative 
regulation of cell 
proliferation, negative 
regulation of growth, 
negative regulation of 
transcription, DNA-
dependent protein amino 
acid acetylation 
RTN4 reticulon 4 
integral to 
endoplasmic 
reticulum 
membrane, 
nuclear envelope 
protein binding 
negative regulation of 
anti-apoptosis, negative 
regulation of axon 
extension, regulation of 
cell migration 
CLIP2 cytoplasmic linker 2 
microtubule 
associated 
complex 
  
HCLS1 
hematopoietic 
cell-specific 
Lyn substrate 1 
DNA-directed 
RNA polymerase 
II, core complex; 
cytoplasm 
protein binding, 
transcription factor 
activity 
erythrocyte differentiation, 
positive regulation of cell 
proliferation, positive 
regulation of tyrosine 
hosphorylation of STAT 
protein, regulation of 
transcription, DNA-
dependent, response to 
hormone stimulus 
U2AFL 
U2(RNU2) 
small nuclear 
RNA auxillary 
factor 1-like 1 
nucleus RNA binding  
ZN232 zinc finger protein 232 
Nucleus, 
intracellular 
zinc ion binding, DNA 
binding 
regulation of transcription, 
DNA dependent 
HS105 
Heat-shock 
protein 105 
kDa  
cytoplasm nucleotide binding response to unfolded protein 
PHF3 PHD finger protein 3 - 
zinc ion binding, DNA 
binding 
multicellular organismal 
development 
PHF20 PHD finger protein 20 - - - 
TPR 
translocated 
promoter 
region (to 
activated MET 
oncogene) 
Cytoplasm, 
nuclear pore 
nucleotide binding, 
ATP binding, serine-
tRNA-ligase activity 
protein import into 
nucleus 
CYTSA 
Cytospin-A 
(NY-REN-22 
antigen) 
- - - 
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LXIII
Gene ontology term anti-
gen name cellular component molecular function biological process 
GOGA
1 
golgi 
autoantigen, 
golgin 
subfamily a 
golgi apparatus - - 
 
